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Comprehensive summary  
 
Background: Antimicrobial resistance (AMR) is a global public health challenge since infection with 
resistant organisms may cause death, can spread across the community, and increase health care costs 
at individual, community and government level as more expensive antimicrobials will have to be made 
available for the treatment of infections caused by resistant bacteria. This calls for urgent and 
consolidated efforts in order to effectively curb this growing crisis, to prevent the world from slipping 
back to the pre-antibiotic era. The World Health Organization made a call in 2011 advocating for 
strengthening of surveillance and laboratory capacity as one-way of detecting and monitoring trends 
and patterns of emerging AMR. Knowledge of AMR guides clinical decisions regarding choice of 
antimicrobial therapy, during an episode of bacteraemia and forms the basis of key strategies in 
containing the spread of resistant bacteria. The current study focused on Staphylococcus aureus (SA), 
Klebsiella pneumoniae (KP), and Pseudomonas aeruginosa (PA), as they are common hospital 
acquired infections which are prone to developing resistance to multiple antibiotics. 
 
Aim: The aim of this project was to assess and utilize the laboratory information system (LIS) at the 
National Health Laboratory Services (NHLS), as a tool for reporting AMR and monitoring resistance 
patterns and trends over time of clinical isolates of SA, KP and PA, cultured from the blood of patients 
admitted to seven tertiary public hospitals in three provinces in South Africa.  
 
Methods: A retrospective and prospective analysis was done on isolates of SA, KP, PA from blood 
specimens collected from patients with bacteraemia and submitted to diagnostic microbiology 
laboratories of the NHLS at seven tertiary public hospitals in three provinces in South Africa. These 
hospitals comprised the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), Chris Hani 
Baragwanath Hospital (CBH), Helen Joseph Hospital (HJH), Steve Biko Pretoria Academic Hospital 
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(SBPAH), Groote Schuur Hospital (GSH), Tygerberg Hospital (TH) and the Universitas Hospital of 
the Free State (UH). For retrospective analysis, data submitted during the period July 2005 to 
December 2009 were used and for prospective analysis, data relating to AMR in SA, KP, PA, 
collected by the Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa, 
(GERMS-SA) from July 2010 to June 2011 were used. AMR in these three pathogens to commonly 
used antimicrobial drugs was systematically investigated. Multivariate logistic regressions models 
were used to assess factors associated with AMR. In addition, a systematic review of research done to 
date on AMR in bacterial pathogens commonly associated with hospital-acquired infections was 
conducted in order to understand the existing antimicrobial surveillance systems and baseline 
resistance patterns in South Africa. 
 
Results: A total of 9969 isolates were reported from the retrospective dataset. These were 3942 
(39.5%) SA, 4466 (44.8%) KP and 1561 (15.7%) PA. From the prospective dataset, a total of 3026 
isolates were reported, 1494 (49.4%) SA and 1532 (50.6%) KP isolates respectively. The proportion of 
invasive bacteraemia was higher in the <5 year old children. Nearly all strains of SA in South Africa 
were resistant to penicillin, and >30% up to as high as 80% were resistant to methicillin-related drugs 
among~560 invasive SA isolates over the two year period. Methicillin resistant Staphylococcus aureus 
(MRSA) rates significantly differed between hospitals (p=<0.001). The proportion of MRSA isolates 
in relation to methicillin-susceptible strains showed a declining trend from 22.2% in 2005 to 10.5% in 
2009 (p=0.042). Emerging resistance was observed for vancomycin: 1 isolate was identified in 2006 
and 9 isolates between July 2010-June 2011, and all except 1 were from Gauteng hospitals. The study 
found increasing rates of carbapenem-resisant KP of 0.4% in 2005 to 4.0% in 2011 for imipenem. The 
mean rate of extended spectrum beta lactamase (ESBL-KP) producing KP was 74.2%, with the lowest 
rate of 62.4% in SBPAH and the highest rate of 81.3% in UH, showing a significant geographical 
variation in rates of resistance (p=0.021). PA showed a tendency for multi-drug resistance with 
resistance rates of >20% to extended spectrum cephalosporins, fluoroquinolones and aminoglycosides 
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respectively. Emerging resistance in PA isolates was observed to colistin, showing a resistance rate of 
1.9% over the 5 years period. In the multivariate model, age <5 years, male gender, and hospital 
location were factors significantly associated with MRSA, while ESBL-KP was significantly 
associated with age <5 years and hospital location. 
 
Concluding remarks: The study has clearly demonstrated that AMR is relatively common in South 
Africa among children <5 years. Enhancement of continued surveillance of nosocomial infections 
through use of routine laboratory data should be reinforced as this will facilitate effective 
interpretation and mapping of trends and patterns of AMR. Therefore, the LIS as a tool for gathering 
such data should be strengthened to provide reliable AMR data for improved understanding of the 
extent of the AMR, and present evidence on which future policies and practices aimed at containing 
AMR could be based. 
 
Key words: Laboratory information system, Trends, Patterns, Antimicrobial resistance, Bacterial 
pathogens, Nosocomial infections, Surveillance, Bacteraemia, Blood culture. 
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Definition of terms 
 
American Type Culture Collection (ATCC) is a biological resource center that focuses on the 
acquisition, authentication, production, preservation, development and distribution of standard 
reference microorganisms, cell lines and other materials for research in the life sciences. 
 
DISA is an orchid, the flower. It is a symbol and name of the laboratory information management 
system (LIMS) used by the National Health Laboratory Service (NHLS). The software was developed 
by the Ifocus Systec Company (Bangalore, India). 
 
JEEVA is an integrated hospital management information system (HMIS) application through which 
all hospital functions are run. These include patients’ registration, laboratory, pharmacy etc. 
 
Laboratory information system (LIS) is a series of computer programs that process, store and 
manage data from all stages of medical processes and tests.  
 
Laboratory information management system (LIMS) sometimes referred to as Laboratory 
information system (LIS) is a software-based laboratory and information management system that 
offers a set of key features that support a modern laboratory operations and is used interchangeably 
with LIS. 
 
Nosocomial infection can be defined as infection occurring after 48 hours of hospital admission, 3 
days after discharge or 30 days after an operation. 
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SENTRY is a program of antimicrobial resistance surveillance for Asia-Pacific regions and South 
Africa. 
 
WHONET is free Windows-based database software developed by World Health Organization for the 
management and analysis of microbiology laboratory data with a special focus on the analysis of 
antimicrobial susceptibility test results. 
 
TrakCare Lab is a laboratory information management system (LIMS) that offers accurate laboratory 
results reporting, improved laboratory efficiency and better business management. 
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Preface 
In November 2009, my supervisor, Professor Jill Murray, understanding my interest and passion in the 
field of infectious diseases, introduced me to the growing need to understand antimicrobial resistance 
surveillance among nosocomial bacteria in South Africa, and trying to answer the question ‘whether 
laboratory information system can be utilised to monitor trends and patterns of resistance among 
nosocomial bacteria?’  
This PhD thesis is submitted in fulfilment of the requirements for a Doctor of Philosophy Degree in 
the subject area of infectious Diseases Epidemiology. The thesis contains a compilation of original 
work done with the guidance of my supervisors: Professors’ Jill Murray, Olga Perovic and Hendrik 
Koornhof. This research was conducted in line within the broader framework of the Antimicrobial 
Resistance Research and Surveillance for nosocomial bacteria which is run by Professor Olga Perovic.  
The thesis presents comprehensive results of a research project that was undertaken in the Division of 
Epidemiology and Biostatistics, School of Public Health of the University of the Witwatersrand and 
the Antimicrobial Resistance Surveillance and Research unit of the National Institute for 
Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS). Appropriate 
acknowledgement of both financial and academic support that was provided during the course of the 
research has been highlighted. Where published work from other sources has been cited, appropriate 
referencing has been done. 
Writing this thesis has not been easy due to its complex nature. I had to deal with a substantial scope 
of knowledge from multiple disciplines, in an attempt to provide a more comprehensive perspective on 
antimicrobial resistance surveillance among nosocomial bacteria in tertiary public hospitals in South 
Africa. These disciplines include microbiology, pharmacology, internal medicine, infectious diseases, 
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health informatics, epidemiology, public health, biostatistics, and data management. Despite such 
upheaval, in the process of putting together this thesis, I have realised that I have actually gained a 
wealth of knowledge in the field of antimicrobial resistance surveillance. 
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Chapter 1   Introduction 
 
This chapter consists of an introduction, which details with the background, the statement of 
the problem and the justification of the study. This provides the extent of antimicrobial 
resistance and the reason for it being a public health problem. The chapter also gives 
background information on the value of surveillance for antimicrobial resistance among 
nosocomial pathogens, using the laboratory information system and the need to focus on 
nosocomial pathogens. Lastly, the aim and specific objectives of the study are highlighted, 
setting the road map of what has been done. 
 
1.1 Background 
Antimicrobial resistance (AMR) is undoubtedly emerging as a medical and public health 
challenge in most health care settings. (1, 2) Antibiotics have for years been effectively used 
for treating infectious diseases and saved millions of lives. (3) However, these gains have 
been reversed due to development of AMR, (4) and mortality due to resistant bacteria is 
considerably high thus adding to the increasing infectious disease burden. (5) Antimicrobial 
susceptibility pattern has changed over time and has to a great extent been propagated by 
inappropriate use of antimicrobial agents that has resulted in emerging resistance. (6) 
 
Since 1941, when penicillin was introduced in the management of bacterial infections, AMR 
has progressively increased. (7, 8) The emergence of bacterial pathogens resistant to 
commonly used antibiotics is causing increasing concern because of its association with high 
levels of morbidity and mortality. (9, 10) High prevalence of resistance to antimicrobial 
agents impacts negatively on the patients and increases the burden on health care 
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expenditures, because of the need for additional diagnostic testing and longer duration of 
hospital stay. (11, 12) 
 
The magnitude of drug resistance has raised the need for continued surveillance of 
antimicrobial susceptibility and to systematically monitor patterns and trends of antimicrobial 
resistance over time. Enhanced information retrieval and better understanding of the 
magnitude of the problem would facilitate timely implementation of appropriate 
interventions, including review of antimicrobial prescriptions policy and treatment guidelines 
that would reinforce prudent antimicrobial use. (13-15) In the face of down scaling of the 
development of new antimicrobial drugs by the pharmaceutical industry, the ultimate long-
term goal of patient management, would be to cure patients and preserve the effectiveness of 
currently available antimicrobials so that they would remain functional for many years to 
come. (16) 
 
There are various surveillance networks that have been established over the years, focusing 
on various pathogens that serve to provide reliable sources of antimicrobial susceptibility 
data. Such data have been used to determine resistance patterns and monitor emerging 
antimicrobial resistance both nationally and internationally. (17, 18) The national and 
international surveillance networks have focused on monitoring antimicrobial resistance 
patterns and trends over time of various bacterial pathogens that cause serious diseases in 
humans. However, at present there is paucity of data in most developing countries regarding 
the burden of antimicrobial resistance, even among nosocomial pathogens which reflect the 
situation in hospitals from where most resistance problems have emerged.  
 
An effective electronic surveillance and monitoring system based on a laboratory information 
system (LIS) that aims to collect isolate-specific, good quality antimicrobial susceptibility 
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test results from clinical laboratories will substantially contribute to early detection of 
emerging antimicrobial resistance problems. To ascertain effective implementation of a 
suitable electronic surveillance system, it was imperative to carry out an evaluation of the 
usefulness and validity of LIS-generated data retrieved from the Corporate Data Warehouse 
(CDW) contracted by the National Health Laboratory Services (NHLS). To perform such an 
evaluation, the effectiveness of the existing LIS to determine the proportion of antimicrobial 
susceptibility of the clinical isolates obtained from hospitalized patients was interrogated. 
Relevant electronic data collected retrospectively over a 4.5-year period was used to study the 
epidemiology of antimicrobial resistance of selected bacterial pathogens that were known to 
be associated with increased proportion of multi-drug resistance in the hospitals.  
 
The relevant bacterial pathogens chosen were Staphylococcus aureus, Klebsiella pneumoniae 
and Pseudomonas aeruginosa. The choice of these pathogens was in keeping with their 
association with multiple drug resistance and in-hospital acquisition. Furthermore they 
represent different spectra of drug susceptibility and therefore are exposed to different 
antimicrobial agents over time and, despite considerable overlap, acquire resistance to 
different antimicrobial agents. S. aureus was included because it represents Gram-positive 
bacteria and has a high mutation rate in genes encoding resistance to antimicrobial agents. It 
is also a very common cause of wound infection which not infrequently leads to blood stream 
invasion in hospitalized patients. It is a common commensal of humans and primarily lives in 
the moist epithelial layer of the anterior nasal area with a carriage rate of about 20% in the 
population. In its carriage capacity over time, as well as during invasive disease, S. aureus is 
frequently exposed to the selection pressure of antimicrobial usage. Carriage is an important 
risk factor for invasive infection, and significantly higher rates of S.aureus infection occur 
among hospitalized patients who have been catheterised as well as patients treated surgically. 
In addition methicillin resistant S.aureus is intrinsically resistant to methicillin and all β-
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lactams, including the isoxazolyl penicillins as well as broad spectrum β-lactams and 
carbapemens. (19) 
 
K. pneumoniae isolates were chosen as they are major emerging pathogens in nosocomial 
infections caused by Gram-negative bacteria belonging to the Enterobacteriaceae family. 
Unlike the Escherichia coli species which has a heterogeneous spectrum of pathogenicity 
(entero-toxinogenic, entero-invasive, entero-pathogenic, urogenic) and was another strong 
candidate for inclusion in the present study, K. pneumoniae has a narrower spectrum and is, 
in addition to wound infections and bacteraemia, associated with respiratory infections 
(pneumonia) and less commonly with urinary tract infections. High prevalence of extended 
spectrum beta-lactamase (ESBL)-producing K. pneumoniae in hospital settings, poses an 
immense challenge in the clinical management of such infections, as treatment options are 
few due to the wide spectrum of antimicrobial resistance encountered in this organism. This 
makes K. pneumoniae an important bacterial species for inclusion in surveillance programs of 
hospital-acquired infections. (20)  
 
P. aeruginosa is an opportunistic pathogen causing serious infections in hospitalized patients, 
mainly among immunocompromised patients with neutropenic patients as a special risk 
group. It is ubiquitous and its natural habitat is environmental niches where water or moisture 
is present e.g. shower tops, water taps and drains, flower vases etc. Treating P.aeruginosa is 
challenging due to inherent resistance to many antibiotics. It commonly produces ESBL 
enzymes, posing treatment difficulties. Furthermore, organisms such as K.pneumoniae and 
P.aeruginosa exhibit co-resistance to many other classes of antibiotics, resulting in the 
limitation of therapeutic options. (21)  
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Blood culture as the source of the three organisms, was chosen as isolates from this source 
(blood) signify bacteraemic episodes and are usually present as a single bacterial species in 
pure culture and are likely to be clinically relevant, as opposed to isolates from other body 
sites where the organisms may be merely present in a colonizing capacity, as opposed to 
causing invasive disease. 
 
The outcome from this research: 1) provides a guide for the enhancement of a LIS for 
antimicrobial resistance surveillance in South Africa, 2) demonstrates the effectiveness of a 
LIS in capturing information related to antimicrobial susceptibility testing in microbiology 
laboratories, and 3) provides a platform for the reinforcement of an electronic based 
surveillance model appropriate for South Africa.  
 
1.2 Statement of the problem 
The rapid emergence and spread of multi-drug resistant community and nosocomial acquired 
pathogens is of great concern in both developed and developing countries. (22, 23) 
Management of infectious diseases in the 21
st
 century is faced with major challenges 
associated with the use of antimicrobial agents. Recent studies have shown an increase in 
Gram-negative and Gram-positive organisms amongst nosocomial pathogens that are multi-
drug resistant, and pose a great challenge for treatment and clinical management. (24, 25) 
While there are attempts by the pharmaceutical industry to manufacture new antibacterial 
agents which are expensive and beyond reach of most patients in developing countries, they 
invariably select for resistance, with a tendency to extend their selective pressure to involve 
resistance among similar drugs classes, diminishing their usefulness over time. The need for 
an effective surveillance system to elucidate the patterns and extent of drug resistance in 
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South Africa appears to be an appropriate intervention. Such a system would help to identify 
patterns and trends of AMR among nosocomial pathogens. (26, 27) The current LIS has not 
been utilized optimally and has shown significant deficiencies with regard to consistent and 
standardized data entry and reporting methodology, for it to be able to function efficiently. 
 
1.3 Rationale of the study 
Reliable information on the patterns of antimicrobial susceptibility of selected nosocomial 
pathogens in public sector hospitals in South Africa would be essential. Such information 
would aid in the assessment of the impact of antimicrobial resistance in the hospitals 
concerned and by extension potentially at the national level. In addition, information on 
AMR could be used in formulating beneficial prevention strategies on different health system 
levels in the country. The antimicrobial susceptibility surveillance data would provide a 
useful platform for planning targeted public health interventions to control spread of 
antimicrobial resistant pathogens in public sector institutions and guide future preventive as 
well as treatment recommendations.  
 
To ensure this was achieved, the current LIS was evaluated checking for consistent, 
standardized data entry and reporting, as well as quality control methodology. This process 
helped in identifying the strengths and weaknesses of the system and gave direction on the 
appropriate ways of improving and making the system more effective. This study was done in 
line with the broad vision of laboratory-based antimicrobial resistant surveillance (LARS), 
whose focus had been to establish a functional integrated antimicrobial resistance 
surveillance system for commonly identifiable nosocomial pathogens in South Africa. Even 
though the focus of the study was on South African surveillance system for nosocomial 
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infections, other African countries would be in a position to implement a similar system for 
their antimicrobial surveillance. This study explored in greater depth the potential landscape 
of resistance surveillance in low income country settings and determined the feasibility of 
enhanced surveillance.  
 
1.4 Literature Review 
 
1.4.1 Basic Microbiology 
1.4.1.1 Staphylococcus 
The genus name Staphylococcus was derived from a Greek term staphylos which means a 
‘bunch of grapes’, coccus means grain or berry (Figure 1.1). ‘Staphylococcus’ therefore 
implies that the cells of these organisms grow in clusters resembling clusters of grapes. 
However, in clinical specimens, the organisms may also appear as single cells, pairs, or in 
short chains. The genus contains over 30 different species and only three of these are of 
clinical significance: S.aureus (causes a wide range of major and minor infections in humans 
and its enzyme coagulase causes clotting of blood plasma), S.epidermidis (usually a skin 
commensal bacterium, causes opportunistic infection associated with prostheses or foreign 
body) and S. saprophyticus (causes urinary tract infection in healthy adult women). (28, 29) 
 
The staphylococci organisms are 0.5-1.5 µm in diameter, non motile, facultative anaerobic 
(i.e. grow in both aerobic and anaerobic environments), and are able to grow in media 
containing a high concentration of salt i.e. 10% sodium chloride as well as in temperatures 
ranging from 10-40
o
C. Staphylococci are present on the skin and mucous membranes such as 
nasopharynx of humans and because shedding of this organism is common, it is responsible 
for the occurrence of nosocomial transmission among hospitalised individuals. (28) 
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Figure 1.1 Staphylococcus aureus resembling grain or berry-like in clusters like bunch 
of grapes (Adapted from www.microbiologyinpictures.com/staphylococcusaureus.html). 
 
S.aureus is a Gram positive coccus, about 1 μm in diameter. The organisms are non-spore 
forming, non-motile, and usually non-capsulate. The organism is non fastidious, capable of 
aerobic and anaerobic respiration. S. aureus causes the following clinical conditions: 
bacteraemia, osteomylitis, skin and soft tissues infection, pneumonia, toxic shock syndrome, 
surgical wound infection, and toxic epidermal necrolysis among others.  
 
The treatments of choice for infection caused by S.aureus are penicillinase stable penicillins, 
since over 80% of hospital isolates are beta-lactames producers. (29, 30) The other challenge 
for treatment is methicillin resistance which has shown to be >30% in South African 
hospitals. (31) For these, vancomycin is indicated, but unfortunately emergence of 
vancomycin resistant S. aureus has been observed. (Chapter 6, table 6.2) The high rates of 
methicillin resistant isolates in many hospitals, is a major public health issue due to clinical 
implications of managing MRSA in the face of high resistance of first line treatment. This 
calls for active enhancement of surveillance of antimicrobial resistance among hospital 
isolates of S. aureus bacteria. 
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1.4.1.2 Klebsiella  
Organisms belonging to the genus Klebsiella are capsulated, Gram negative rods, non-motile, 
approximately 1-2 µm in length (Figure 1.2). The capsule gives the mucoid appearance of 
isolated colonies and enhances virulence of organisms in vivo. Klebsiella genus belongs to 
the Enterobacteriaceae family, and the organisms are aerobic or ‘facultatively anaerobic’, 
ferment glucose and produce catalase but not oxidase. Hence the species and genera of the 
family of Entrobacteriaceae can be distinguished from each other by using biochemical tests 
in the clinical microbiology laboratory. The most commonly isolated members of this genus 
are K. pneumoniae and K. oxytoca, the latter being occasionally encountered in clinical 
specimens. (29, 30). The organisms grow at temperatures between 12
o
C to 43
o
C, and are 
found in the normal flora of the mouth, skin, and intestines. 
 
Figure 1.2 Microscopic appearance of encapsulated non-motile rod-shaped Klebsiella 
pneumoniae bacterium (Adapted from www.microbiologyinpictures.com/klebsiellapneumoniae.html) 
Klebsiella pneumoniae is clinically the most important member of the Klebsiella genus of the 
Enterobacteriaceae. It is common cause of infections among immunocompromised 
hospitalised individuals. The organism causes among others the following illnesses: severe 
bronchopneumonia, bacteraemia and meningitis, and milder wound and urinary tract 
infections etc. Mortality associated with illness such as bacteraemia is high. (29) However, 
the main relevance of this micro-organism in humans is that it commonly causes surgical 
wound infections, urinary tract infection and bacteraemia among hospitalised individuals. 
The challenge in clinical management of these micro-organisms is related to plasmid 
P a g e  |35 
 
  
mediated multiple antibiotic resistances, limiting the choice of effective antimicrobial agents. 
(30) Regular surveillance to determine patterns of antimicrobial resistance would assist to 
guide empirical treatment and improve treatment outcomes. 
 
1.4.1.3 Pseudomonas aeruginosa 
This micro-organism is non-spore forming, motile by means of polar flagella, non-capsulated, 
straight or slightly curved Gram-negative rods typically arranged in pairs (Figure 1.3). The 
size of the micro-organisms measures 0.5 to 0.8 µm by 1.5 to 3.0 µm. The micro-organisms 
are saprophytic and found mostly in soil, water, and other moist environments. P. aeruginosa 
is an opportunistic pathogen and patients usually become infected through contact and spread 
if exposed to environmental sites colonised by these bacteria. The micro-organism typically 
produces a blue green pigment (pyocyanin) and a yellow-green pigment (pyoverdin). (28-30) 
 
Figure 1.3 Appearance of Pseudomonas aeruginosa on Gram stain: rod-shaped cells 
arranged in pairs (Adapted from Todar’s online textbook of bacteriology) 
 
P. aeruginosa causes infections on the skin, burn wounds and nosocomial pneumonia in 
critically ill hospitalised individuals under intubation. In addition, P. aeruginosa can also 
cause bacteraemia, osteomylitis, endocarditis and urinary tract infection. P. aeruginosa is a 
common pathogen that causes nosomial infection among hospitalised individuals, and is a 
major lung pathogen among patients with cystic fibrosis. (30) Infections caused by 
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P.aeruginosa are clinically challenging to manage owing to intrinsic resistance to multiple 
antibacterial agents and the pathogen has a strong ability to acquire resistance from other 
antimicrobials during the course of treatment, particularly with prolonged broad spectrum 
antibiotics. (29, 32) 
 
Owing to its inherent ability to develop resistance, effective monitoring patterns of resistance 
to antipseudomonal drugs would help to guide clinicians in their choice of antibiotics for 
empirical management of such infections, thereby enhancing infection control to minimise 
continued spread of resistant strains.  
 
1.4.2 Mechanisms of action for antibacterial agents 
Effectiveness of antibacterial agents can be sub-classified into four modes of action: i) 
interference with cell wall synthesis; ii) inhibition of protein synthesis; iii) interference with 
nucleic acid synthesis; iv) interference with the integrity of bacterial cell and outer 
membranes. (33) Antibacterial agents including beta-lactams comprising penicillins, 
carbapenems, cephalosporins, monobactams as well as glycopeptides which includes 
vancomycin and teicoplanin, exert their antibacterial effect through inhibition of bacterial cell 
wall synthesis. (33, 34). The beta-lactams inhibit bacterial cell wall synthesis through 
interfering with enzymes required for the synthesis of the peptidoglycan layer. Glycopeptides 
such as vancomycin and teicoplanin hinder bacterial cell wall synthesis through binding to 
the terminal D-alanine residues of the nascent peptiglycan chain creating an inability for the 
cross linking steps that are required for stable bacterial cell wall synthesis to take place. (34) 
Other antibacterials such as aminoglycosides, macrolides, tetracyclines, chloramphenicol etc. 
produce their antibacterial effect through inhibiting bacterial protein synthesis. (33, 34) 
Bacterial ribosomes differ in structure from their counterparts in eukaryotic cells as such 
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antibacterial agents make use of these differences to selectively inhibit bacterial growth. 
Antibacterial agents such as tetracyclines and aminoglycosides bind to the 30S subunit of the 
ribosome, and agents such as macrolides and lincomycin as well as chloramphenicol binds to 
the 50S subunit. 
Antibacterial agents in the fluoroquinolone group produce their antibacterial effect through 
disruption of DNA synthesis by DNA gyrase and topoisomerase IV enzymes, causing lethal 
double-strand DNA break during DNA replication process. (35) Others such as 
sulphonamides and trimethoprim interfere with folic acid synthesis leading to inhibition of 
DNA synthesis. The trimethoprim and sulfamethaxazole combination inhibits two steps in the 
enzymatic pathway for folic acid synthesis by bacterial cells. This dual combination 
potentiates the antibacterial activity of one another through synergistically acting against an 
array of pathogenic bacteria. (36) Lastly, disruption of bacterial membrane structure is 
another recognised mechanism of action and forms the basis for the action of polymyxins. It 
is hypothesised that polymyxins exert their inhibitory effects through increasing bacterial 
membrane permeability leading to leakage of bacterial contents and eventual death of 
bacterium. (37) 
 
1.4.3 Mechanisms of Antibacterial Resistance 
There are a variety of mechanisms by which bacterial can manifest resistance to antibacterial 
therapy. The following are some of the ways bacteria can manifest resistance: i) The bacteria 
might acquire genes encoding enzymes, such as beta-lactamases, which are enzymes that 
neutralize the activity of beta-lactam molecules before they exert their effects against 
susceptible bacteria; ii) The bacteria might acquire efflux pumps that remove the antibacterial 
agent from the bacterial cell before it reaches and exerts its effect at its target site; iii) The 
bacteria might acquire genes for a metabolic pathway that eventually produces altered 
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bacterial cell walls that no longer contain the binding site of the antibacterial agent or the 
bacteria might acquire mutations affecting ribosomes which might limit access of 
antibacterial agents to their intracellular target sites. (38) In this situation, bacteria that are 
normally susceptible might acquire resistance to antibacterial agents through mutation and 
selection or through acquiring from other bacteria the genetic information that encodes 
resistance. This might occur through genetic transfer mechanisms that includes 
transformation, transduction or conjugation. (38) 
 
Bacteria susceptible to antibacterial agents can acquire resistance via new mutations. (34) 
These bacterial cell mutations might cause resistance through: i) altering target protein to 
which antibacterial agents binds through modifying the nature of the binding sites (such as a 
change in penicillin-binding protein 2b in pneumococci that results in pneumococcal 
resistance to penicillin by homologous recombination of DNA from oral streptococci and not 
by mutation); ii) up regulating the production of enzymes that inactivate the antimicrobial 
agents (for example erythromycin ribosomal methylase in staphylococci and more 
importantly, beta-lactamases and cephalosporinases that hydrolise beta-lactam agents acting 
on bacterial cell wall synthesis); iii) down regulating or altering an outer membrane protein 
channel that antibacterial agents require to gain entry into the cell (for example, OmpF porin 
in E. coli for fluoroquinolone resistance); iv) up regulating efflux pumps that drive out 
antibacterial compounds from the bacterial cell ( i.e. efflux of fluoroquinonolones in S. 
aureus and P. aeruginosa). (34) 
In all the scenarios presented above, bacterial strains carrying resistance-conferring mutations 
are selected through antibacterial use that selectively kill susceptible strains and allows the 
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new resistant strains to survive and multiply. This phenomenon of acquired resistance that 
develops as a result of chromosomal mutation and selection is called ‘vertical evolution’. 
In addition, bacterial pathogens also develop resistance through acquisition of new genetic 
material from other resistant organisms, a process called ‘horizontal evolution’ or horizontal 
gene transfer of resistance. In this case also, as is the case with vertical evolution, 
mechanisms of genetic transfer include: conjugation, transduction and transformation. For 
each of these mechanisms, transposons, plasmids, or integrons might facilitate transfer of 
resistance genes between bacterial strains or species, leading to acquired resistance. (34) 
Mutation and selection, together with the mechanisms of genetic exchange, enable many 
bacterial species to adapt quickly to the introduction of antibacterial agents into their 
environment, developing antibacterial resistance in the process. 
 
1.4.4 Overview of studies quantifying impact of nosocomial infections 
Nosocomial infections, also called “hospital-acquired infections”, are infections acquired 
after more than 48 hours of patient admission in the hospital and such infections should not 
be present or incubating at the time of admission. (39) Nosocomial infections are an 
important cause of morbidity and mortality and have become a major focus of infection 
prevention across the globe in recent times. (40) Such infections are increasingly becoming 
important public health problems due to increasing economic impact in populations since 
such infections are associated with development of antimicrobial resistance to several drug 
classes. (41) 
 
Occurrence of nosocomial infection in hospitalised patients come as a result of 
interrelationship of several factors including, but not limited to: compromised immunity 
among patients; invasive surgical/medical procedures; poorly ventilated and overcrowded 
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hospital wards. In addition, transmission of infection in hospitals can also be facilitated by 
poor infection control practices. Nosocomial infections are one of the leading causes of death 
(42-48) and are associated with high economic costs due to long hospital stay. (49-51) 
 
Previous studies documented prolonged duration of hospitalisation due to acquisition of 
nosocomial infections. (48) Prolonged hospital stay increases direct hospital costs and 
indirect costs due to loss of work resulting from unproductivity of the patient. Prolonged 
admission is directly linked to increase in drug use, requests for additional laboratory and 
other diagnostic tests, as well as nursing-related and other costs which all lead to increased 
financial burden.  
 
The selective pressure of intense antibiotic use promotes emergence of antibiotic resistance, 
(49-51) underpinning the importance of antimicrobial stewardship that would enhance 
prudent use of antibiotics. (52, 53) This underscored the need for an extensive investigation 
into current trends of antimicrobial susceptibility among common nosocomial pathogens. 
Therefore performing an analysis of laboratory-based surveillance data aggregated from 
various participating clinics/hospitals through an electronic surveillance system is an ideal 
approach to unravel antimicrobial resistance patterns and trends over time in health care 
settings. (41) Such information would guide establishment of appropriate and effective AMR 
control measures. 
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1.4.5 Laboratory Information System  
 
1.4.5.1 Definition 
A laboratory information system (LIS) is a computer-based application software product that 
is used in the laboratory to manage analyses and standard samples, tests results, laboratory 
staff and analytic equipment, as well as for the purpose of generating commercial reports and 
other functions. (54) In this thesis LIMS (Laboratory information management system) and 
LIS will be used interchangeably as the two terms have subtle differences when used in 
certain contexts. 
 
The roots of LIMS were in laboratory automation. (55) The standardisation and updating of 
the medical laboratory testing procedures are the fundamental guarantees to the quality of test 
results. Therefore, LIS is formed from the connection of a variety of analytical instruments 
based on the network information system software, and its quality control function should 
meet the requirements of clinical laboratory quality assurance. LIS is a powerful software 
system and include a series of functions such as patient information database, data reception, 
quality control data management, data analyses and laboratory management. LIS has played 
an important role in laboratory management and improving the efficiency of laboratory 
routine work and ensure the reliability of laboratory data. (56) 
 
1.4.5.2 Objectives of LIMS  
The objectives for the establishment of LIMS were: i) to increase productivity, ii) to enhance 
laboratory compliance with Good Laboratory Practice guidelines, iii) to eliminate calculation 
and transcription errors, iv) to achieve automated generation of reports and integration with 
word processing, v) to speed up the interpretation of data, vi) to bar code labels for samples 
and rapid data entry, vii) to verify data entry, viii) to achieve a flexible and expandable 
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system, xi) for the system to incorporate sample tracking and scheduling, x) to accommodate 
on-line access to historical analytical data. (57) 
 
1.4.5.3 Historical basis 
The development of LIMS has spanned over 30 years. The first of such systems were 
chromatography data systems, developed and introduced by major manufacturers of analytic 
equipment’s such as Hewlett Packard, Perkin Elmer, and Beckmann Instruments. (54, 55) 
Introduction of computer technologies in late 1970s and early 1980s enhanced the process of 
laboratory information management. The technology of LIMS developed from in-house 
software products aimed to meet certain needs. There are now over 100 firms across the 
globe that produces such software products and utilise a number of specification documents 
such as standards for LIMS that regulate their activity. (58) 
 
1.4.5.4 Main Functions 
The main functions of LIS are operated interactively on a mini computer which enables the 
laboratory complete control over daily processing. Collection of results from automated 
analysers is accomplished via a micro-processor network. Links are provided to a central 
main frame computer for immediate patient on-line identification and historical data 
processing. LIS is designed to manage all the operations involved in laboratory activities; in 
our situation we can give an example of the central computer as the Corporate Data 
Warehouse (CDW). The system has 14 main components, as outlined below. (59) 
1. Registration of test requests  
2. Production of specimen collection sheet and identification labels  
3. Confirmation of specimen collection  
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4. Production of aliquot labels  
5. Work load inquiry 
6. Production of worksheet  
7. Manual entry of test results entry 
8. Automated entry of test results 
9. Results inquiry 
10. Preliminary report 
11. Final report 
12. Daily activities reports 
13. Statistical reports 
14. Billing 
 
The main functions of LIS are as listed above. Functions 1, 3, 7 and 8 are the main input 
processes. They are used to select tests to be done according to the request form, to notify 
when the necessary specimen becomes available, and register the corresponding test results 
after analysis.  
 
The collection sheet includes specimen identification labels to be put onto specimen tubes. 
The collection sheet, identification labels, aliquot labels, and worksheet are designed to 
diminish clerical work in the laboratory as well as in laboratory-related activities. All the 
above functions are used intensively during daily routine along with maintenance functions 
like test request collection. Statistical reports and billing are produced on a periodical basis.  
 
The mini computer software is designed in a modular manner. Most features of the system 
can, therefore, be adapted to the needs of the user by setting the proper information in the 
corresponding module and this can be accomplished without any change to the program code. 
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Furthermore, the user can make the system evolve with changing needs, altering the 
parameters value. (59) 
 
1.4.5.5 System security 
To safeguard the LIS, the system security is provided along the following lines: data entry 
validation, system access control and memory protection. 
 
1.4.5.6 Main advantages  
The main advantages of LIS that could be realised by the laboratories include: i) reduced 
clerical workload; ii) improved evaluation of workload, iii) faster communication, iv) 
improvement of information given to clinicians: adapted reference values, interpretation, 
comments, v) improved retrieval operations, vi) faster billing; data storage, ease of data 
manipulation and data integrity. All this together produces increased productivity of the 
laboratories.(57, 59) Details of LIMS work flow are presented in figure 1.4 below. 
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Figure 1.4 Schema representing generic LIMS work flow. 
 
Figure 1.4 reproduced with permission from Christine Paszko, Ph.D., Vice President of Sales & Marketing, 
Accelerated Technology Laboratories, Inc., West End, NC 27376 (Email address: CPaszko@atlab.com) 
 
1.4.5.7 Public Health Function of LIS 
In industrialised countries, LIS is a component of the clinical and public health laboratory 
infrastructure. The system helps to monitor disease profiles, including chronic and infectious 
diseases, but can also be used to monitor development of antimicrobial resistance through 
standardised and integrated laboratory-based surveillance. A properly-designed health 
management information system (HMIS) comprising of reliable, accurate and timely 
available data is widely viewed as the pillar of a good public health system.  
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Integrating the LIS into HMIS can effectively support several public health functions and 
programs such as epidemiology, surveillance and monitoring, assessment of outcomes, policy 
analysis, research, program planning and evaluation among others. (41, 60, 61) A LIS is 
therefore crucial as a system capable of maintaining an integrated data flow between various 
health facilities e.g. focusing on diseases of outbreak potential, but can also facilitate prompt 
delivery of results to clinical care providers at all levels of care. Through a reliable 
computerised system for laboratory data entry, access and retrieval of data would be ideal in 
addressing important issues, such as sample tracking, automated delivery of patient reports as 
well as generation of aggregate reports among other functions. (62) 
 
In this regard, data from an integrated network of NHLS clinical laboratories using an 
electronic surveillance system that collects microbiological data from all clinical 
microbiology laboratories across the Republic of South Africa could be a reliable source of 
data for analysis. This would include comprehensive information that could provide valuable 
insights into patterns, trends over-time and prevalence of important micro-organisms 
associated with antimicrobial resistance problems. Good examples would be S. aureus, K. 
pneumoniae and P. aeruginosa micro-organisms, which could serve as indictator bacteria for 
antimicrobial resistance surveillance in hospital settings. Such surveillance would allow 
investigating the extended spectrum beta-lactamase (ESBLs), methicillin-resistant S. aureus 
(MRSA) and other multidrug resistance patterns and trends according to patient location, 
geographic distribution and specimen source. A well established LIS would therefore, in the 
long run, improve health system functions and delivery of quality care through strengthening 
larger public health systems and ensure proper utilisation of data for better clinical as well as 
public health outcomes. (41, 62) Figure 1.5 below illustrates the critical steps for the 
implementation of an effective nationwide LIS. 
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Determine functional
 requirements at 
typical sites
1
Form Working 
Group
7
Negotiate 
Provider contact
8
9
Initiate project,
LIS changes and 
system validation
Deploy LIS and
plan for next
phases of project
Develop RFP using
HLR template
6
Distribute RFP and
select provider
4
Define scope and
needed resources
5
3
Decide standard or
rapid methodology
 
Figure 1.5 Critical steps to implement an effective LIS nation wide. HLR: High Level 
Requirements; RFP: Request For Proposal 
 
Adapted from: Guide book for Implementation of Laboratory Information Systems in Resource Poor 
Settings. Association of Public Health Laboratories Publication, January 2006 (41) 
 
1.4.6 Surveillance Systems for Antimicrobial Resistance 
Public Health Surveillance is defined as the ‘ongoing and systematic collection, analysis and 
interpretation of outcome-specific data essential to the planning, implementation, and 
evaluation of public health practice, closely integrated with timely dissemination of these 
data to those who need to know; and the application of these data to the control and 
prevention of human disease and injury’. (63) Even though few international antimicrobial 
resistance surveillance initiatives seem to correspond to this definition (17), in the context of 
this definition, major challenges exist including lack of appropriate denominator data. In 
addition variation in blood culture taking practices when LIS is based on bacteraemic 
episodes, are barriers to the establishment of an effective surveillance system and is viewed 
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to be a low-cost tool used to generate locally valuable information on antimicrobial resistance 
profiles. The ideal surveillance system therefore, can also function as a quality assurance tool, 
bridging standardized reporting and methodological issues in identification of resistant 
pathogens as well as improve the quality of antimicrobial susceptibility testing. (64) 
 
1.4.6.1 Surveillance Initiatives for antimicrobial resistance in South Africa 
For many years, South Africa has had no active and functional national electronic 
surveillance system for monitoring antimicrobial resistance in hospital acquired infections. 
The South African Antibiotic Stewardship Programme (SAASP) has been instrumental in 
reinforcing the prudent use of antimicrobials through the antimicrobial stewardship. Some 
issues on how to contain resistance have been previously handled by the South African 
Society of Clinical Microbiology, formerly National Antimicrobial Surveillance Forum 
(NASF). This grouping has been involved in passively collating antimicrobial data in public 
and private health care sectors. An established entity within NHLS situated at the National 
Institute for Communicable Diseases (NICD) called the Group for Enteric, Respiratory and 
Meningeal diseases Surveillance (GERMS-SA) operating in all of the nine provinces also 
focuses on surveillance of community-acquired pathogens and monitors resistance profiles. 
Another initiative was introduced in KwaZulu-Natal (KZN) for surveillance of E. coli in 
2000/2001 (65) and also the Veterinary Surveillance of Antimicrobial Resistance in South 
Africa. (66) 
 
As of 2010, the Antimicrobial Resistance Surveillance and Research (ARSR) within the 
Centre for Opportunistic, Tropical and Hospital Infections was established at NICD to run an 
active laboratory based surveillance system for monitoring resistance to nosocomial 
pathogens realizing the increasing burden of hospital acquired infections commonly 
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associated with high rates of resistance. These are the main initiatives undertaken towards 
continued monitoring of antimicrobial resistance in South Africa.  
 
1.4.6.2 International surveillance networks for antimicrobial resistance 
Increasing antimicrobial resistance poses a major threat to global public health. Therefore, 
collective action is required to secure an effective multinational antimicrobial surveillance 
system to monitor the antimicrobial resistance profile and ensure rational use of 
antimicrobials. (67) The global antimicrobial resistance challenge, equally requires a 
concerted multinational force. This is in view of the negative impact of globalization at 
spreading infectious diseases vis-à-vis spreading of antimicrobial resistance. (16, 68) No 
country acting independently can effectively contain antimicrobial resistance.  
 
It was in this context that the Global Antibiotic Resistance Partnership (GARP) initiative was 
established so that countries could actively work together to generate surveillance data that 
could be analyzed to predict or show trends of antimicrobial resistance. (69) The SENTRY 
Antimicrobial Surveillance Program was instituted in 1997 to monitor trends in antimicrobial 
resistance patterns in nosocomial and community-acquired infections worldwide so as to 
define appropriate control measures for antimicrobial-resistant pathogens. (70) The 
Alexander Project, an international surveillance network examining trends and patterns of 
antimicrobial susceptibility for community-acquired respiratory tract infections, begun its 
work in 1992. (71-76) The European Antimicrobial Resistance Surveillance System (EARSS) 
(77) currently known as the European Antimicrobial Resistance Surveillance Network 
(EARS-Net) (78), founded in 1998, is a pan European antimicrobial surveillance network 
which has been focussing on major invasive pathogens of clinical and epidemiological 
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relevance and provides antimicrobial resistance data that are validated and comparable across 
the network. (79) 
 
The World Health Organization (WHO) has over the years instituted several antimicrobial 
resistance surveillance networks to contain development and global spread of antimicrobial 
resistance. (15, 16, 60) These include a Collaborating Centre for Surveillance of 
Antimicrobials (CCSA), which was instituted for the purpose of monitoring trends of 
antimicrobial resistance among various bacterial pathogens; (60) such as the Gonococcal 
Antimicrobial Surveillance Programme (GASP), initiated to contain antimicrobial resistance 
encountered in gonococci infections and the WHONET software designed for management 
and analysis of antimicrobial resistance data. (80) 
 
The initiatives detailed above are among the most well known initiatives that have been 
established to monitor and provide objective data on antimicrobial resistance trends and 
profiles, in order to use such data to develop strategies to contain the continued development 
and spread of antimicrobial resistance around the globe. Table 1.1 provides a detailed 
overview of major national and international surveillance networks established for purposes 
of antimicrobial resistance surveillance. 
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Table 1.1 Major Surveillance Networks for Antimicrobial Resistance 
 
Name   Acronym Pathogens involved Web address Extent of 
Surveillance 
European Antimicrobial 
Resistance Surveillance System 
EARSS S. pneumoniae, S aureus, 
Enterococcus, E. oli, 
K.pneumoniae, 
P.aeruginosa. 
http://earss.rivm.nl/ Pan-European 
The Surveillance Network –USA  TSN S. aureus http://eurofinsmedinet.com USA, Europe 
Canadian Bacterial Surveillance 
Network 
CBSN S. pneumoniae, 
H.influenzae 
 
 
http://microbiology.mtsinai.on
.ca/research/cbsn 
Canada 
World Health Organization:  
 Centre for Surveillance of 
Antimicrobial Resistance 
 WHONET software 
 
 
 Surveillance of 
antimicrobial resistance 
 
 Gonococcal Antimicrobial 
Surveillance Programme 
 
 
WHO 
 
 
 
 
 
 
 
 
 
GASP 
 
 
Various Pathogens 
 
 
An information system for 
monitoring antimicrobial 
resistance 
 
 
 
 
Neisseria gonorrheae only  
 
 
http://who.int/drugresistance 
 
http:/who.int/drugresistance/w
honetsoftware/en/ 
 
http://who.int/drugresistance/s
urveillance/en/ 
 
 
http://who.int/hiv/strategic/sur
veillance/en/gasp1998.pdf 
 
 
International 
Antimicrobial Surveillance 
Program for Asia-Pacific region 
& South Africa 
SENTRY S. pneumoniae,  
H. influenzae,  
M. catarrhalis 
http://health.gov.au/internet/m
ain/publishing.nsf/Content/cda
-pubs-cdi-2003-cdi27suppl-
htm- 
International 
Centres for Disease Control  
 National Antimicrobial 
Resistance Monitoring 
System 
 National Nosocomial 
Infections Surveillance 
System 
 
 
NARMS 
 
 
 
NNIS 
 
 
For enteric bacteria 
 
 
Only isolates associated 
with nosocomial infections 
http://cdc.gov/narms/ 
 
 
 
 
USA 
Alexander Project  For community acquired lower  respiratory tract pathogens  International 
 
Surveillance Initiatives for Antimicrobial Resistance in South Africa 
Group for Enteric Respiratory 
and Meningeal Pathogens  
GERMS-
South Africa 
For community acquired and 
hospital pathogens 
http://nicd.ac.za/units/germs
/germs.htm 
National/South 
Africa 
South African Society of 
Clinical Microbiology 
SASCM Monitoring of antimicrobial 
resistance patterns in the 
public and private medical 
sector in South Africa 
http://fidssa.co.za/A_NASF
_Overview.asp 
National/South 
Africa 
Veterinary Surveillance of 
antimicrobial resistance in South 
Africa 
  http://www.ncbi.nlm.nih.go
v/pubmed/15580774 
National/South 
Africa 
Global Antibiotic Resistance 
Partnership  
GARP Global antimicrobial 
resistance monitoring 
initiative  
http://resistancestrategies.or
g/wpcontent/uploads/2010/0
4/GARP-SA-8-9-Feb-
Agenda.pdf 
International 
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1.4.7 Surveillance of selected pathogens of Clinical and Epidemiological 
Relevance 
1.4.7.1 Methicillin-resistant S. aureus (MRSA) 
Data are scarce on the antimicrobial susceptibility profiles of South African MRSA isolates 
in both public and private health care systems. The Marais et al, study which is the first report 
on antimicrobial susceptibility patterns in MRSA isolates in South Africa, showed antibiotic 
resistance of MRSA ranging between 55% and 78% to tetracycline 
trimethoprim/sulfamethoxazole, erythromycin, gentamicin and ciprofloxacin, respectively. 
All isolates in this study were susceptible to teicoplanin, linezolid, vancomycin and 
quinopristin/dalfopristin. (26) It was therefore imperative to establish MRSA prevalence in 
South Africa.  
 
As a step in that direction, the Antimicrobial Resistance Surveillance and Research (ARSR) 
unit was initiated at the National Institute for Communicable Diseases with a goal to 
determine the proportion of S. aureus strains resistant to methicillin in blood isolates from 
tertiary public hospitals associated with academic institutions in South Africa. The ARSR 
performs minimum inhibitory concentration (MIC) determinations of vancomycin against S. 
aureus strains, using the micro-dilution, agar-dilution or Etest methods. These methods are 
also used to determine the susceptibility of isolates to rifampicin and linezolid which are the 
most common alternative treatment options for MRSA. The key element would be to report 
antimicrobial susceptibility test (AST) results on the primary isolate from the blood specimen 
obtained during a bacteraemic episode which on identification proves to be a coagulase-
positive S. aureus. (77, 81) 
 
For reliable results of MRSA susceptibility testing, protocol recommends the use of a 
cefoxitin disk diffusion test or to alternatively use the oxacillin agar screen plates or the 
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oxacillin disk diffusion test even though the latter is less reliable. It is recommended that 
participating laboratories in the antimicrobial resistance (AMR) surveillance program report 
susceptible, intermediate or resistant (S/I/R) isolates tested on the basis of Clinical and 
Laboratory Standards Institute (CLSI) guidelines including interpreting the MIC or zone 
inhibition diameter if at all possible. Invasive S. aureus isolates from blood should be 
reported per patient per quarter. There is no need to report a second isolate during a febrile 
episode, even if the susceptibility pattern is different from that of the first isolate. (77) 
 
1.4.7.2 Klebsiella pneumoniae and extended spectrum beta-lactamases (ESBLs)  
There is a paucity of data on antimicrobial susceptibility profiles of blood culture isolates of 
Klebsiella pneumoniae in the South African public health care system. Brink et al, were the 
first authors to report on antimicrobial susceptibility of blood culture isolates in private sector 
hospitals in South Africa and they showed that the overall proportion of resistance to 
Escherichia coli blood culture isolates to ampicillin and fluoroquinolones was 84% and 20% 
respectively, and a further 5% of ESBL production among all isolates of E. coli in private 
health care institutions. Even though E. coli is important, our primary focus would be on K. 
pneumoniae, a Gram-negative bacterium and the main producer of extended spectrum beta-
lactamases (ESBLs). (27) Information on levels of resistance to conventional antibiotics is 
essential for public sector health care institutions in South Africa, as it would help guide 
appropriate empirical therapy for invasive bacterial infections.  
 
Successful antimicrobial resistance surveillance (AMRS) requires reliable reporting of AST 
results for the primary isolates of K. pneumoniae from blood culture per each patient 
investigated. If the antimicrobial resistance surveillance were to succeed, regular reporting to 
monitor susceptibility patterns of such invasive organisms is vital. Ideally, the first invasive K 
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pneumoniae isolate from blood per patient per quarter should be reported, and differences in 
susceptibility patterns in blood culture isolates need to be noted and reported. (77) 
 
1.4.7.3 Pseudomonas aeruginosa 
There are scanty data available on antimicrobial susceptibility patterns of isolates of 
Pseudomonas aeruginosa in public health care institutions in South Africa. A study done by 
Perovic et al, at an academic hospital in Johannesburg, South Africa showed an association 
between P. aeruginosa bacteraemia and outbreaks caused by multiple-resistant genotypes. In 
this study, 57.1% of the patients had a nosocomially-acquired infection. (82) The prevalence 
and extent of antimicrobial resistance among P.aeruginosa bacteria in public sector health 
care institutions in South Africa still remains unknown, since the Perovic et al, study only 
looked at data from 1998-1999 and this is over a decade ago. The resistance profiles and 
incidence of disease might have changed with time and the current status might be different. 
For the AMRS program to be effective, it is required to report AST results for the primary 
isolates of P. aeruginosa from blood cultures per each patient investigated. (77) 
 
1.5 Research Question 
This study was set to answer the question “Can the NHLS DISA laboratory information 
system or equivalent be utilized for surveillance of antimicrobial resistance for nosocomial 
pathogens in public tertiary hospitals in South Africa?” 
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1.6 Aim of the study 
The aim of this thesis is to assess utilization of the LIS at NHLS, as a tool for reporting 
antimicrobial resistance (AMR) and monitoring resistance patterns and trends over time, for 
clinical blood culture isolates of Staphylococcus aureus, Klebsiella pneumoniae, and 
Pseudomonas aeruginosa isolated from patients admitted in tertiary public hospitals in South 
Africa.  
 
1.6.1 Specific Objectives 
The specific objectives are outlined below with a description of how they were studied: 
 
1. Conduct a systematic review with the aim of finding out the prevalence of antimicrobial 
drug resistance among S. aureus, K. pneumoniae, and P. aeruginosa from published 
literature, and to understand whether or not such data were part of an ongoing 
surveillance system for nosocomial infections in South Africa. 
 
2. Perform a critical analysis of the utility of LIS of the NHLS as a surveillance tool for 
antimicrobial resistance profiles in selected nosocomial pathogens (isolated during 
bacteraemic episodes from blood cultures of patients in tertiary public hospitals in South 
Africa, retrieved from the Central Data Warehouse (CDW) of the NHLS from Mid 2005 
to December 2009): 
i) Describe the strengths and limitations of the use of routine laboratory data relating to 
blood culture isolates of the selected pathogens through assessing simplicity, 
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flexibility, data quality, acceptability, sensitivity, positive predictive value, 
representativeness, timeliness, completeness and stability. 
ii) Assess laboratory methods and how they would impact on antimicrobial resistance 
surveillance.  
 
3. Evaluate the suitability of the NHLS LIS as a monitoring tool for recording antimicrobial 
resistance trends and patterns in tertiary public hospitals in South Africa. To achieve this, 
we carried out data analysis to: 
i) Describe the demographic profile of patients with clinical isolates of selected 
pathogens admitted in tertiary public hospitals in South Africa, from mid 2005 to 
December 2009. 
ii) Determine antimicrobial resistance patterns of selected pathogens at different tertiary 
public hospitals in South Africa, from mid 2005 to December 2009. 
iii) Detect emergence of resistance and monitor trends over time of antimicrobial 
susceptibility of selected pathogens in tertiary public hospitals in South Africa from 
mid 2005 to December 2009. 
iv) Describe the potential pitfalls of the LIS as a surveillance tool for monitoring 
antimicrobial resistance using CDW data from mid 2005 to December 2009. 
 
4. Compare prospectively antimicrobial resistance data submitted from tertiary public 
hospitals to the ARSR Unit over a 12-month period, from July 2010-June 2011 (as the gold 
standard) with antimicrobial resistance data retrieved from the CDW for the 2005 to 2009 
period. To achieve this objective we aimed to specifically:  
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i) Determine the proportion and patterns of antimicrobial resistance of selected 
pathogens over a 12 months period in tertiary public hospitals in South Africa 
between 1
st 
July 2010 and 31
st
 June 2011. 
ii) Compare patterns of antimicrobial resistance data to various antimicrobials that are 
commonly used in hospitals from July 2010 to June 2011 period, with retrospective 
(2005 to 2009) period, so as to ascertain reliability of routine data sources. 
 
5. Describe how the question of AMR surveillance is being dealt with in another African 
country such as Tanzania, in East Africa. 
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Chapter 2 Study Methods 
 
In this chapter, a detailed outline of the general study methods is provided, which consists of 
an in-depth description of the laboratory based investigation, the study design, sampling, data 
acquisition from the CDW, data management, data analysis methods, ethical consideration 
for use of secondary data as well as general limitations of the study methods.  
 
2.1 Laboratory based surveillance 
Pathogens isolated from blood were tested for susceptibility to commonly used antimicrobial 
agents at NHLS laboratories. These were preferred as the sensitivity at identifyinbg 
pathogenic bacteria is higher than other specimens. Susceptibility testing was performed in 
tertiary hospitals using existing methods such as disk diffusion and/or in vitro minimum 
inhibitory concentration (MIC) determinations, with internationally accepted breakpoint 
concentrations denoting susceptibility, intermediate resistance and full resistance. 
Antimicrobial susceptibility of these pathogens was assessed using the following 
antimicrobials agents: broad spectrum penicillins, including amino-ureido - and isoxazolyl 
penicillins, carbapenems and ß-lactamase inhibitors plus ß-lactam antibiotics, 3rd generation 
cephalosporins, fluoroquinolones, aminoglycosides, glycopeptide, chloramphenicol and 
trimethoprim/sulphamethoxazole. (26, 82) 
 
2.2 Study design and setting 
This was a retrospective record review covering the period 2005 to 2009 with a prospective 
component conducted during period July 2010 – June 2011 that used data of clinical isolates 
of selected bacterial pathogens collected at seven NHLS sites situated at tertiary public 
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hospitals linked to academic institutions in three provinces in South Africa. The sites were: i) 
from Gauteng Province, Charlotte Maxeke Johannesburg Academic (CMJAH), Chris Hani 
Baragwanath (CHBH), Helen Joseph (HJH), Steve Biko Academic Hospital (SBAH) linked 
to Witwatersrand and Pretoria Universities; ii) from Free State Province, Universitas Hospital 
linked to the Free State University; iii) from Western Cape Province Hospitals, Groote 
Schuur Hospital (GSH), and Tygerberg Hospital (TH) linked to Cape Town and Stellenbosch 
Universities, respectively.  
 
Two criteria were used in determining inclusion of laboratories into this study i) that they 
were linked to reputable academic institutions (Wits, UCT, Free State, SUN, UP) with good 
quality assurance practices of laboratory methods likely to yield reliable results as well as 
computerised laboratory systems from which data required for the present study could be 
readily accessed; ii) laboratories that were interfaced to the CDW in Johannesburg and are 
part of the NHLS but also cover a wider spectrum of patients infected with the three selected 
organisms exhibiting antimicrobial resistance. The map below (Figure 2.1) highlights 
population size of each province that formed part of our population from which the 
bacteraemia patients were drawn. The population size might have been a determinant of the 
number of isolates from each province, with more isolates coming from Gauteng, then 
Western Cape and lastly Free State.  
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Fig: 2.1 Map of the Republic of South Africa showing population distribution in each 
Province 
 
2.3 Sampling and sample size 
The study used all records of blood culture isolates from the seven hospitals submitted to and 
reported by the NHLS laboratories from the aforementioned sites from July 2005 to 
December 2009 (objective 3), and July 2010 to June 2011 (objective 4). All entries in the 
database with information on susceptibility test results were used to analyse patterns of 
antimicrobial resistance. 
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2.4 Data Collection 
For the retrospective study, data of blood culture isolates of selected pathogens were 
extracted from the Corporate Data Warehouse (CDW). The following variables were 
included: age, gender, geographical location, province, hospital name, year of entry, name of 
organism, antibiotics used for susceptibility testing and susceptibility results of each 
antibiotic tested. For the prospective study, surveillance in real-time required collection of the 
actual data as they became available during the year concerned. However, in this study data 
of blood culture isolates were obtained from the ARSR and contained all variables as outlined 
for the retrospective study above except year of test as data were collected only over a 1 year 
period.  
 
2.5 Data Management 
This part of the methods section is presented in three sections: Section 2.5.1 and 2.5.2 looks 
at how we managed the 2005 to 2009 blood culture data and section 2.5.3 deals with how the 
July 2010 to June 2011 blood culture data were managed.  
 
2.5.1 Data extraction for 2005-2009 blood culture data 
In this section we describe processes and procedures that were done, including programs used 
to extract data from the CDW and procedures describing how data were merged together to 
make a coherent single database in a flat file format.  
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Table 2.1 SQL statement programmed to extract data from the CDW 
 
SQL Statement 
--***** WO514421 Public Health 2005 to 2009 - changed to include bloods only 17th 
Nov**** 
select distinct t3.lab_no, t8.unique_patient_id, province, location_name, ward_name, 
tested_age_years, gender, specimen_type ,organism_name, drug_name, 
 decode(sensitivity, 'R', 'RESISTANT', 'S', 'SUSCEPTIBLE', 'I', 'INTERMEDIATE') as 
sensitivity,  taken_date, tested_date from  target.fct_sensitivity_results t3, 
target.dim_organisms t2, target.dim_drugs t4, target.dim_locations t6, 
target.dim_patient_specimens t8, target.dim_dates t1  
    where t3.organism_id = t2.dimension_key  
    and t3.drug_id = t4.dimension_key  
    and t3.location_id = t6.dimension_key 
    and t3.lab_no = t8.lab_no  
    and sensitivity in ('R', 'S', 'I') 
    and trunc(t3.taken_date) = t1.day  
    and reviewed_status_flag = 'REVIEWED' 
    and health_sector = 'PUBLIC HEALTH SECTOR' 
    and location_code in ('BAG', 'JOH', 'PRE', 'GRS', 'TYG', 'UNV') 
    and organism_code in ('STAAU', 'KLEPN', 'PSEAE') 
    and specimen_type in ('BLOOD', 'BLOOD AND CEREBROSPINAL FLUID', 'BLOOD 
CULTURE', 'FAN AEROBIC (BACT/ALERT BTL)', 'FAN ANAEROBIC 
(BACT/ALERT BTL)', 'MYCOLYTIC F (BACT/ALERT BTL)', 
'PAEDIATRIC (BACT/ALERT BTL)', 'STD AEROBIC (BACT/ALERT BTL)', 'STD 
ANAEROBIC (BACT/ALERT BTL)', 'VENOUS BLOOD') 
    and cal_year_number = 2005 --, 2006, 2007, 2008, 2009) 
    order by province, t8.unique_patient_id, t3.lab_no 
 
Table 2.1 highlights the exact SQL statement that was written and applied to the CDW 
repository to extract specific parameters of blood culture data required for analysis as 
outlined in section 2.5.1.2. Executing this query, blood culture data with specified parameters 
were extracted for each individual year 2005, 2006, 2007, 2008 and 2009, resulting in five 
data tables. For purposes of simplicity and comparison, these data tables were merged to form 
one single flat file. The step by step process of how five data tables were merged to form one 
single table for 2005 to 2009 is outlined below. 
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2.5.1.1 Combining NHLS Results Spreadsheets into One Microsoft Access Table 
Step 1: All excel worksheets were imported as single Microsoft Access tables. They were 
named 2005, 2006, 2007, 2008 and 2009 respectively. 
Step 2: A copy of the 2005 table was made and then renamed appropriately to 
“ALL_NHLS”. 
Step 3: An append query was create that appended the 2006 table to the 2005 table. The SQL 
view of the query “Append_2006” was appropriately viewed in access file. 
Step 4: The append query was then run. 
Step 5: Steps 3 and 4 were repeated for the 2007, 2008 and 2009 tables. The result was a 
single data table with all data values from 2005 to 2009. 
2.5.1.2 Querying: Antimicrobial Susceptibility by Specific Pathogens 
The query interrogated the database for records where the given pathogen, drug and 
resistance levels were available. Three queries were designed for the pathogens SA, KP and 
PA and as a researcher I needed to enter a specific antibiotic at run-time to get the relevant 
records for that particular medication that had undergone sensitivity testing. The following 
fields in excel spreadsheet were interrogated: i) organism_name, ii) drug_name, and iii) 
sensitivity. 
 
2.5.2 Data cleaning procedure for 2005-2009 dataset 
In this section we describe data manipulation and details of exclusion of duplicates as well as 
exclusion of records outside of the duration of the study.  
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Table 2.2 Processing of data after extraction from the CDW: 2005-2009 dataset 
 
Sample size attrition 2005 2006 2007 2008 2009 Overall 
Overall 
cleaned 
Start sample 9,528 25,151 25,497 23,467 22,371 106,014 106,014 
Following removal duplicates: 
patient id, organism, drug, taken 
date 8,087 21,946 21,535 20,257 19,546 91,371 91,371 
Following reshape (long to wide - 
drug and resistance) 900 2,500 2,423 2,655 2,378 10,856 10,856 
Remove repeat organism test for 
an individual within 21 days 744 2,120 2,055 2,238 2,068 9,225 9,218 
 
The start sample was the number of records extracted from the CDW data base in long 
format, after applying the SQL program. The data was in long format hence the numbers of 
records extracted were extensively exaggerated. The exact number was, however, obtained 
after reformatting the data structure from long format to wide format; so that each record had 
all its parameters in a single row compared to multiple rows for a single test result. At the 
end, after excluding all duplicates as well as those which had repeated blood culture tests 
within 21 days. Seven more records from 2004 (9218 records) were obtained and carried over 
for further analysis.  
Table 2.3 Stata output after adding omitted data from Helen Joseph hospital 
 
Data long -> wide 
-------------------------------------------------------------------------- 
Number of obs. 4880 -> 754 
Number of variables 10 -> 43 
j variable (35 values) drug -> (dropped) 
xij variables: 
r_ -> r_AMIKACIN r_AMPICILLIN ... r_VANCOMYCIN 
---------------------------------------------------------------------------
tab year 
       year |      Freq.     Percent        Cum. 
------------+----------------------------------- 
       2004 |          3        0.03        0.03 
       2005 |        812        8.14        8.17 
       2006 |      2,294       23.00       31.18 
       2007 |      2,209       22.15       53.33 
       2008 |      2,393       24.00       77.33 
       2009 |      2,261       22.67      100.00 
------------+----------------------------------- 
      Total |      9,972      100.00 
 ------------+----------------------------------- 
 
The first time the CDW data were extracted, blood culture data from Helen Joseph hospital 
were inadvertently omitted. Using a similar SQL program, data from Helen Joseph were 
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extracted and additional data (n=4880) were obtained. This data table was also restructured 
from long to wide format for drug profile and yielded 754 observations. This data was 
appended to the previous dataset with 9218 observations (Table 2.2, section 2.5.2) yielding a 
total of 9972 observations after ascertaining that no further duplicates were available in the 
dataset. Table 2.3 displays full dataset showing the yearly breakdown as well as appended 
dataset from Stata 12 outputs, after excluding 3 records from 2004, a total of 9969 records 
were analysed. 
2.5.3 Data cleaning procedure for 2010-2011 blood culture dataset 
This section provides a detailed outline of data cleaning and processing procedure of data that 
were extracted from the GERMS-SA database. We highlight details of exclusion of missing, 
non reference organism, as well as records outside of the study area and duration of the study. 
The procedure for data extraction for this particular dataset was the same as the one 
documented in section 2.5.1. 
Table 2.4 Data cleaning and processing after extraction from the GERMS-SA database: 
June 2010 to July 2011 dataset 
 
Sample size attrition FS GP KZN LP WC Overall 
Overall 
cleaned 
Start sample 407 4388 614 17 1520 6946 6946 
Following removal LP & 
KZN* 407 4388 - - 1520 6315 6315 
Following removal of hospitals 
not included in the study** 407 4384 - - 1513 6305 6305 
Following removal if missing 
or organism not Klebs/Staph!! 
     
6305 5004 
Following removal if year was 
2012 & organism not SA & 
KP! 
     
5004 3026 
 
*LP &KZN were not included in the study hence had to be excluded (631 observations omitted). 
**Excluded data from hospitals not part of the study 30, 40, 72 (10 observations omitted) 
!!Organism not Klebs or Staph species were excluded (1301 observations omitted) 
! Reference organism not KP &SA, and tested outside the study period < July 2010 & > June 2011(1978 observations 
omitted). 
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The start sample of 6946 isolates in table 4 highlights the total number of records that were 
extracted from the GERMS-SA database and presented as a flat file in excel spreadsheet. The 
data were then transferred into Stata version 12 for cleaning and further processing. The 
number of isolates totalling 6946 included data from outside of the study period (July 2010 to 
June 2011), as such, the number of records appears to have reduced dramatically after 
cleaning had been completed. The number of 3026 isolates (SA=1494, KP=1545) was 
obtained after exclusion of observations from provinces and hospitals that were not part of 
the study as well as observations with missing data on organism name or organism belonging 
to the reference species (SA & KP). In addition, organisms that were neither Klebsiella 
pneumoniae nor Staphylococcus aureus (i.e. K. oxytoca, K. terrigena, K. planticola, K. 
ozaenae) were also excluded from the dataset. In the end, 631 observations from KZN and 
LP were excluded, 10 observations from non-study hospitals were excluded, 1301 
observations with missing data on organism that did not belong to Klebsiella and 
Staphylococcus species were excluded, and 1978 isolates that were reported either before 
July 2010 or after June 2011 were also excluded. Therefore, a total of 3026 observations were 
carried over for further analysis of patterns of resistance and associated risk factors.  
 
2.5.4 Assessing completeness of data & importation to Stata software 
In this section we describe procedures followed for ascertaining reliability of data, cleaning 
data and importation of data to Stata for further analysis. Assessment of validity and 
reliability of the routine data was done by performing in-depth verification and quality 
analysis of available data from LIS. Missing information and errors on entry were 
investigated and assessed for completeness of data to be able to determine reliability of the 
data. As the opportunity to verify data with original data source was limited for the 
retrospective data, no attempt was made to do this. However, data that were entered 
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prospectively were interrogated to ascertain completeness through verifying missing data and 
uploading data directly from automated Micro Scan as a way of minimising incompleteness. 
The processing of data cleaning and verification of entries was done in MS Excel 
spreadsheets before exporting to Stata software version 12 (StataCorp Limited, College 
Station, Texas, USA) for detailed analysis.  
 
2.6 Data Analysis 
2.6.1 Descriptive Analysis 
Descriptive analysis was done to show the distribution of characteristics of study sample and 
results presented as proportions in figures (histograms) and tables. All variables, including 
age, were categorized for subsequent analysis.  
 
2.6.2 Unadjusted Analysis 
A primary unadjusted statistical analysis was done using all entries in the database for the 
period 2005-2009. The crude resistance estimates were determined as well as trends and 
patterns of different antimicrobial agents for the three bacterial pathogens. We compared this 
with prospective data collected from July 2010 to June 2011. Bivariate cross-sectional 
comparisons were done using Pearson chi-square tests of independence for categorical 
variables. Associations were determined using univariate logistic regression analysis since 
the nature of the outcome variable was dichotomous. 
 
2.6.3 Adjusted Analysis 
Secondary adjusted analysis was conducted on potential confounding variables, such as age, 
gender, year, geographical location, hospital, and province. For binary variables, we 
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performed a chi-square test to compare differences in proportions between the two groups. 
Since the outcome variable was dichotomous (Resistant: Yes, No), adjusted comparisons 
were done using multiple logistic regression to account for covariates. Variables that were 
associated with the outcomes were selected by a backward elimination regression analysis. A 
likelihood ratio test with p≤ 0.05 significance level was used to compare the fit of different 
models, one of which was nested within the other. This was done to assess if a simplified 
assumption for a model was valid. The odds ratios were calculated against the reference 
values of the outcome variable. Odds ratios were reported to show associations between 
resistance and different covariates. Resistance rates were compared across age-groups, 
gender, geographical regions (provinces), hospitals and year of infection with the assumption 
that the null hypothesis showed that there was no association between provinces, hospitals, 
year, and resistance rate. The significance level was predetermined at 0.05 with 2-tailed P 
values.  
 
2.7 Ethical Consideration 
The protocol was approved by the Human Research Ethics Committee of the University of 
the Witwatersrand (approval number M10625). This study was part of a larger National 
Institute for Communicable Diseases (NICD) surveillance programs that obtained ethical 
clearance for ARSR and GERMS-SA to conduct communicable diseases surveillance. 
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2.8 Limitations of the study 
The major limitation of this study as a whole was incompleteness of microbiological data, an 
inherent problem with surveillance systems. Also differences in quality of susceptibility 
testing between different participating laboratories were obstacles for reliable comparison of 
data originating from various laboratories. 
 
2.9 Dissemination of findings 
The findings of this study were disseminated to a wider scientific community through 
publications in peer reviewed journals and presentations at national and international 
conferences. The published and unpublished papers together form the basis for this doctoral 
thesis. 
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Chapter 3 Systematic Review of Published Literature : 
Antimicrobial Resistance Surveillance among Nosocomial 
Pathogens in South Africa 
 
This chapter gives details of the findings of a systematic review of published literature on 
antimicrobial resistance in South Africa. The findings have been published in a paper 
entitled "Antimicrobial Resistance Surveillance among Nosocomial Pathogens in South 
Africa: Systematic Review of Published Literature”, Journal of Experimental & Clinical 
Medicine, Volume 4, Issue 1, Pages 8-13. Jan 2012 (Appendix 12.3). 
 
3.0 Abstract 
Background: There has been significant increase in the prevalence of antimicrobial drug 
resistance in sub-Saharan Africa. This may increase health care costs due to patients’ need for 
more diagnostic tests, longer hospitalization and poor outcome. Therefore, monitoring 
systems for resistance patterns are needed to effectively minimise poChapter 4or outcome. A 
systematic review was conducted to find out the prevalence of antimicrobial drugs resistance 
among Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa and to 
understand whether or not such data was part of an ongoing surveillance system for 
nosocomial infections in South Africa.  
 
Method: An online search of main databases including Cochrane Library, PUBMED and 
MEDLINE was done using search terms: “antimicrobial resistance” and “surveillance”, 
“antimicrobial susceptibility” and “surveillance” or “Staphylococcus aureus” or “Klebsiella 
pneumonia” or “Pseudomonas aeruginosa”; “nosocomial” or “hospital acquired”, “South 
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Africa” or “Africa”. We also did manual search of local conferences, theses and dissertations 
to identify relevant articles. 
 
Results: In total, 41 manuscripts were identified of which eight were analyzed. There is no 
evidence of ongoing antimicrobial resistance surveillance for nosocomial pathogens in South 
Africa. Data reported in this review seem to have been analysed on ad hoc basis and do not 
show a particular resistance pattern, however, data shows evidence of resistance to commonly 
used antimicrobial drug in this population: for S. Aureus resistance to cloxacillin was 29%; 
and 38% to erythromycin; for K. pneumonia resistance to ciprofloxacillin was 35% and 99% 
to ampicillin; and for P. aeruginosa, the mean resistance to ciprofloxacillin was 43% and 
35% to amikacin.  
 
Conclusion: Surveillance of antimicrobial resistance is essential to better understand the 
complexity of antimicrobial resistance development. Such evidence would be used in 
developing an effective surveillance programme to monitor patterns and trends of resistance 
overtime.  
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3.1. Introduction 
Antimicrobials are essential for the treatment of infectious diseases. However, a high 
prevalence of resistance impacts patient outcomes negatively. Antimicrobial resistance 
increases health-care costs due to a need for more diagnostic tests, additional drugs for 
treatment, and longer duration of hospitalisation. (12, 32) Therefore, the emergence and 
spread of antimicrobial-resistant organisms from hospital to the community, is a growing 
public health challenge in South Africa and worldwide. Antimicobial resistance is associated 
with a high level of morbidity and mortality, and for this reason, antimicrobial resistance 
requires effective monitoring to determine patterns and trends over time. (83-86) For South 
Africa, such information is particularly important because of the HIV/AIDS epidemic and 
increased antimicrobial consumption due to frequent episodes of opportunistic infections. 
 
Antimicrobial resistance surveillance is crucial for evaluating the use of empirical 
antimicrobials for treatment. (26) Continuous monitoring and a better understanding of the 
profile and magnitude of antimicrobial resistance are therefore required. This will help 
address the problem of increasing rates of antimicrobial resistance in South Africa. The 
European Antimicrobial Resistance Surveillance System (EARSS) is an electronic laboratory 
information system that has been used as a tool for identifying emerging antimicrobial 
resistance. (87) In South Africa, an equivalent national surveillance system to monitor the 
status of antimicrobial resistance for nosocomial pathogens has not yet been established. For 
this reason and as an interim exercise, this review was initiated to gather scientific evidence 
of the extent and patterns of antimicrobial resistance in selected hospital-acquired pathogens 
in South Africa. 
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3.2. Methodology 
3.2.1 Online Search Strategy 
A comprehensive search of biomedical databases was carried out to find all relevant 
manuscripts published in English. The search aimed at identifying relevant peer-reviewed 
epidemiological studies that would provide adequate information on antimicrobial 
surveillance initiatives in South Africa. 
 
3.2.2 Search engines, dates of publications and search words used 
The following search terms were used: “antimicrobial resistance’ and “surveillance”; 
“antimicrobial susceptibility” and either “surveillance” or “Staphylococcus aureus” or 
“Klebsiella pneumoniae” or “Pseudomonas aeruginosa”; “nosocomial” or “hospital 
acquired” or “South Africa” or “Africa”. We focussed on searching pathogen-specific 
literature and data for this review using manuscripts identified through an extensive search of 
the following databases: Cochrane Library (July 2011); MEDLINE (1966 to July 2011); 
African Journal on line (AJOL) (1980 to July 2011), EMBASE (1980 to July 2011); and 
LILACS (1982 to July 2011) on www.bireme.br. 
 
3.2.3 Manual Search Strategy 
We also carried out a manual search and review of the reference lists of the identified articles. 
Additionally, as findings of studies are not always published conventionally, we manually 
searched the abstracts and proceedings within the past 10 years of the following conferences: 
“OIE International Conference on Antimicrobial Resistance”, “Conference on Antibiotic 
Resistance Prevention and Control” (ARPAC), “Public Health Association of Southern 
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Africa” (PHASA), “Federation of Infectious Diseases Society of South Africa” (FIDSSA), 
“Global Antimicrobial Resistance Program” (GARP), “Congress European Society of 
Clinical Microbiology and Infectious Diseases” (ESCMID), and the “Congress of the 
International Society for Infectious Diseases”. Such conference proceedings outline major 
group sessions for microbiology and infectious diseases specialists working within the field 
of antimicrobial resistance. We did not obtain any relevant data from these searches. In 
addition, informal approaches were made to individuals and organizations within the field of 
hospital infection control and antimicrobial resistance surveillance for information regarding 
unpublished data, dissertations and theses.  
 
This search yielded four of the 8 papers that were included for analysis. Data for rates of 
antimicrobial resistances were presented as means. 
 
3.3 Results 
3.3.1 Antimicrobial resistance surveillance for invasive pathogens in 
South Africa 
A good surveillance system for antimicrobial resistance monitoring should involve ongoing 
collection and collation of both clinical and microbiological data, with an emphasis on 
timeliness, accuracy, consistent and standardised methods of collection and analysis, using a 
centralised laboratory with appropriate control measures focused on reporting on nosocomial 
pathogens. Such a system has not been established in South Africa. However, although 
different methods were used, they were all approved by the National Committee for Clinical 
Laboratory Standards (NCCLS), predecessor of the Clinical Laboratory Standards Institute, 
and therefore suitable for trend analysis e.g. ciprofloxacin resistance in K. pneumoniae 
increased in academic hospitals from 18% (24/1324 isolates in 1990) to 28% (498/1778 
isolates) in 2007. 
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From the included studies, lack of clinical data and quality assurance information are 
deficiencies requiring attention; nonetheless, some steps have been taken to contain resistance 
development. Prudent use of antimicrobial (antimicrobial stewardship) has been looked at 
through the South African Antibiotic Stewardship Programme (SAASP) while the South 
African Society of Clinical Microbiology formerly the National Antimicrobial Surveillance 
Forum (NASF), focuses on AMR surveillance and reporting using passively collating 
antimicrobial data in public hospitals through the National Health Laboratory Services 
(NHLS) and in private health- care sectors through private microbiology laboratories. 
 
The Antibiotic Study Group of South Africa has been active since 1976 (88), this group 
joined public sector surveillance in 2002 as NASF, meeting and sharing information, and 
several publications in the area of antimicrobial resistance has been released. (88-91) More 
recently, the Group for Enteric, Respiratory and Meningeal Diseases Surveillance (GERMS-
SA), an established entity within the National Institutes for Communicable Diseases (NICD), 
has been established, which operates in all nine provinces, focussing on surveillance of 
community-acquired pathogens and monitoring resistance profiles.  
 
As of 2010, a surveillance to monitor resistance among S. aureus and K. pneumoniae was 
established as part of GERMS-SA. Another initiative was introduced in KwaZulu Natal for 
surveillance of E. coli in 2000/2001 (65) and the Veterinary Surveillance of Antimicrobial 
Resistance in South Africa has been involved in monitoring resistance among zoonotic 
infections. (66) Table 3.1 illustrates hospitals and laboratories that contributed antimicrobial 
susceptibility data for the studies that were included in this review. 
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Table 3.1 Public and private sector laboratories that participated in antimicrobial 
susceptibility data over the period 2000-2011 
 
Public Sector Hospitals/NHLS laboratory* Private sector laboratories ^^ 
Chris Hani Baragwanath Hospital Drs Bouwer & Partners (Ampath) 
Charlotte Maxeke Johannesburg Academic Hospital Drs Dietrich & Voigt (Pathcare) 
Steve Biko Academic Hospital Drs du Buisson, Bruinette & Partners (Ampath) 
Dr George Mukhari Hospital Drs Mauf & Partners (Lancet) 
Pelonomi & Universitas Hospital Drs Swart & Marais (Ampath) 
Groote Schuur Hospital Drs van Rensburg Pathologists 
Tygerberg Hospital Drs Vermaak & Partners 
Green Point NHLS Laboratory Niehaus & Botha 
King Edward VIII  
No. 1 Military Hospital   
NHLS=National Health Laboratory Service 
* NHLS from Gauteng Province (Johannesburg, Pretoria), Free State Province (Bloemfontein), KwaZulu Natal 
Province (Durban and Western Cape Province (Cape Town). ^^ Private laboratories in Gauteng Province 
(Johannesburg, Pretoria), KwaZulu Natal Province (Durban), Western Cape Province (Cape Town) and Free 
State Province (Bloemfontein) 
 
3.3.2 Description of study settings and study designs (27, 91-98) 
A total of 41 manuscripts were identified: 26 identified through database searches and 15 
through manual searches in libraries and among personal contacts. Twenty-three were 
excluded as they did not meet the criteria for inclusion which was full text articles with 
antimicrobial susceptibility data reported from multiple sites. This left behind 18 that had 
full-text article reviews to further assess for eligibility, and 10 more were further excluded. 
Eight manuscripts published between 2000 and 2011 were identified and included in this 
review (Figure 3.1).  
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Figure 3.1 Flow diagram of antimicrobial resistance studies included in the review. Note, 
from PRISMA: www.prisma-statement.org. 
 
Of the eight manuscripts, five were published prior to 2007. All manuscripts identified for 
this review included susceptibility data from only four of the nine provinces of South Africa. 
Five of these studies were from public sector tertiary hospitals and three were from private 
sector laboratories, predominantly from urban settings across South Africa. (Table 3.2) 
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Seven of these studies produced results from surveillance data aggregated from more than 
seven sites nationwide, while one study produced results from surveillance data from 16 
hospitals within KwaZulu Natal province. None of the eight studies detailed the study design 
used, other than stating that the study was “multi-site and used data of blood culture isolates 
from microbiology laboratories”. Only one study used isolates from respiratory aspirates. 
(96) All except one study from various public sector hospitals within KwaZulu Natal 
Province used retrospective laboratory data. (97) (Table 3.2) 
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Table 3.2 Characteristics of antimicrobial resistance studies in South Africa 
 
BAL= bronchial alveolar lavage; CSF=cerebral spinal fluid; EC= Escherichia coli; HI=Haemophilus influenza; 
KP= K. pneumoniae; MEF=middle ear fluid; NHLS= National Health Laboratory service; PA=P. aeruginosa; 
SA=S. aureus; SA= Republic of South Africa; SP= Streptococcal pneumonia 
Author   Year Pathogen Location Sample 
Type 
Source of 
information 
Study 
Design 
Bamford et 
al.
87 
2009 SA, KP, 
PA & 
others 
8 NHLS 
Laboratories 
Blood & 
CSF 
NHLS 
Surveillance 
data 
Not specified 
National 
Antibiotic 
Surveillance  
Forum
92
 
 
2008 SA, KP, 
EC & 
others 
Private labs, 
number of 
labs involved 
not 
mentioned 
Blood & 
Urine 
Private 
laboratories 
data 
Not Specified 
Brink et 
al.
22
  
2007 SA, KP, 
PA & 
others 
7 Private 
laboratories 
Blood Private 
laboratories 
data  
Not specified 
Sein et al.
89
  2005 SA, KP, 
EC & 
others 
7 NHLS 
laboratories 
Blood & 
CSF 
NHLS 
Surveillance 
data 
Retrospective 
approach 
Essack et 
al.
91
  
2005 SA, KP, 
PA & 
others 
Laboratories 
in 16 
hospitals 
Blood Public 
sector 
surveillance 
data  
Multicentre 
Study in 
RSA 
Liebowitz et 
al.
90 
2003 KP & 
others 
12 Private 
laboratories 
Sputum, 
bronchial 
brush, 
BAL, 
pleural 
fluid, sinus 
tap, MEF, 
pharyngeal 
swabs 
Private labs 
data 
Multicentre 
study in RSA 
Crewe-
Brown et 
al.
88 
2001 SA, KP, 
EC & 
others 
8 NHLS 
Laboratoriess 
Blood & 
CSF 
Public 
sector 
surveillance 
data  
Not specified 
Antibiotic 
Study 
Group.
85 
2000 SA, KP 
& others 
8 NHLS 
Laboratories 
 Blood & 
CSF 
Public 
sector 
surveillance 
data 
Not specified 
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3.3.3 Description of microbiological methods (27, 91, 93-95, 98) 
Seven of the studies were conducted using data from blood and cerebral spinal fluid (CSF); 
(27, 91, 93-95) one study used data from respiratory aspirates and urine. (98) The 
methodologies of antibiotic susceptibility testing were described in seven studies, all of 
which mentioned the use of the CLSI breakpoints formerly NCCLS to determine 
antimicrobial susceptibilities. Two studies described in detail other methods used for 
susceptibility testing of various antibiotics, such as Kirby-Bauer disk diffusion, Broth micro 
dilution, E-test and use of automated Vitek 2 system. (27, 96) Only one study mentioned 
quality control in identification and susceptibility testing as per CLSI recommendations. (27) 
All studies used only one sample per patient hence duplicate samples were excluded to 
minimize over-representation of the cases that had multiple and frequent cultures. Two 
studies that reported antimicrobial susceptibility of respiratory tract pathogens, mentioned 
intermediate- and high-level resistance for such organisms. (94, 96) 
 
3.4 Resistance rates for different pathogens 
 
3.4.1 Staphylococcus aureus (27, 91, 93-95, 97, 98) 
Susceptibility data for S. aureus were reported in seven studies. (Table 3.2) Five of these 
studies were from public sector laboratories and two studies from private sector 
laboratories.(91, 93-95, 98) Geographically, all studies identified were performed in urban 
areas except one study done in Durban, which included isolates from district and regional 
hospitals. Specimen types included blood and CSF, except one study that included respiratory 
aspirates. (Table 3.2) The resistance rate of S. aureus to cloxacillin was 29% (range 23-69%); 
erythromycin 38% (25-46%); gentamicin 20% (range 7-45%), and methicillin resistance 
(MRSA) was 33% (17-59%). As much as cloxacillin resistance is synonymous for MRSA 
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there were differences in the way resistance was reported in the papers included in this 
review. No resistance to linezolid has been reported since its introduction in 2000, while 
frequency of resistance to glycopeptides was uncertain due to disagreement on optimization 
of vancomycin susceptibility testing. (Figure 3.2) 
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Figure 3.2 Proportion of antimicrobial resistance among S. aureus. 
 
Note: Data were from seven published studies, between 2000 and 2009.* Different methods were used to 
determine MRSA status (Cloxacillin resistance of 29% vs. 33% MRSA, there was no record for cefoxitin 
screening for MRSA which might explain the difference) 
 
3.4.2 Klebsiella pneumoniae (27, 91, 93-98) 
Most studies that reported on susceptibility patterns for Klebsiella pneumoniae were 
published by the Antibiotic Study Group that used data mostly from large public sector 
academic hospitals that provide services to a diverse population group. Clinical isolates were 
predominantly from blood & CSF culture (four studies), blood culture only (one study), 
blood & urine culture (one study) and respiratory aspirates (one study). The resistance of K. 
pneumoniae to ciprofloxacin was 35% (range 15-65%), cefuroxime 52% (range 27-72%), 
gentamicin 50% (range 18-70%) and ampicillin 99% (range 88-100%) (as expected, as all KP 
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carry blaSHVgene). Resistance was almost non-existent for imipenem, meropenem and 
moxifloxacin. (Figure 3.3) 
 
 
Figure 3.3 Proportion of antimicrobial resistance among K.pneumoniae. Note: The data 
were from eight published studies from 200-2009 
 
3.4.3 Pseudomonas aeruginosa (27, 93, 97) 
Three studies reported resistance rates for P aeruginosa, two of which were from blood 
culture isolates and one from non-specific sources.(27, 93, 97) The resistance among P. 
aeruginosa to ciprofloxacillin was 43% (range 30-75%), gentamicin 50% (range 10-65%), 
amikacin 35% (11-67%) and aztreonam 42% (range 25-75%). Resistance to polymyxin was 
<5% (range 0-5%) and was reported in a single study. (27, 93, 97) Resistance rates to almost 
all drugs tested were greater than 30%. (Figure 3.4)  
 
A study done by Perovic et al using data from 1998 to1999 at Chris-Hani Baragwanath 
hospital showed that there was an association between P. aeruginosa bacteraemia and 
outbreaks caused by multiple-resistant genotypes. In this study, the proportion of 
nosocomially-acquired infection was 57.1%. (99) The resistance profiles and incidence of 
disease are likely to have changed during the 10-year period, and the current status may be 
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different but is unknown. This review shows high resistance rates of P. aeruginosa to most 
conventional antibiotics. 
 
 
Figure 3.4 Proportion of antimicrobial resistance among P.aeruginosa. Note. Data were 
from three published studies from 2005-2009 
 
3.5 Presence of Extended-Spectrum Beta-Lactamases (ESBLs) 
Seven studies included in the review reported on extended spectrum beta-lactamases (ESBLs) 
in K. pneumoniae. In academic hospitals, the rates of ESBLs increased from 33% (436/1324) 
in 1999 to 49% (869/1778) in 2007. These studies used the double-disk method and reported 
resistance rates as high as 59% and 62% in private hospitals and public sector hospitals, 
respectively. A study done by Sabiha Essack at a teaching hospital in Durban between 1994 
and 1996 investigated ESBL-mediated resistance in South African nosocomial origin of K. 
pneumoniae and demonstrated that each of the isolates expressed 1-6 β-lactamases. (100) 
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3.6 Discussion 
This systematic review assessed the literature about the prevalence of resistance to commonly 
used antimicrobials as well as whether or not such data were part of an ongoing surveillance 
system for nosocomial infections in South Africa. We found that no national surveillance 
system existed that collected and collated data year on year, to assess trends and resistance 
pattern for nosocomial pathogens. In addition we found a high overall proportion of 
resistance to antimicrobials used for empirical treatment.  
 
Except for resistance to polymixins which is very uncommon in P. aeruginosa isolates, 
resistance rates to other antimicrobials commonly used for the treatment of infections caused 
by this bacterium are high. The study found a low level of resistance among Klebsiella 
pneumoniae to moxifloxacin and carbapenems and a pattern of high resistance to other 
classes of antimicrobials that are commonly prescribed. S. aureus, showed no resistance to 
teicoplanin, vancomycin, and linezolid, but high resistance to other classes of antimicrobials. 
This is similar to resistance pattern in Central African countries, as shown in a review by 
Vlieghe et al, (101) even though their study focussed mostly on community acquired 
pathogens. 
 
Several limitations have been observed in this study: Firstly, studies included in this review 
reported laboratory data on antimicrobial-resistant isolates with no clinical data; hence, they 
could not link resistant isolates to clinical findings. Secondly, most studies included in this 
review aggregated data from different laboratories which employed varied laboratory 
techniques. This was not ideal for surveillance purposes but all methods were NCCLS/CLSI 
approved. Thirdly, data used were collected retrospectively, except for a single study by 
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Brink et al that collected data prospectively. (27) Use of retrospective data has several 
limitations, including incomplete data that are subject to numerous biases. Fourthly, most if 
not all, studies lacked demographic data; hence, it was difficult to compare community-
acquired versus hospital-acquired infections. Lastly, variation in clinical specimens, taking 
practices between different institutions might alter consistency and comparability of data 
reported from these various studies. Furthermore, this study included invasive pathogens 
from blood cultures as well as pathogens from respiratory specimens and, in the case of P. 
aeruginosa, also from other sources, including burns. It should be noted that blood culture 
isolates are highly predictive of truly invasive disease and unlikely to be contaminants. It is 
true that resistance may first arise from infections from other sites including skin and 
intestinal tract. Blood culture isolates that are resistant to antibiotics are very likely to be 
virulent while cultures from other sites where colonization occurs, the resistant organisms 
may be less virulent and harbour resistance mutations which arise at a fitness cost and 
therefore less likely to be invasive.  
 
In spite of the limitations mentioned above, there is growing evidence of escalating rates of 
antimicrobial resistance to several conventional antimicrobials. Even though vancomycin 
resistance is still negligible, ESBL and MRSA rates are high in these urban academic centers 
and private institutions. This is consistent with growing evidence of global trends of 
antimicrobial resistance reported previously showing a significant increase in of incidence of 
cefotaxine-resistant Acinatobacter infections as well as antimicrobial resistance in common 
bacteria health care associated pathogens such as Staphylococcus aureus, Pseudomonas 
aeruginosa, Klebsiella pneumonia among others. (102, 103) Recent published data shows 
that rate of resistance is rapidly growing in China (22% average growth over six years, 1994 
to 2000), Kuwait (17% average growth over four years, 1999 to 2003), and the U.S (6% 
average growth over three years, 1999 to 2002). (104) 
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This emphasizes the fact that surveillance is essential to further our understanding of 
antimicrobial resistance development and how it relates to prescription practice. (100, 101) 
Such undertaking will pave the way for designing interventions that could overcome 
resistance development to established antimicrobial agents. 
 
3.7 Conclusions 
Evidence suggests that antimicrobial resistance rates to nosocomial pathogens are generally 
high in South Africa. This is an emerging threat to public health and clinical management of 
patients with such infections in the face of dwindling antimicrobial development. We believe 
that a good surveillance system would enhance effective monitoring of emerging resistance 
and changes in resistance profiles, and identify significant differences in trends and 
distribution of antimicrobial resistance. 
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Chapter 4: Laboratory Information System: A surveillance 
tool for monitoring trends and patterns of resistant strains 
of important nosocomial bacteria 
 
This chapter highlights findings of a critical analysis of the utility of the laboratory 
information system (LIS) of the National Health Laboratory Services (NHLS). The aim was 
to investigate the effectiveness of LIS in capturing reliable antimicrobial resistance data of 
important nosocomial bacteria i.e. S. aureus, K. pneumoniae and P. Aeuginosa, isolated from 
tertiary public hospitals in South Africa. This chapter has two sections: i) section 4.1 ‘The 
role of laboratory information system in antimicrobial resistance surveillance; ii) section 4.2 
Laboratory methods and its impact on antimicrobial resistance surveillance. 
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4.1 The role of a Laboratory Information System in antimicrobial 
resistance surveillance 
 
4.1.1 Introduction 
The laboratory information system is a technique that the laboratory uses to deliver accurate 
and understandable results to the clinician who requested the analysis within a reasonable 
timescale. The system entails a sequence of events which includes ‘transferring of a sample 
to the laboratory, analysing the sample, checking results or reanalysing the sample and 
releasing results to the clinician who requested the test’. In short, the concept of LIS refers to 
the computerised laboratory system or automation of clerical labour-intensive activities 
associated with the processing of laboratory results to improve accuracy and turnaround time 
of results. Automation of laboratory activities removes the element of manual reporting and 
allows access to retrospective data for analysis. (105) Previous studies have reported an 
improvement in the accuracy of data and turnaround time of laboratory results after 
installation of the LIS. 
 
Therefore, due to the complex and large volume of data that these laboratories manage, and 
the continued demand for data to aid public health surveillance for effective disease 
prevention, there is a need for an operational LIS that can efficiently integrate and handle all 
sophisticated processes and procedures related to data from different laboratory departments 
including, but not limited to, microbiology, parasitology, virology, histopathology, 
biochemistry, haematology, endocrinology, cytology, toxicology, serology, immunology etc. 
(106, 107) Data for all such activities aggregates at the corporate data warehouse (CDW) 
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repository. This data could be used to measure sample volumes, estimate revenue, turnaround 
time, budgeting; monitoring antimicrobial resistance etc. 
4.1.2 General description of LIS components and function (related to 
Figure 1) 
A laboratory information system as illustrated in Figure 4.1 below constitutes the following 
components: hardware (computer system), software (computer programs), human capital 
(people who order laboratory tests, transports samples, etc.), laboratory procedures (i.e. blood 
culturing, susceptibility testing etc.) and data (laboratory results). 
 
 
Figure 4.1 The Components of a Laboratory Information System 
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These components support each other interactively in the collection, processing, storage, 
distribution of data obtained during laboratory procedures. The system simplifies the process 
of tracking and sorting laboratory data, improves turnaround time of laboratory results and 
allows retrospective analysis of data for surveillance or research purposes. (54) Figure 4.2 
below describes diagrammatically the processes and procedures in the function of a LIS.  
 
Figure 4.2 Flow chart showing Laboratory Information Management System processes 
and procedures (108) 
 
The LIS is a complex system that simplifies and improves efficiency of laboratory operations, 
minimise data entry errors and deliver valid and reliable laboratory results to the patient and 
clinician in the most efficient way. In addition the system provides a platform for surveillance 
such as monitoring antimicrobial resistance following utility of retrospective data archived in 
the LIS database. (54) In South Africa, the NHLS LIS operates on software supplied by the 
Laboratory System Technologies (Pty) Limited, known as DISAlab.  
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4.1.3 The National Health Laboratory Services (NHLS) 
The NHLS is mandated by the National Department of Health to provide public health 
laboratory services throughout South Africa. The aim is to deliver laboratory data to support 
clinical decision making within a reasonable and acceptable time so as to achieve good 
clinical outcomes among the patient population, and to attain improved laboratory 
performance and communication with clinicians. The NHLS provides laboratory and related 
public health services to over 80% of the population through a national network of over 300 
laboratories, which is an integration of state owned laboratories: laboratories of the National 
Institute of Communicable Diseases (NICD) and the National Institute of Occupational 
Health (NIOH). These laboratories provide services to all public clinics and hospitals.  
 
The process of accreditation of the laboratory allows for checking and assessing of errors, 
and acceptable limits are always incorporated into the system. As a researcher, it is advisable 
to apply acceptable standards to the data so as to account for any margin of error i.e., 5% 
error margin. For internal quality control measures, the LIS has check points to minimise data 
errors, but also validates data entries. In the event of failed validation, verification of data 
entered is done manually by another laboratory member of staff. For external quality control, 
there is a process of external quality assurance/quality control (QA/QC) that happens in all 
NHLS laboratories. This process is described in greater detail in section 4.2.  
 
The NHLS DISA LIS, which has been in use for several years, is now migrating to TrakCare 
Lab, which is currently being rolled out in all the 322 laboratories by Health Systems 
Technology. (107, 109) Processes and procedures of the operations of the LIS will be 
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discussed in this section, drawing a parallel between the outing of DISA Lab and the 
incoming of TrackCare, weaknesses and strengths will be highlighted and suggestions for 
improvement of the LIS in the context of its role, as a tool for surveillance of antimicrobial 
resistance will be highlighted. 
 
4.1.4 The DISALab LIS 
The DISALab is a laboratory information system that was developed and maintained by 
Laboratory System Technologies (Pty) Ltd. The NHLS adopted the DISA LIS which has 
been in use for over 20 years. 
 
4.1.4.1 DISALab System Modification 
In response to the growing demand for accurate laboratory billing as well as understanding 
the volume of laboratory specimens sent for analysis in the public microbiology laboratories, 
and the provision of reliable laboratory data, the system has undergone several software 
modifications. Such modifications were in line with changes in the Information Technology 
(IT) industry as a result of developments of new software programs etc. Since its inception, 
DISA has of May, 2013 run more than 420 upgrades to the original program. 
 
The DISALab system, that NHLS has been using over the past two decades has a built-in 
function that automatically updates the records once data is entered, hence each time a record 
is entered on the registered particulars, all corresponding records get updated automatically. 
Any change that happens to a particular record gets an automatic update of that record. 
Information is also recorded on the system to be able to capture who entered the changes into 
the system and at what time were such changes made. The IT managers for each laboratory 
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were able to alter certain segments of the system to suit the needs of the local laboratory, as 
such all changes taking place at each site by the IT personnel were noted at the DISA head 
office. Such changes led to an improvement in the functioning of the DISALab system.  
 
4.1.4.2 The DISALab Hardware and Software System 
All NHLS laboratories use automated equipment for incubation of the blood culture 
specimens. The BACT ALERT 3D (BA-3D) is the most commonly used blood culturing 
machine in NHLS microbiology laboratories. These machines function on a continuous basis, 
as new samples are loaded one after the other. The BA-3D machines are linked to the user 
interface, which transmits all the data electronically from the source to the user computers i.e. 
in clinics and hospitals where results are accessed electronically. Only relevant data from the 
BA-3D machine are selected and delivered to the central data point (data server). DISALab 
system is accessible at https://labresults.nhls.ac.za and using a drop down menu, the user is 
requested to select the province of operation; the system will then ask for the log in details.  
 
The DISALab, a password protected system, was installed as a local system without inter-
hospital connectivity; however a joint interoperability function had been established, since all 
data from different NHLS laboratories converged and aggregated at the central NHLS server 
in Johannesburg. The central data point was interlinked with individual servers located in 
different NHLS laboratories in all provinces.  
 
All NHLS laboratories in each province routed data into a local provincial server only. From 
the local server data is transferred automatically to the central repository ‘the corporate data 
warehouse’ (CDW) at the NHLS headquarters in Sandringham, Johannesburg. For this 
reason, individuals who want to access at results from the DISALab website may only be able 
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to access results from a particular geographical area as the connectivity is not in real time, but 
also, that each province feeds data into a local server.  
 
The DISALab LIS operates on the Open DataBase Connectivity (ODBC) system, which is an 
open standard application programming interface (API) for accessing a database (107, 110) 
and allows upgrades, which are often necessitated by frequent advancement occurring in the 
overall information technology industry. (111) 
 
4.1.4.3 LIS quality control mechanism 
The DISALab LIS has some built-in quality control mechanisms. The interface is validated 
continuously, to ensure that accurate information is transmitted to the central repository each 
time the scheduled data transfer procedure takes place. This helps to check for errors and 
confirm if the results produced are as expected.  
 
The LIS is programmed to provide information off hand on the laboratory staff that 
performed a particular procedure and the time of the day. The system has built in memory 
that records all information pertaining to the user or an individual that entered the 
information. In the event that an error occurred, it is possible to identify the source of the 
error observed on the database, hence it is possible to rectify the error, but also minimise the 
possibility of erroneous reporting of results occurring from simple human mistakes.  
 
The variable time in the LIS database needs to be emphasised as it is an essential component 
of quality control. For this reason, time is indicated for each activity on the laboratory request 
form. This variable ‘time’ helped, to a great extent, to track down the source of any error as 
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the laboratory in-charge would be able to identify the laboratory staff responsible for the 
procedure and the time of the day when the error occurred.  
 
Parameters entered into the LIS database are the following: Sample ID, time collected, time 
registered, demographics such as date of birth or estimated age, gender, hospital, ward, 
province, clinical diagnosis (scanty data), organism cultured, drug sensitivity 
((resistant/sensitive (R/S); minimum inhibitory concentration (MIC)), date sample was first 
registered and tested, date and time results were reviewed, instrument used for testing, 
sensitivity of antimicrobials, date clinician printed the results and the first laboratory where 
specimen was taken. If the sample was referred, then the results are only collected from the 
referring laboratory and not the laboratory where the test was done, as such, delays in getting 
the results might occur in the process. 
 
4.1.5 Data Flow from the laboratory to the CDW 
The blood culture results were entered into the LIS data base by the laboratory technologist 
as previously described. The data were then transmitted to a local laboratory repository prior 
to being relayed to a central repository. The first step that takes place in the laboratory is 
essentially immediately, while the second step may take up to 6 - 24 hours to be completed. 
At the CDW, data is processed 4 times per day and due to the fact that data is not in real time 
with the current DISA-Lab LIS, report generation can be difficult since data need to be 
extracted first and then processed.  
 
The system is highly fragmented and data is processed in batches, coming from 
approximately 13 repositories in the 8 provinces. The rate of blood culture data flow between 
entry of data, laboratory storage and the central repository depends on the volume of data at 
P a g e  |96 
 
  
each point in time and the technology (network) involved. In tertiary academic hospitals, data 
movement takes relatively less time from one point to the other, compared to other facilities. 
 
The CDW houses data repositories from all laboratories within the NHLS that are interlinked 
to the DISALab LIS, including microbiology data from blood cultures, cerebral spinal fluid 
cultures, stool and urine cultures, pus swabs among others. Since the focus of the chapter is 
assessing use of LIS for monitoring antimicrobial resistance, the information will focus on 
blood culture data from microbiology laboratories. As described above, DISALab LIS 
operates on Open DataBase Connectivity (ODBC) system, an open standard ‘application 
programming interface’ (API) for accessing databases.  
 
4.1.6 Data flow from CDW to utilisation 
Blood culture data from laboratories, are aggregated at the CDW. Here data can be extracted 
manually as requested by researchers for a particular purpose once an approval is granted by 
the data manager in-charge of the CDW. The CDW is directly interconnected with the 
DISALab, which means that the CDW personnel have direct access to data coming from all 
NHLS laboratories using the DISALab System.  
 
To simplify the process, data are extracted manually with the aid of a well developed 
structured query language (SQL) program as shown in Table 2.1, Section 2.5 ‘data 
management’. The CDW composition is limited in terms of what epidemiological 
investigations could be executed from the data, as the blood culture data does not contain 
clinical parameters, hence investigations linking clinical outcomes to antimicrobial resistance 
may not be undertaken. 
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4.1.7 Critical assessment of challenges of LIS and data quality 
The focus of this section is to understand the dynamics of the NHLS LIS, key operational 
challenges and its role in monitoring antimicrobial resistance to nosocomial pathogens in the 
country. The DISLab was designed to be flexible, changing and revolving all the time, hence 
it is subject to constant improvement. 
 
4.1.7.1 Different version of DISALab 
The NHLS LIS was running on different versions of DISALab due to differences in the roll 
out time and user preferences, such that changes that are suggested globally might not all be 
affected by different laboratory managers in different laboratories. Some laboratories might 
prefer to make few modifications based on their needs while others might not have changed 
anything at all. This made it difficult for all laboratories to work on standardised data 
protocols. Such a situation could have propagated differences in blood culture data quality, 
including differential AMR rates observed from various laboratories and which aggregates at 
the CDW. It might also be due to differential laboratory practices leading to selective testing 
of certain antibiotics. (section4.2, Table 4.1) 
 
4.1.7.2 Replication and data errors 
The CDW cannot replicate data in the database since data found at the repository were 
electronically transferred from the different sources. However, the CDW programmer does 
interrogate the data that gets extracted and performs data extraction error identification 
exercise as standard practice. The errors assessed are mostly those on codes that were used by 
the laboratories, e.g., the identification code in the CDW database for example Universitas 
hospital is 53. Before any changes could be effected on the data, ample verification of data is 
P a g e  |98 
 
  
done. Therefore, it is recommended to incorporate an error rate into the system that is 
universally acceptable. 
 
4.1.7.3 Lack of access to original data source 
The CDW does not have access to the original data source, such as the laboratory request 
forms. However, DISALab maintains master data (standard reference data) for all NHLS 
laboratories, which means that laboratories use the same table of codes. The master data is 
administered at the NHLS central corporate office and facilitates easier merging of data from 
different laboratories without any major problems. 
 
4.1.7.4 Duplicate data 
Duplicate entries can pose a challenge. The blood culture data entry must have the same ID 
number, name and surname, date collected, area/place, hospital and results. Unless the blood 
culture data entries have all similar records, that particular entry could only be assumed as a 
duplicate entry. 
 
4.1.7.5 Variation in LIS 
There are major challenges relating to the NHLS LIS, which might originate from wide 
variation in the operations of the LIS between different laboratories. These appear to lead to 
wide variations in procedures that are used for gathering and reporting of blood culture data. 
Some of the underlying causes of such wide variability might be: 
 Different reporting styles between different laboratories, including different names used 
by different instruments. 
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 Instruments used vary between different laboratories (other laboratories use more 
advanced instruments than others) as documented in section 4.2  
 Lack of standardisation across different laboratories which might affect scope of 
generated data. 
 
4.1.7.6 Structure of LIS  
Often unforeseeable errors might have been difficult to deal with despite the fact that the 
program has been regularly monitored to enhance accuracy of the data that was entered onto 
the LIS database. The system generates a turnaround time of blood culture results i.e. the 
system has the ability to demonstrate time in and time out in terms of the sample processing 
and results outcome. However, this approach might have been problematic in conditions 
when the date structures were different i.e. dd-mm-yy or yy-dd-mm, but also where time was 
not entered into the database. The system might then have registered‘00’ for such data points 
indicating missing data on time. For this reason, laboratory data has to be treated with caution 
due to such omissions.  
 
4.1.7.7 Capacity of the LIS 
How large is the interconnectivity? Due to the large capacity of data handling, the LIS can be 
challenging in terms of its effectiveness. Should the LIS be too large, it might not function 
effectively. Hence utilisation of individual or separate servers by each laboratory as a way of 
making the system effective, becomes a major limitation in terms of national antimicrobial 
resistance surveillance programs, as the individual local servers are not interconnected to 
each other hence aggregating data becomes problematic. This means that each server 
transmits data separately into one central repository. Due to the efficiency of the network 
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services, or phone line, not all data might end being transmitted to the central repository. 
Some data get lost en-route the electronic transmission.  
 
4.1.7.8 Database structure 
The CDW operates on a relational database model. For a researcher to access data from the 
central repository there is need to design a query to extract the data of interest, and then 
assess what each query is giving back in terms of the data parameters that a researcher is 
interested in. To improve validity and reliability of data extracted from the CDW, there is 
need to create a micro strategy for the LIS, which would enhance the data that an individual 
wants to retrieve. 
 
4.1.7.9 Data Security System 
The LIS data is password protected and each of the local laboratories has an electronic gate 
keeper, to monitor and minimise data errors that could happen, but also to access the data for 
research use (https://labresults.nhls.ac.za). Since data comes from varying sources, it’s 
usually unclean with numerous errors hence strict measures need to be taken before making 
appropriate use of the data 
 
4.1.7.10 Turn around time 
In a situation where time is not recorded, it is advisable to use laboratory time as a starting 
point so as to be able to calculate the turn-around time for the laboratory results. However, if 
time entered into the system is ‘o’ instead of leaving the cell blank, the system will read ‘0’ 
as real zero time instead of missing data. In this situation data would obviously end up being 
skewed as it would cause ‘o’ inflated data. 
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4.1.7.11 LIS Performance  
To achieve sustained data quality, the following procedures need to be followed: 
 The laboratory clerks that register patients’ details into the LIS need to undergo regular 
intensive refresher training as they do not have basic knowledge of laboratory sciences as 
such they might not understand all processes involved with blood culture data. 
 
 There is need to settle on a standard data collection tool, modify the tool as necessary as 
is possible and when required, so that the laboratories settles on the real required data 
elements and in so doing, enhance aggregation of quality data into the database. 
 
 There is need to filter out data errors so that data suits the needs of the user. To 
thoroughly ascertain data quality, it is advisable to exclude irrelevant data elements in the 
database.  
 
 For the researcher to be able to access valuable information there is need to invest a lot of 
input into the laboratory information system because correct input data is essential to 
ensure accuracy and reliability of blood culture data. 
 
 There is need for standardisation of laboratory procedures and skills building i.e. 
providing similar training to laboratory technicians/technologists, registry clerks etc., 
across sites, with the aim of generating same competencies which will ultimately improve 
overall data output. 
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 Incorporation of an automatic review program into the LIS to detect data errors and 
ensure accuracy of the data at the point of data entry into the database system. 
 
4.1.8 Laboratory methods 
Different laboratories have different volumes of blood cultures being processed and possibly 
used different methods of blood culturing and susceptibility testing. The assumption was that 
if laboratories used different methods, they may produce results showing different 
antimicrobial susceptibility patterns which may be due to variation in the laboratory methods 
used for blood culture procedures. 
 
Based on the above assumption, a further investigation was done to determine; i) whether 
laboratories use different blood culture methods and procedures, ii) whether different 
methods for susceptibility testing use different MIC breakpoints, existence of equalities and 
non-equalities among different methods applied in various laboratories, some of which might 
influence differences in resistant pattern. Detailed findings are highlighted in section 4.2. 
 
The operations of clinical microbiology laboratories and LIS interconnectivity in South 
Africa may not be comparable to that of the western world, where they use machines to the 
high end of the spectrum, where all process are automated i.e. such as computerized clinical 
decision support systems (CCDSS) in the USA/UK, which are information technology-based 
systems designed to improve clinical decision-making. (112) 
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4.1.9 Future dimensions of LIS-Trackcare 
The NHLS has embarked on upgrading the LIS to make it function in real time. The DISA 
Lab LIS, which has been in use for several years by the NHLS, has now been replaced by 
TrakCare laboratory information system. The TrakCare system is being rolled out in all 
NHLS laboratories throughout the nine provinces of the country. (107) Since the process is 
being implemented in phases, the NHLS will experience an overlap in the LIS operations. 
However, the ultimate goal is that NHLS LIS migrates completely from DISALab to 
TrakCare LIS.  
 
There are challenges inherent with introduction of new system into a program. However, it is 
envisaged that the operations of the laboratories and turnaround time for results would 
improve greatly with a system that works on real time. Also that the interconnectivity will be 
enhanced such that patients’ results from any province can be accessed nationwide as 
opposed to the current system where laboratories operate independent of each other, hence 
should a patient move to another province, his/her laboratory data could not be accessed. The 
new TrakCare LIS has an in-built capacity to synchronise data across various sites as a means 
of improving efficiency in patient follow up and billing for laboratory tests.  
 
To overcome data transfer delays, TrakCare LIS system is programmed to use redundant 
telephone lines. The system was programmed to be linked to a wider network area as well as 
to the central server at NHLS head offices in Johannesburg. Since information will be 
directed to the central server from which it could be extracted for analysis. Patient follow up 
would be easier should a patient move from one geographical area to the next.  
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With the new LIS, patients’previous blood culture results, that were done at another clinic or 
laboratory will be traced backwards and followed up effectively. The system permits 
validation of data in an easier way through web access. However with the new LIS, a 
different database structure is being used hence current data from the DISA Lab LIS might 
possibly not be transferable. The system might also not allow direct local access to the data 
such as extraction for analysis but could be visualised across other clinics or hospitals since 
its web access. Patient data will be available even though not everyone will be able to access 
the data due to a built in password protection program.  
 
Since the system operates in real time, attending doctors might be limited to access data 
pertaining to their patients only. There has been constant development of the LIS program to 
be able to address any new needs of the user because there are indications that the new 
system might not have the ability to constantly update compared to DisaLab. At the same 
time the new LIS looks to be labour intensive. Such a scenario might create a problem to 
balance reliability and functionality of the TrakCare LIS. 
 
In comparison, the new system, TrakCare LIS, is designed to provide a web-based access, 
such that results for individual patients could be accessed anywhere the patient would go for 
medical services within the public sector system. TrakCare LIS interface is configured using 
the same standard tests that the NHLS laboratories perform as well as the general working 
style. However, TrakCare LIS system is not as flexible to the local needs of the laboratories 
as the DISA Lab system has been.  
 
TrakCare LIS system only allows for global changes, i.e. changes to entire network. This 
means that any changes made to the system by the user within the NHLS network will be 
universal and will affect all NHLS laboratories across the country. This means that the local 
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IT personnel are left with no opportunity to modify the system so as to suit their local needs. 
However, the major advantage is that the TrakCare LIS has been designed, validated and 
standardised with contributions and close involvement of information technology (IT) 
managers from various NHLS sites, hence the system has a high acceptability level by the 
end users as it is being rolled out.  
 
4.1.10 Blood culture data quality 
To improve data quality and minimise improper estimates of antimicrobial resistance that 
could lead to misinterpretation of the findings, consider excluding from the database data 
elements that are not compatible. When manual data extraction of blood culture data is 
performed at the CDW, an individual researcher needs to systematically exclude certain data 
elements that are inappropriate compared with the data parameters normally encountered in 
surveillance analysis. 
 
There is need to monitor specific areas where problems with data quality could be identified 
and appropriate intervention undertaken to improve data quality. To achieve this, the 
following issues need to be considered: 
 Whether a researcher would accept at face value what was extracted from the database 
using the designed query?  
 Whether a researcher would be able to make any request for specific, logical, clear and 
unambiguous data elements in the query design? (For more details, refer to 2.5 data 
management, section 2.5.1, Table 2.1). 
 
To improve the quality of data aggregated at the CDW, there is great need for various players 
from the different NHLS laboratories to team up so as to minimise major variability of 
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antimicrobial resistance patterns that might be originating to a large extent from data entry 
errors. In addition laboratories should always run regular validation exercises to make sure 
that data gathered is accurate and reliable. 
 
To improve surveillance of antimicrobial resistance there is a need for the NHLS to introduce 
instruments that could be effectively utilized to generate reliable data elements to be used for 
various epidemiological investigations as well as aid clinical decision making regarding 
bacteraemia episode by clinicians in the clinical departments.  
 
4.1.11 Conclusion 
The LIS was not primarily designed as a research or surveillance tool. Its function has been to 
generate data that could be used for appropriate and accurate billing of all tests done in the 
lab. Data has also been used to understand the volume of tests done, the time it takes to get 
results back to the patient and use such data to plan service delivery of the NHLS. We believe 
such a system can be used as an effective surveillance tool to monitor development of 
antimicrobial resistance to nosocomial pathogens in our population, since the process of 
acquiring blood culture data is inherently ongoing. Therefore, understanding the shortfalls of 
the system and suggesting ways of improving the overall system performance is a step in the 
right direction, if there is a well established and functioning antimicrobial resistance 
surveillance program. Such a program would enhance our ability to contain the growing crisis 
of antimicrobial resistance that threaten our ability to treat patients effectively in South 
Africa.  
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4.2  Differences in Laboratory Methodology and their Impact on 
Antimicrobial Resistance Surveillance 
 
4.2.1 Introduction 
Retrospective analysis of data from the CDW revealed that there were significant variations 
in patterns of antimicrobial resistance by hospitals. (Chapter 5, Table 5.2, Chapter 6, Table 
6.7 and 6.8) We therefore aimed to understand whether differences exist in laboratory 
methodology and assess whether such differences could have a significant impact on quality 
of antimicrobial resistance data and patterns of resistance as observed. 
 
4.2.2 Methodology 
4.2.2.1 Design and study setting 
This qualitative observational study was conducted between June 2011 and January 2013. 
The NHLS clinical microbiology laboratories servicing public tertiary hospitals associated 
with academic institutions in three provinces were involved in the study (details of the sites 
have been provided in Chapter 2, section 2.2). The map of the Republic of South Africa 
below highlights the geographical location of the study sites (Figure 4.3) where a systematic 
observation of laboratory procedures and practices was undertaken mostly within 1-2 
working days per each laboratory. 
 
4.2.2.2 Data sources and collection procedure  
The procedure for gathering information followed a systematic approach which was a 
combination of: i) an in-depth orientation of the activities of the laboratory in general with a 
more in-depth focus on the activities of specific microbiology department, ii) series of 
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informal discussions with individual members of staff who do blood cultures in the 
department, iii) observation of the activities taking place in the laboratory in general, but with 
a focus on the microbiology laboratory specifically blood culturing as well as, iv) a question 
and answer feedback with members of the microbiology department at each hospital. Staff 
members in the IT department were also involved and this helped to gather detailed 
information on the functionality of the laboratory as well as data flow from the front desk, 
where specimen registration takes place. A standard observation checklist (Appendix 12.4) 
was specifically developed and used for this purpose, to ascertain standardised data collection 
in all the study sites. 
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Map of the Republic of South Africa
Sentinel surveillance sites July 2010- June2011
Figure 4.3 Map of the Republic of South Africa showing study sites 
Free State province: Universitas Hospital complex; Western Cape Province: Groote Schuur & Tygerberg 
Hospital; Gauteng province: Charlotte Maxeke Johannesburg Academic Hospital, Helen Joseph, Chris Hani 
Baragwanath Hospital, Steve Biko Pretoria Academic Hospital. 
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4.2.2.3 Data sources and approach to collection 
Interviews and informal discussions were done with laboratory staff in the microbiology 
department, who deal with specimens i.e. blood or cerebral spinal fluid (CSF), stool, urine, 
pass swabs, joint and peritoneal fluids for culturing. The purpose was to understand the 
operations of the laboratory regarding specimen registrations, processing, results 
dissemination, data entry as well as the interconnectivity of the LIS.  
 
The pathologists provided more technical and academic details regarding blood culture 
procedures while laboratory managers provided more detailed information regarding the 
logistics and operations of the microbiology laboratory. In addition, laboratory technologists 
explained in detail the whole process of doing a blood culture and susceptibility testing (from 
specimen receipt to blood culture results, validation of results by pathologist and entry of 
results into LIS).  
 
The registry clerks explained the details about specimen sorting from all clinical departments. 
The specimens are sent to the appropriate laboratory department; registration of the specimen 
to make sure that specimen identification is in line with patient identification. This 
undertaking by the laboratory staff eliminates the allocation of results to the wrong patient.  
 
The IT managers gave a detailed description of the operations of the LIS, how data is 
transmitted to the central repository and limitations of the system, including data loss during 
electronic transmission from local server to the CDW. 
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4.2.3 Results 
4.2.3.1 The results are summarised in the flow chart presented below  
 
The chart below describes flow of blood culture specimens and results as well as the flow of 
data from the NHLS microbiology laboratories to the central repository (CDW). 
 
Figure 4.4 Diagrammatic representation of the NHLS blood culture data flow and 
interlinkage with the Laboratory Information System 
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Step 1: All specimens (blood culture and others) from the different clinical departments and 
wards are received in the laboratory central reception area. 
 
Step 2: The specimens are registered and the following details are entered into the system: 
name of patient, ID number, ward where admitted and hospital, a unique code is allocated 
here. Patient details for each specimen are entered into the system and a code is generated for 
that particular patient. This code becomes the patient identifier and is pasted on specimen 
bottle for ease of identification. Such attention aids the laboratory staff to avoid giving results 
to the wrong patient.  
 
Step 3: The specimens are then sorted in order of specimen type, i.e. blood culture, full blood 
count, urine, microscopy etc. Thereafter, specimens are distributed to the appropriate 
departments for processing.  
 
Step 4: Blood culture are processed in the microbiology laboratory. Here, an active 
verification process of blood culture bottles is done against information documented on the 
laboratory request form from the clinical departments/wards. This process helps to ascertain 
that a particular specimen bottle belongs to a particular patient.  
 
Step 5: Once the blood culture specimen bottle has been delivered to the microbiology 
laboratory, the specimens, first, get processed in the culture room. Each sample details are 
first entered into the register book thereafter each specimen bottle is inserted into the 
BacT/ALERT® 3D incubator, where blood culture specimen normally stay for up to a 
maximum of 5-7 days (Figure 4.5). This machine falls in the category of microbial detection 
system and is fully interfaced with the LIS program. Positive blood cultures are identified 
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each time an indicator light of the incubator bleeps up against a particular blood culture 
bottle. The positive culture bottle is then removed from the BacT/ALERT® 3D for further 
processing.  
 
 
Figure 4.5 The pictograph of the BACT/ALERT 3D incubator. 
 
This picture of the BA-3D was taken in the NHLS microbiology laboratory at the Charlotte Maxeke 
Johannesburg Academic Hospital. (P. Nyasulu) 
 
Step 6: Gram staining is then done to identify the organism, and positive Gram stain results 
are then communicated to the physicians in the wards. 
 
Step 7: Antimicrobial susceptibility testing is then carried out to find out which antibiotics 
the cultured bacteria are sensitive to. Usually within 2-28 hours after receipt of the blood 
culture specimen, the patient would have received the results at the Universitas hospital 
complex while at CMJAH blood culture turnaround time is ~48 hours from receipt of 
specimen to release of susceptibility results. 
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Step 8: Blood culture and antimicrobial susceptibility results are entered into LIS. If API 
method was used, the data are entered manually. The Vitek and Micro Scan (Figure 4.6) are 
fully automated machines. They are used for antimicrobial susceptibility detection. Results 
from the machine are automatically entered into the LIS since the interface of the 
microbiology detection machines feeds into the DISAlab. Antimicrobial susceptibility data 
from Vitek and Micro-Scan are electronically transmitted to the local server.  
 
Figure 4.6 The pictograph of the Micro Scan 
 
This picture of the MicroScan was taken in the NHLS microbiology laboratory at the Charlotte Maxeke 
Johannesburg Academic Hospital on the 5
th
 of September, 2012. (P. Nyasulu) 
 
Step 9: Once susceptibility results are ready and verified by the Pathologist, the clinicians are 
informed and guided accordingly on the choice of appropriate antibiotics to prescribe to 
patients. The Pathologist then signs off the printout of the results authorising the laboratory 
technician to enter results on the LIS computer and release the results to the clinical 
department or wards.  
 
P a g e  |115 
 
  
Step 10: Blood culture now on the LIS, can also be accessed directly by clinician in various 
clinical departments once an individual logs on to the DISALab LIS computer. 
 
Step 11: From the automated machines, blood culture data automatically aggregates at the 
local server of each laboratory. 
 
Step 12: Then from each local server, blood culture data are transmitted to the central data 
warehouse (CDW) in Johannesburg via the File Transfer Protocol (FTP). DISA Lab does not 
operate in real time hence regular transfer of data takes place.  
 
Step 13: The major challenge encountered at steps 11 and 12, which can compromise data 
integrity is lack of appropriate data linkage, because the current set up can sometimes affect 
data transfer in times when the network or phone line is off or the LIS computer has a 
technical problem (Figure 4.7). In addition, time is an essential data component hence time 
gets recorded so that all changes made to the data at any point in time could be traced back, 
by looking at what time a particular individual made any change (this is a built-in security 
control method of DISA Lab).  
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Figure 4.7 The pictograph of the LIS computer 
 
This picture of the LIS computer is linked to all blood culture processing machines. It was taken in the NHLS 
microbiology laboratory at the Charlotte Maxeke Johannesburg Academic Hospital on the 5
th
 of September, 
2012. (P. Nyasulu) 
 
Step 14: At the CDW, data extraction for analysis of antimicrobial resistance patterns from 
blood cultures takes place (Further details are given in section 4.1.6). 
 
4.2.3.2 Standard operating procedures 
Most microbiology laboratories operated on set standard operating procedures (SOPs). These 
procedures were available and visibly displayed in some but not all microbiology 
laboratories. For example, at the Universitas hospital complex, the SOPs were not seen, either 
they were not available or were just not displayed. This could be a sign that even if the SOP 
existed, it is not a common point of reference. However, in other microbiology laboratories 
such as Groote Schuur hospital, SOPs were visibly displayed and actively used as a point of 
reference. The following SOPs were noted at this site: 
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 MIC0712: Maintenance and loading the Bactec 9120/9240 blood culture system. 
 MIC0713: Processing of Bactec culture bottles 
 MIC 0732: Antimicrobial sensitivity testing 
The microbiology laboratory at GSH follows the designed protocol on how antimicrobial 
susceptibility testing should be done, standard method (disk diffusion according to Kirby-
Bauer, E-Test derivative of agar dilution etc.). Automated reading of the antimicrobial 
susceptibility test is done if performed through the computerised machines linked with the 
LIS. For other hospitals, similar standard procedures are followed with differences in their 
operations. 
4.2.3.3 Similarities and differences in Laboratory Methods and Procedures 
Table 1 summarises some of the observed similarities and differences in laboratory methods 
as well as equipments used for blood culturing in various NHLS laboratories. 
 
Table 4.1 The table shows the comparative assessment of NHLS blood culture 
methodology 
 
  Hospital 
Parameters Assessed CMJAH CHB SBPAH HJ TH 
Micro-SOP √ √ √ √ √ 
Automated organism 
identification/susceptibility 
testing 
Microscan Microscan Vitek 2 Microscan Vitek 2 
Automated Blood Culture BA-3D BA-3D BA-3D BA-3D BA-3D 
Specimen registration √ √ √ √  
Results entry Manual Manual Manual Manual Manual 
LIS access in the ward √ √ √ √ √ 
Results validation  Registrar Pathologist Pathologist Pathologist Pathologist 
CPU √ √ - √ - 
Susceptibility testing 
guidelines 
CLSI CLSI CLSI CLSI CLSI 
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From table 4.1, we concluded that no major differences exist in the methods of blood 
culturing and susceptibility testing between different NHLS sites. The microscan and vitek2 
systems were validated and pathologists were of the opinion that these machines produced 
similar results.  
 
4.2.3.4 Limitations 
There were over 300 NHLS laboratories nationwide during the and over 50 of these were in 
KwaZulu Natal (KZN). This means that only about 250 of these NHLS laboratories operated 
on a FTP system transferring data from the microbiology laboratories to the CDW. In this 
case, data functionality might be compromised due to other network program activities of the 
system.  
 
4.2.4 Discussion and Conclusion 
We observed that different laboratories use different volumes of blood sample in processing 
blood cultures and subtle differences in methods of blood culturing and susceptibility testing. 
The study was done to address the assumption that if different methods were used, then the 
laboratories may produce different antimicrobial susceptibility culture results simply because 
the methods used are different and not because the differences are geographically inherent.  
 
There were few observed differences in the operational procedures as well as the microbial 
detection systems used in different laboratories. Such differences might not influence blood 
culturing outcomes that could lead to major differences in resistance pattern. In addition, 
some laboratories such as GSH, are better equipped than others such as UH, which might be 
an indication of differences in the distribution and or availability of resources. There is need 
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to understand equalities and non equalities among the different laboratory methods as some 
of these might influence differences in resistant pattern. 
 
In addition, since data is not in real time and that the system operates on multiple servers 
transferring data from local servers into one central repository, there is need to design a 
program that could be executed to extract data for analysis and reporting each time data are 
required.  
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Chapter 5 Evaluating the suitability of the LIS as a 
monitoring tool for recording antimicrobial resistance 
trends and patterns in tertiary public hospitals in South 
Africa 
 
This chapter provides findings of a critical assessment of LIS through analysis of blood 
culture data from seven NHLS clinical microbiology laboratories aggregated at the CDW 
from 2005 to 2009. The aim was to assess reliability of the NHLS LIS as a tool for reporting 
antimicrobial resistance among blood culture isolates of nosocomial bacterial pathogens from 
public hospitals in South Africa. 
 
5.0 Abstract 
Aim: To evaluate suitability of a laboratory information system (LIS) on reporting 
prevalence, patterns and time trends, and associated demographic factors of resistance to 
commonly used antibiotics for selected pathogens from blood specimens. 
 
Methods: A retrospective analysis was conducted of routine data recorded on the LIS of 
blood-culture isolates of Staphylococcus aureus (SA), Klebsiella pneumoniae (KP), and 
Pseudomonas aeruginosa (PA) collected by the National Health Laboratory Service (NHLS) 
between July 1, 2005 and December 31, 2009 from diagnostic microbiology laboratories at 7 
tertiary public hospitals in South Africa. Antimicrobial resistance to commonly used 
antimicrobials was systematically recorded and analysed. Multivariate logistic regression 
models were used to assess factors associated with antimicrobial resistance.  
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Results: Information on 9969 isolates was available, of which 3942 (39.5%), 4466 (44.8%) 
and 1561 (15.7%) were SA, KP and PA, respectively. The proportion of resistance across all 
antibiotics tested was highest in the 30-39 year age-group for SA (28.4%) and PA (51.5%), 
but for KP, the highest proportion (73.3%) was in the 5-9 year age-group. SA and PA 
resistance was similar between males and females. For KP, a higher percentage of the isolates 
from females were resistant. The highest proportion of resistance at specific sites to non-wild 
type isolates was as follows: 47.9% of SA resistant isolates were from Tygerberg hospital, 
72% of KP resistant isolates were from Universitas hospital and 67.1% of PA resistant 
isolates were from Steve Biko Pretoria Academic hospital. SA resistance to cloxacillin was 
39% and to vancomycin <0.1%. KP resistance to carbapenems was low; imipenem 0.1% 
(range 0%-0.5%) and meropenem 0.1% (range 0%-0.3%), ertapenem 2% (range 0.5%-4.6%) 
- as was resistance to colistin 1.7% (range 0-2.6%). PA resistance to colistin was 1.9% (range 
0.0 -13.3%). There was a significantly increasing trend of KP resistance to ciprofloxacin 
(32.6% to 64.9%, p<0.001), cotrimoxazole (67.5% to 81.6%, p<0.001) and cefotaxime-
ceftriaxone (55.5% to 73.2%, p<0.001) over the study period. PA resistance to meropenem 
showed a significant increasing trend from 2006 (27.5%) to 2009 (53.9%) ( p<0.001). Age 
group <5 years, female gender, hospital location and year of infection were significantly 
associated with higher antimicrobial resistance. 
 
Conclusions: The proportion of antimicrobial resistance reported by the LIS was high and 
shows a significant increasing trend among individual agents, i.e. ciprofloxacin, 
cotrimoxazole among others. Enhancement of continued surveillance of antimicrobial 
resistance among bloodstream hospital-acquired infections is recommended. Such data would 
aid the understanding of the magnitude of the problem and provide solid evidence upon 
which policies and practices aimed at containing antimicrobial resistance could be generated. 
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5.1 Introduction 
The magnitude of antimicrobial drug resistance has accentuated the need for continued 
surveillance of antimicrobial susceptibility.(76, 113, 114) Resistance of bacterial pathogens 
to conventional antimicrobials has become a global problem with hospital infections 
becoming more challenging among immune-compromised individuals, emphasizing the 
importance to systematically monitor patterns and trends of antimicrobial resistance over 
time. (16, 115, 116) 
 
Enhanced information retrieval and better understanding of the magnitude of the problem 
would facilitate timely implementation of appropriate interventions including review of 
antimicrobial prescriptions policy and treatment guidelines that would reinforce prudent 
antimicrobial use. (117-119) In the face of a decline in the development of new antimicrobial 
drugs by pharmaceutical companies, the long-term goal of patient management would be to 
preserve the effectiveness of currently available antimicrobials so that they would remain 
functional for years to come. (16) 
 
Surveillance networks such as the European Antimicrobial Resistance Surveillance System -
EARSS (Europe) (120) and the National Nosocomial Infections Surveillance System-NNIS 
(USA) (121) have been established over the years focusing on pathogens that serve to provide 
reliable sources of antimicrobial susceptibility data. Such data have been used to determine 
resistance patterns and monitor emerging antimicrobial resistance. (17) However, at present 
there is scarcity of data from most developing countries regarding the burden of antimicrobial 
resistance, even among nosocomial pathogens which reflect the situation in hospitals from 
where most resistance problems have emerged. A recent systematic review showed evidence 
of resistance to commonly used antimicrobial drugs in the South African population. The 
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proportion of methicillin-resistant Staphylococcus aureus (MRSA) was 35% while Klebsiella 
pneumoniae showed increasing resistance to 3
rd
 generation cephalosporins or isolates 
producing extended-spectrum beta-lactamases (ESBLs) from 33% to 49%, and from 18% to 
28% for fluoroquinolones in academic hospitals from 1999 and 2007. Resistance among 
Pseudomonas aeruginosa isolates to ciprofloxacin was 43%. (31) Antimicrobial resistance is 
a major catalyst for therapeutic failure of antimicrobial agents prescribed empirically. 
Frequently in low resource settings where laboratory facilities are not available, clinicians 
have to rely on clinical diagnosis and empirical treatment for patient management. (75, 113, 
122) 
 
Knowledge of local prevalence of pathogens and antimicrobial resistance serves as a guide 
for routine antimicrobial prescription. Ideally, clinical decision-making regarding choice of 
effective antibacterials should be guided by global (for empiric treatment) and local 
knowledge of antimicrobial resistance epidemiology. (122) In addition, antimicrobial 
resistance surveillance data would guide planning of targeted public health interventions to 
control the development of antimicrobial resistance and spread of resistant pathogens in 
hospitals. (16) 
 
Data on resistance patterns would augment infection control measures and promote improved 
antimicrobial prescribing habits among clinicians. (115) This study investigated the 
suitability of Laboratory Information System (LIS) reporting of antimicrobial resistance 
prevalence, patterns and temporal trends as well as demographic factors associated with 
antimicrobial resistance among three selected pathogens, Staphylococcus aureus (SA), 
Klebsiella pneumoniae (KP) and Pseudomonas aeruginosa (PA), causing blood stream 
infections in patients admitted at tertiary public hospitals in South Africa. 
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5.2 Methodology 
 
5.2.1 Study Design 
This was a retrospective analysis of routine blood culture data reported from 2005-2009 by 
the NHLS and extracted from the CDW situated at the corporate office of the NHLS at 
Sandringham, South Africa. The study was approved by the Human Research Ethics 
Committee, University of the Witwatersrand, approval number M10625 (Appendix 12.3.8). 
 
5.2.2 Participating Institutions 
Seven tertiary public hospitals were included in the study: Charlotte Maxeke Johannesburg 
Academic hospital (CMJAH), Steve Biko Pretoria Academic hospital (SBPAH), Chris Hani 
Baragwanath hospital (CHBH) and Helen Joseph (HJ) from Gauteng province; Universitas 
Hospital (UH) from Free State province; Groote Schuur (GSH) and Tygerberg hospitals (TH) 
from the Western Cape. All the hospitals involved were associated with academic 
institutions. 
 
5.2.3 Laboratory Methods 
The NHLS academic laboratories used the automated BactAlert system for blood culture 
investigations and automated MicroScan or Vitek 2 systems, or conventional biochemical 
methods for identification of pathogens. Antibiotic susceptibility testing was done following 
the Clinical Laboratory Standards Institute (CLSI) guidelines. Various methods were used 
including testing by disk diffusion technology such as the Kirby-Bauer and Etest methods or 
automated testing using MicroScan or Vitek 2 systems. Quality control for susceptibility 
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testing was taken into account at each participating site. It is standard practice worldwide for 
quality control procedures to be used for drug susceptibility testing, including the use of 
dedicated international strains such as S. aureus for Gram-positive bacteria and E. coli for 
Gram-negatives, as well as standardization of inoculums size and incubation period. Only 
single episodes of bacteraemia were recorded by the laboratory to avoid bias in susceptibility 
reporting. Table 5.1 below shows details of methods of susceptibility testing for blood culture 
isolates in use by participating microbiology laboratories for the selected organisms. (123) 
 
Table 5.1 Laboratory methods used in testing for antimicrobial susceptibility of Gram-
negative bacilli and Staphylococcus aureus 
 
Organism 
Group 
CHB CMHAH SBPA
H 
HJ UH GSH TH 
Gram-negative 
bacilli 
^MicroScan MicroScan Vitek 
2* 
Vitek 2 Disc 
diffusion 
 
Vitek 2 Vitek 2 
Staphylococcus 
aureus 
Disc 
diffusion,  
Etest 
Disc 
diffusion, 
Etest 
MicroScan 
Vitek 
2* 
Etest 
Disc 
diffusion 
Etest 
Disc 
diffusion 
 
Disc 
diffusion, 
Etest 
Disc 
diffusion 
Etest 
 
*Vitek: BioMerieux, North Carolina. ^MicroScan: Dade Behring Inc, Califonia 
 
5.2.4 Data Extraction 
Data were extracted on all blood culture positive isolates of SA, KP and PA reported within 
the study period by DISA-LIS at NHLS. Susceptibility data reported by DISA were extracted 
from the CDW data repository by running SQL query from several database servers, details 
are described in chapter 2 section 2.5.1. Blood culture data of isolates from all wards 
including casualty department reported between July 1, 2005 and December 31, 2009 were 
included. All demographic and microbiological variables to be included in the analysis were 
extracted. Patterns and trends of resistance were expressed in terms of the number of non-
wild type isolates divided by the total number of blood culture isolates for each organism. 
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The variable ‘resistance’ was inferred when the growth of an isolate was found to be 
inhibited at internationally recognised “critical concentrations” of the antibiotics on 
susceptibility testing. Other covariates were demographic and geographic characteristics 
including: age, gender, province and names of hospitals, wards and year of data collection.  
 
5.2.5 Statistical Analysis 
Data were checked and cleaning for each included variable was done. Data were then 
analysed using Stata version 11 (StataCorp Limited, College Station, Texas, USA). 
Univariate analysis was done to describe the frequency distribution of the selected pathogens 
as well as the distribution of the proportion of resistant isolates of the selected pathogens per 
antibiotic tested. Associations between resistance and various presumed risk factors 
(province, organism, age, gender, hospital wards and specimen collection year) were 
analysed using Pearson chi-square test for categorized variables. A multivariate logistic 
regression model was used to investigate independent predictors of antibiotics-specific 
resistance as well as composite resistance based on a set of antibiotics. Two-sided p values of 
<0.05 were considered significant. 
 
5.3 Results 
 
5.3.1 Demographic and geographical characteristics of bacteraemia 
episodes 
There were 9969 single bacteraemia episode-linked isolates of selected pathogens within the 
study period of which 3942 (39.5%) were SA, 4466 (44.8%) were KP and 1561 (15.7%) were 
PA. The <5 years age-group had the most blood stream isolates in the case of each of the 
three respective pathogens: mean of 306 SA episodes per annum for the first 4 years of life, 
418 episodes of KP and 111 of PA. Comparable mean annual figures for the 20-59 years age-
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group were 48.5 episodes of SA, 48.2 of KP and 19.9 of PA, i.e. 6.3 times fewer cases of SA, 
8.7 times fewer of KP and 5.6 times fewer of PA episodes than in the <5 years age-group. 
There were more bacteraemic episodes caused by each of the three pathogens in males than 
in females. The proportion of bacteraemic episodes in relation to numbers of admissions and 
duration of patients’ stay in hospital is not available for comparison of frequency of 
organism-specific bacteraemic episodes between hospitals. However, considering the relative 
percentages of organism-specific episodes in each hospital, SA episodes at Helen Joseph 
(49.8%), Tygerberg (47.1%) and Groote Schuur (45.5%) against mean of 40.3% of all 7 
hospitals; KP episodes at Universitas (52.1%) and SBPAH (51.3%) against the 7-hospital 
mean of 45.5%; and PA episodes at SBPAH (20.1%) and CMJAH (19.2%) against the 7-
hospital mean of 15.2% suggest possible excess of SA, KP and PA cases at the named 
hospitals. Because of confounding factors, the validity of such an approach is questionable. 
The numbers of episodes per annum for the respective pathogens for the period 2006-2009, 
varied from 871 to 965 (mean 902) for SA, 974 to 1124 (mean 1030.5) for KP and 347 – 368 
(mean 357) for PA. (Table 5.2)  
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Table 5.2 Distribution of demographic and geographical characteristics of patients 
presenting with bacteraemia episode caused by the three organisms  
 
Characteristic Staphylococcus aureus Klebsiella pneumonia Pseudomonas aeruginosa 
Age  n/N *(%) n/N *(%) n/N *(%) 
<5 1224 (31.1) 1673 (37.5) 444 (28.4) 
5-9 95 (2.4) 60 (1.3) 34 (2.2) 
10-19 231 (5.9) 194 (4.3) 67 (4.3) 
20-29 504 (12.8) 439 (9.8) 223 (14.3) 
30-39 598 (15.2) 611 (13.7) 235 (15.1) 
40-49 482 (12.2) 458 (10.3) 188 (12.0) 
50-59 354 (9.0) 421 (9.4) 151 (9.7) 
60-69 270 (6.9) 336 (7.5) 126 (8.1) 
≥70 184 (4.7) 274 (6.1) 93 (6.0) 
Gender    
Male 2185 (57.4) 2421 (56.0) 858 (57.0) 
Female 1619 (42.6) 1902 (44.0) 648 (43.0) 
Hospital     
Charlotte Maxe JAH 611 (15.5) 670 (15.0) 304 (19.5) 
Chris Hani Bara 1120 (28.4) 1382 (30.9) 454 (29.1) 
Helen Joseph 374 (9.5) 268 (6.0) 109 (7.0) 
Steve Biko PAH 438 (11.1) 786 (17.6) 307 (19.7) 
Universitas 173 (4.4) 261 (5.8) 67 (4.3) 
Groote Schuur 556 (14.1) 531 (11.9) 135 (8.7) 
Tygerberg  670 (17.0) 568 (12.7) 185 (11.9) 
Province     
Gauteng 2543 (64.5) 3106 (69.6) 1174 (75.2) 
Free State 173 (4.4) 261 (5.8) 67 (4.3) 
Western Cape 1226 (31.1) 1099 (24.6) 320 (20.5) 
Year     
2005 335 (8.5) 344 (7.7) 133 (8.5) 
2006 965 (24.5) 974 (21.8) 355 (22.7) 
2007 849 (21.5) 1002 (22.4) 358 (22.9) 
2008 922 (23.4) 1124 (25.2) 347 (22.2) 
2009 871 (22.1) 1022 (22.9) 368 (23.6) 
 
*The proportions (%) are number of isolates for each characteristic (n) / total number of isolates for each 
individual pathogen (N). The total number of isolates for each characteristic were SA =3 942; KP = 4466; PA = 
1561, except for gender, where the total number of isolates were: SA = 3804; KP = 4323; PA = 1506 due to 
missing data on gender. 
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5.3.2 Distribution of antimicrobial resistance rates among selected 
pathogens 
The pattern of resistance to various antibiotics was fairly similar between the three pathogens. 
For S. aureus, resistance is still detected for linezolid (0 out of 70) and minimal (1 out of 865) 
for vancomycin and is <15% for fusidic acid. For other antibiotics, SA resistance is above 
20% with variation between individual antibiotics and >15% across all ages for clindamycin. 
For KP, resistance is almost not detected for meropenem and imipenem and slowly gaining 
ground for etrapenem. Resistance to amikacin is below 30% while for the rest of the 
antibiotic resistance is >30% across all age-groups. Among PA isolates resistance rate was 
mostly >30% across all age categories for all antibiotics except for ceftazidime that showed 
resistance rate of below 20%. Figure 5.1* - 5.3 below shows the distribution of antimicrobial 
resistance rate of SA, KP and PA by Age-group. 
 
 
Figure 5.1 Antimicrobial resistance rate of Staphylococcus aureus isolates for the period 
2005 to 2009 by age-group  
 
*There were only 3 isolates investigated for rifampicin resistance and all three were resistant. The percentage 
figures for rifampicin resistance in the various age groups should therefore be treated with reserve. 
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Figure 5.2 Antimicrobial resistance rate of Klebsiella pneumoniae isolates for the period 
2005 to 2009 by age-group 
 
 
Figure 5.3 Antimicrobial resistance rate of Pseudomonas aeruginosa isolates for the 
period 2005 to 2009 by age-group 
 
5.3.3 Distribution of antimicrobial resistance rate by gender 
There is a preponderance for higher proportions of resistant isolates, >60% of SA resistance 
isolates to various antibiotics among males compared to females for ciprofloxacin, fusidic 
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acid, gentamicin and ampicillin and lower proportions, <40% of SA resistant isolates among 
males than females for clindamycin, erythromycin and cotrimoxazole. SA resistance to 
rifampicin and cloxacillin appears similar. However, the observed variation in proportions of 
resistant isolates between males and females was not significant. The trend of KP resistance 
shows that proportion of resistance is lower among males compared to females among most 
antibiotics with the exception of amikacin, the rate is higher among males compared to 
females, but has similar proportions of resistance between males and females for 
ciprofloxacin and ampicillin.  
 
For PA, the proportions of resistance between males and females is almost similar for most of 
the antibiotics except for ciprofloxacin, gentamicin and imipenem, where the resistance is 
>30%, while for meropenem and tobramycin, the proportion of resistance is higher among 
females than males with resistance >40%. No real difference in proportion of resistance was 
observed for other antibiotics, i.e. cefepime and ceftazidime. Figure 5.4-5.6 below shows the 
distribution of antimicrobial resistance rate of SA, KP and PA by gender. 
 
Figure 5.4 Antimicrobial resistance rate of Staphylococcus aureus isolates for the period 
2005 to 2009 by gender 
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Figure 5.5 Antimicrobial resistance rate of Klebsiella pneumoniae isolates for the period 
2005 to 2009 by gender 
 
 
Figure 5.6 Antimicrobial resistance rate of Pseudomonas aeruginosa isolates for the 
period 2005 to 2009 by gender 
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5.3.4 Patterns of S. aureus resistance 
SA resistance to ciprofloxacin ranged 20% - 100% across all sites. There was no data for 
ciprofloxacin susceptibility testing at SBPAH and scanty data at CHB, HJ, UH and TH. The  
Frequencies of clindamycin (72%) and rifampicin (60.7%) resistance in SA at TH are high 
and do not appear to be linked to macrolide (erythromycin) resistance (44.1%). Resistance to 
vancomycin was <0.5% and the rate of MRSA were highest at TH 43% (range 0.4% - 43%, 
there is a concern about recording resistance to cloxacillin or cefoxitin in LIS at different 
sites). Resistance to cotrimoxazole ranged 25% - 37% and gentamicin resistance ranged from 
40% - 67% across all hospitals. There was scanty data for other drugs to make any 
meaningful analysis. (Table 5.3) 
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Table 5.3 Antimicrobial resistance patterns of selected blood borne infections, by hospital, during 2005 – 2009 period 
 
Organism/drug Total CMJAH CHB HJ SBPAH UH GSH TH p-value 
Staphylococcus aureus % (n/N)**                 
Ampicillin  95.7(3,322/3,471) 96.8(481/497) 98.8(941/952) 97.4(295/303) 88.2(365/414) 92.1(140/152) 94.7(482/509) 96.0(619/644) 0.85 
Cloxacillin 15.4(588/3,828)* 4.2(25/595)* 0.4(4/1,103)* 3.8(14/366)* 5.0(21/422) 30.4(51/168) 37.0(193/522) 43.0(280/652) <0.001 
Vancomycin 0.12(1/865) 0.0(0/34) 0.0(0/11) 0.0(0/25) 0.0 (0/37) 0.0 (0/108) 0.0 (0/337) 0.3(1/313) 0.94 
Gentamicin 51.8(428/827) 40.0(6/15) 25.0 (3/12) 66.7(6/9) 22.2(2/9) 50.0(1/2) 46.6(132/283) 55.9(278/497) 0.02 
Erythromycin 34.5(802/ 2,326) 40.5(104/257) 26.6(92/346) 53.6(59/110) 19.0(65/343) 40.9(54/132) 29.7(153/515) 44.1(275/623) <0.001 
Linezolid 0.0(0/70) 0.0(0/6) 0.0(0/4) 0.0(0/3) 0.0(0/1) 0.0(0/32) 0.0(0/15) 0.0(0/9) na 
Clindamycin 32.4(650/2,005) 17.9(40/224) 23.6(77/326) 32.1(27/84) 14.6(50/343) 33.1(47/142) 28.2(147/522) 72.0(262/364) <0.001 
Rifampicin 39.9(194/486) 25.0(3/12) 0.0(01/14) 55.6(5/9) - 30.0(3/10) 32.1(95/296) 60.7(88/145) <0.001 
Fusidic acid 8.5(33/388) 11.1(1/9) 9.1(1/11) 0.0(0/3) 0.0(0/3) 25.0(2/8) 0.7(2/269) 31.8(27/85) <0.001 
Cotrimoxazole 29.9(577/1,930) 36.8(89/242) 30.9(100/324) 27.9(22/79) 50.0(3/6) 28.5(43/151) 24.6(128/521) 31.6(192/607) 0.02 
Klebsiella pneumonia % (n/N)** 
        
Ampicillin_Amoxy 99.5(3,769/ 3,789) 99.8(617/618) 99.5(1298/1305) 100.0(253/253) 99.3(739/744) 98.4(246/250) 99.3(277/279) 99.7(339/340) 0.16 
Amoxiclav 64.8(2,550/3,936) 64.0(336/525) 73.0(869/1,190) 64.4(154/239) 59.2(439/741) 55.7(113/203) 52.7(263/499) 69.8(376/539) <0.001 
Imipinem 0.1(4/3,059) 0.0(0/386) 0.2(2/863) 0.0(0/156) 0.0(0/568) 0.0(0/221) 0.2(1/493) 0.3(1/372) 0.79 
Meropenem 0.1(5/3,046) 0.0(0/397) 0.1(1/890) 0.0(0/162) 0.2(1/565) 0.0(0/141) 0.2(1/495) 0.5(2/396) 0.66 
Ertapenem 2.0(50/2,474) 2.6(9/349) 2.8(18/652) 3.5(5/145) 0.8(4/533) 4.6(10/220) 0.8(3/376) 0.5(1/199) 0.01 
Cefazolin 86.3(1,864/2,161) 94.8(349/368) 97.1(789/813) 90.9(140/154) 65.2(329/505) 77.8(168/216) 0.0(0/2) 86.4(89/103) <0.001 
Ceftazidime 82.0(2,428/2,962) 91.1(346/380) 95.5(799/837) 91.7(144/157) 69.1(425/615) 91.3(94/103) 58.7(289/492) 87.6331/378) <0.001 
Cefuroxime 73.8(2,437/3,301) 82.3(354/430) 93.3(746/800) 81.4(144/177) 62.6(423/676) 61.6(138/224) 59.5(297/499) 67.7(335/495) <0.001 
Cefoxitin 52.0(357/687) 65.6(40/61) 73.0(65/89) 42.9(21/49) 49.3(213/432) 37.5(3/8) 23.8(10/42) 83.3(5/6) <0.001 
Cefotaxime/ceftriaxone 66.0(2,238/3,390) 58.3(342/587) 65.1(822/1,263) 58.0(148/255) 68.1 (425/624) 92.5(124/134) 59.9(161/269) 83.7(216/258) <0.001 
Cefepime 79.8(2,364/2,963) 92.9(315/339) 94.4(794/841) 92.5(135/146) 69.8(396/567) 55.7(107/192) 59.5(292/491) 84.0(325/387) <0.001 
Piperacillin-tazobactam 66.3(1,820/2,745) 75.5(247/327) 83.9(590/703) 79.8(138/173) 69.7(430/617) 51.6(96/186) 29.6(137/463) 65.9(182/276) <0.001 
Gentamicin 58.7(2,242/3,820) 53.2(289/543) 69.5(726/1,045) 55.2(123/223) 53.2(387/723) 56.7(136/240) 57.8(289/500) 54.0(292/541) <0.001 
Tobramycin 80.4 (1,564/1,946) 89.6(233/260) 95.9(561/585) 89.6(103/115) 93.0(40/43) 60.0(102/170) 55.9(264/272) 86.7(261/301) <0.001 
Amikacin 26.4(695/ 2,631) 21.3(62/291) 33.8(162/479) 21.9(28/128) 40.2(471/674) 17.2(33/192) 14.9(74/498) 17.6(65/369) <0.001 
Ciplofloxacin 51.8(1,380/2,666) 48.5(191/394) 55.6(424/763) 77.7(139/179) 47.6(280/588) 43.1(56/130) 46.5(133/286) 48.2(157/326) <0.001 
Nalidixic-acid 83.8(586/699) 93.2(82/88) 95.4(313/328) 85.9(73/85) 70.2(33/47) - 53.2(67/126) 72.0(18/25) 0.001 
Nitrofurantoin 92.3(262/284) 75.0(6/8) 80.0(4/5) 95.5(63/66) 100.0(47/47) 66.7(2/3) 88.9(112/126) 96.6(28/29) 0.02 
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Chloramphenicol 72.3(704/974) 89.2(173/194) 95.9(372/388) 82.9(68/82) 100.0(1/1) - 29.2(90/308) 0.0(0/1) 0.01 
Colistin 1.7(4/230) 0.0(0/16) 0.0(0/2) 2.5(1/40) 2.6(1/38) - 0.0(0/116) 0.0(0/18) 0.03 
Cotrimoxazole 73.8(2,547/ 3,451) 89.2(173/194) 95.9(372/388) 82.9(68/82) 100.00(1/1) - 29.2(90/308) 0.0(0/1) <0.001 
Pseudomonas 
aeruginosa 
% (n/N)** 
        
Imipinem 46.7(334/715) 31.0(36/116) 57.6(83/144) 55.6(15/27) 59.12(107/181) 29.4(15/51) 24.5(24/98) 55.1(54/98) <0.001 
Meropenem 44.4(319/718) 27.5(33/120) 61.2(93/152) 59.3(16/27) 58.1 (104/179) 33.3(9/27) 18.6(19/102) 44.1(45/102) <0.001 
Ceftazidime 20.1(287/1,431) 10.4(30/288) 21.2(89/419) 9.7(10/103) 39.5(118/299) 33.3(9/27) 13.1(17/130) 8.5(14/165) 0.001 
Cefepime 36.0(367/1,021) 25.3(41/162) 36.6(108/295) 18.9(11/58) 45.8(120/262) 32.6(15/46) 24.3(26/107) 50.6(46/91) <0.001 
Piperacillin-tazobactam 31.9(452/1,419) 13.1(36/264) 29.5(118/400) 13.6(14/103) 64.0(178/278) 18.5  (12/65) 33.3(40/120) 30.2(54/179) <0.001 
Gentamicin 34.3(461/1,343) 19.8(49/249) 38.0(130/342) 28.7(27/94) 41.87(121/289) 26.3(15/57) 30.3(40/132) 43.9(79/180) <0.001 
Tobramycin 48.2(364/ 755) 32.2(47/146) 57.2(123/215) 42.3(22/52) 79.5(58/73) 26.5(13/49) 25.2(30/119) 70.3(71/101) <0.001 
Amikacin 29.4(236/804) 19.4(31/160) 32.6(70/215) 50.0(22/44) 45.2(56/124) 18.8(19/48) 21.4(22/103) 23.6(26/110) <0.001 
Ciprofloxacin 35.1(343/976) 21.43(39/182) 43.7(86/197) 46.9(30/64) 45.3(121/267) 29.7(11/37) 35.5(27/76) 18.9(29/153) 0.01 
Colistin 1.9(4/212) 0.0(0/22) 4.6(2/44) 0.0(0/5) 0.0(0/107) - 0.0(0/19) 13.3(2/15) 0.01 
 
*Susceptibility suppression pattern at certain sites under reported resistance to cloxacillin. 
CMJAH = Charlotte Maxeke Johannesburg Academic Hospital; SBPAH = Steve Biko Pretoria Academic Hospital; CHB = Chris Hani Baragwanath Hospital; HJ = Helen Joseph Hospital; UH = 
Universitas Hospital; GSH = Groote Schuur Hospital; TH = Tygerberg Hospital. ** % (n/N) proportion of resistant isolates (number resistant/total number of isolates tested;  
Chi square p-value of independence showing significant difference in resistance between year of testing. 
Data from CMJAH, SBPAH, CHB and HJ for cloxacillin resistance were unreliable, as NHLS laboratories in Gauteng province had systematic error in reporting MRSA. 
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5.3.5 Trends of S. aureus resistance 
The total number of reported cloxacillin-resistant SA declined progressively from 182 to 91 
during the period 2006 to 2009 as did the ratios of resistant to susceptible isolates (expressed 
in percentages). A decline in MRSA in recent years has also been reported in Scottish and 
European hospitals due to rigorous infection control measures such as simple hand washing 
before touching patients, eating food and after using the toilet. The total numbers of resistant 
isolates of SA, but not the ratios of resistant to susceptible cultures, also showed steady 
declines in the case of gentamicin, clindamycin and rifampicin resistance. (Table 5.4) 
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Table 5.4 Trends of antimicrobial resistance rate of selected blood borne infections by year 
 
Antibiotics tested  Total 2005 2006 2007 2008 2009 p-value 
Staphylococcus aureus  % (n/N) **           
 
Ampicillin  95.7(3,322/3,471) 96.2(305/317) 95.9(869/906) 94.9(755/795) 95.6(688/720) 96.2(705/733) 0.774 
Cloxacillin  15.4(588/3,828)* 22.2(74/334) 19.0(182/960) 14.5(123/848) 14.4(118/817) 10.5(91/869) 0.042 
Vancomycin 0.1(1/865) 0.0(0/106) 0.4(1/288) 0.0(0/212) 0.0(0/145) 0.0(0/114) 0.735 
Gentamicin 51.8(428/827) 53.6(59/110) 45.5(141/310) 46.5(87/187) 67.8(97/143) 57.14(44/77) <0.001 
Erythromycin 34.5(802/2,326) 40.1(95/237) 40.3(242/601) 29.6(182/614) 31.2(148/475) 33.8(135/399) <0.001 
Clindamycin 32.4(650/2,005) 37.1(79/213) 38.0(194/511) 26.3(145/552) 32.2(125/388) 31.4(107/341) <0.001 
Rifampicin 39.9(194/486) 32.0(24/75) 35.5(59/166) 34.6(44/127) 66.7(46/69) 42.9(21/49) <0.001 
Fusidic acid 8.5(33/388) 11.7(8/68) 6.2(9/146) 5.3(6/114) 16.3(7/43) 17.7(3/17) 0.070 
Cotrimoxazole 29.9(577/1,930) 33.3(67/201) 33.1(168/508) 24.9(128/514) 29.6(117/395) 31.1(97/312) 0.042 
Klebsiella pneumonia % (n/N) ** 
      
Amoxiclav 64.8(2,550/3,936) 60.0(189/315) 60.1(527/877) 61.6(559/908) 70.1(629/897) 68.8(646/937) <0.001 
Imipinem 0.1(4/3,059) 0.4(1/255) 0.0(0/663) 0.0(0/653) 0.1(1/736) 0.3(2/732) 0.377 
Meropenem 0.2(5/3,046) 0.0(0/255) 0.0(0/683) 0.3(1/669) 0.1(1/714) 0.4(3/725) 0.363 
Ertapenem 2.0(50/2,474) 2.4(4/166) 2.7(11/410) 2.7(14/529) 1.2(8/665) 1.9(13/704) 0.350 
Ceftazidime 82.0(2,428/2,962) 77.2(180/233) 79.0(512/648) 78.0(533/683) 85.5(591/691) 86.6(612/707) <0.001 
Cefuroxime 73.8(2,437/3,301) 65.5(188/287) 70.2(512/729) 69.3(516/745) 79.3 (593/748) 79.3(628/792) <0.001 
Cefoxitin 52.0(357/687) 13.9(11/19) 35.7(51/143) 62.7(133/212) 69.4(120/173) 52.5(42/80) <0.001 
Cefotaxime-ceftriaxone 66.0(2,238/3,390) 55.5(127/229) 56.9(376/661) 62.4(498/798) 72.2(618/856) 73.2(619/846) <0.001 
Cefepime 79.8(2,364/2,963) 73.2(164/224) 76.5(484/633) 76.6(518/676) 84.7(599/707) 82.9(599/723) <0.001 
Piperacillin-tazobactam  66.3(1,820/2,745) 58.6(123/210) 61.7(383/621) 62.5(422/675) 72.3(457/632) 71.7(292/407) <0.001 
Gentamicin 58.7(2,242/3,820) 52.4(176/336) 53.9(498/923) 51.5(468/909) 66.5(535/805) 66.7(565/847) <0.001 
Tobramycin 80.4(1,564/1,946) 75.8(116/153) 81.3(377/464) 79.3(318/401) 82.8(360/435) 79.7(393/493) 0.375 
Amikacin 26.4(695/2,631) 21.2(54/255) 22.3(152/683) 32.0(197/615) 25.9(138/531) 28.2(154/547) <0.001 
Ciprofloxacin 51.8(1,380/2,666) 32.6(69/212) 40.5(231/570) 48.7(299/614) 58.5(397/679) 64.9(384/591) <0.001 
Chloramphenicol 72.3(704/974) 62.8(81/129) 69.2(189/273) 67.2(160/238) 67.2(158/208) 92.1(116/126) <0.001 
Colistin  1.7(4/230) 3.6(1/28) 0.0(0/22) 7.7(1/13) 0.0(0/13) 1.3(2/154) 0.401 
Cotrimoxazole 73.8(2,547/3,451) 67.5(201/298) 69.7(556/798) 69.1(547/792) 77.5(605/781) 81.6(638/782) <0.001 
Pseudomonas aeruginosa % (n/N) ** 
      
Imipinem 46.7(334/715) 47.5(29/61) 31.3  (47/150) 47.3(79/167) 46.4(70/151) 58.6(109/186) <0.01 
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Meropenem 44.4(319/718) 48.2(27/56) 27.5(42/153) 45.2(76/168) 47.8(76/159) 53.9(98/182) <0.01 
Ceftazidime 20.1(287/1,431) 17.1(21/123) 11.8(39/330) 21.5(73/339) 23.5(69/294) 24.6(85/345) <0.01 
Cefepime 36.0(367/1,021) 36.6(34/93) 26.3(55/209) 32.1(87/271) 41.5(85/205) 43.6(106/243) <0.01 
Piperacillin-tazobactam  31.9(452/1,419) 13.1(36/264) 29.5(118/400) 13.6(14/103) 64.0(178/278) 18.5  (12/65) <0.01 
Gentamicin 34.3(461/1,343) 39.0(48/123) 21.7(73/336) 37.5(50/133) 45.6(108/237) 36.4(107/294) <0.01 
Tobramycin 48.2(364/755) 38.7(24/62) 40.2(68/169) 60.2(112/186) 54.9(89/162) 40.3(71/176) <0.01 
Amikacin 29.4(236/804) 25.7(18/70) 16.2(29/179) 31.8(62/195) 30.7(60/163) 34.0(67/197) <0.01 
Ciprofloxacin 35.1(343/976) 25.9(28/108) 21.3(49/230) 36.3(86/237) 36.8(77/209) 53.7(103/192) <0.01 
Colistin  1.9(4/212) 0.0(0/7) 4.6(1/22) 0.0(0/56) 1.9(1/54) 2.7(2/73) 0.67 
 
** % (n/N): proportion of resistant isolates (number resistant/total number of isolates tested 
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5.3.6 Demographic factors associated with S. aureus resistance 
The age-group <5 years was significantly associated with SA resistance to antimicrobials. 
Children <5 years were 74% more likely to have had incidence of SA resistant isolates (AOR 
1.74, CI 1.33-2.28) compared to the 20-29 years age-group. There was a significant 
association between antimicrobial resistance and hospital location. SA isolates at UH were 
three times more likely to be resistant to antimicrobials, (AOR 3.08. CI 2.10-4.52); SA 
isolates from Groote Schuur hospital were appreciably more likely to be resistant to 
antimicrobials (AOR 3.78, CI 2.85-5.01). At Tygerberg hospital, SA isolates were 4.8 times 
more likely to be resistant to antimicrobials (AOR 4.75, CI 3.60-6.20). In general SA isolates 
from UH, GSH, TH were significantly more likely to be resistant to antimicrobials. (Table 
5.5) 
 
5.3.7 Patterns of K. pneumoniae resistance 
For the 5-year study period, the carbapenems covered the widest range of K. pneumoniae 
isolates. Cephalosporin resistance in KP was high but varied widely e.g. 
cefotaxime/ceftriaxone resistance was 50.0% - 65.1% for five of the seven hospitals, 83.7% 
and 92.5% for the other remaining two hospitals. Cefepime resistance was high in the three 
Johannesburg hospitals (92.5% - 94.4%) compared to 55.75 – 84.0% for the other remaining 
four hospitals.  
 
Carbapenems and colistin resistance for KP shows to be still very low: imipenem and 
meropenem resistance at 0.1% each and ertapenem at 2.0%; colistin resistance at 1.9% while 
resistance rates for co-amoxiclav in KP isolates averaged at 64.8% for the seven hospitals 
while resistance to piperacillin-tazobactam with two exceptions were >65%. At four of the 
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seven hospitals, resistance to cotrimoxazole was in excess of 70%. The mean resistance rates 
for aminoglycosides were amikacin 26.4%, gentamicin 58.7% and tobramycin 80.4%.  
Ciprofloxacin resistance rates in KP at the seven hospitals were ~50%. Piperacillin-
tazobactam resistance in KP was high with a mean resistance of 66.3% and rates varying 
from 29.6% at GSH to 83.9% at CHB. (Table5.3) 
 
5.3.8 Trends of K. pneumoniae resistance 
There is a marked rise of ciprofloxacin resistance (32.6% in 2005 to 64.9% in 2009, p<0.001) 
and cotrimoxazole resistance (67.5% in 2005 to 81.6% in 2009, p<0.001). High rates of 
cephalosporin resistance maintained or slight increases seen over the 2005 to 2009 period, 
e.g. ceftazidime resistance 77.2% - 86.6%; cefotaxime (55.5% - 73.2%). There were high 
rates of aminoglycoside resistance showing a slight rise of resistance over this period, i.e. 
amikacin 21.2 - 28.2 %; gentamicin 52.4 - 66.7%; tobramycin 75.8 - 79.7%. There were 
significant differences in rate of KP resistance by year of study among most of the antibiotics 
except for carbapenems, nitrofurantion, tobramycin and colistin p>0.05. (Table 5.4) 
 
5.3.9 Demographic factors associated with K. pneumoniae resistance 
For KP, age-group <5 years was significantly associated with antibiotic resistance with 
children <5 years being 49% more likely to have KP resistant isolates (AOR 1.49, CI 1.19 - 
1.88) compared to the 20 - 29 years age-group. Females were more likely to have resistant 
KP isolates than males (AOR 1.13 CI 1.00 - 1.29). There was a significant association 
between antimicrobial resistance and hospital location. KP isolates at UH were 39% more 
likely to be resistant to antimicrobials (AOR 1.39, CI 1.01 - 1.91); even though KP isolates 
from HJ, GSH and TH were more likely to be resistant to antimicrobials, this was not 
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statistically significant hence not reported in detail here. KP isolates reported in 2008 and 
2009 were more likely to be resistant to antimicrobials; however this was not statistically 
significant. (Table 5.5) 
 
5.3.10 Patterns of P. aeruginosa resistance 
The mean ceftazidime resistance rate in PA was 20.1% and 36.0% for cefepime. Carbapenem 
resistance in PA was 46.7% and 44.4% respectively for imipenem and meropenem and 31.9% 
for piperacillin-tazobactam. The antibiotic with the greatest spectrum of activity against P. 
aeruginosa for the study period was colistin with a resistance rate of 1.9% (range 0% - 
13.3%). Colistin resistance was absent in PA in four of the seven hospitals where 
susceptibility testing was performed. The mean ciprofloxacin resistance was 35.1% and for 
amikacin, gentamicin and tobramycin resistance rates in PA were 29.4%, 34.3% and 48.2% 
respectively. (Table 5.3) 
 
5.3.11 Trends of P. aeruginosa resistance 
The range of ciprofloxacin resistance was (25.9% - 53.7%) over the period 2005 – 2009; 
moderate increases in aminoglycoside resistance among PA isolates over the study period 
were observed (amikacin 25.7% – 39.1%, gentamicin 21.7% – 53.7%, and tobramycin 38.7% 
- 60.2%). Cephalosporin resistance equally showed moderate rise i.e. ceftazidime 17.1% - 
24.6% and cefepime 36.6% – 43.6%. Carbapenems resistance rate showed moderate rises 
~45% - ~55% for imipenem and meropenem resistance over the 2005 – 2009 periods. (Table 
5.4) 
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5.3.12 Demographic factors associated with P. aeruginosa resistance 
For the 5-year study period, hospital location was associated with antibiotic resistance. 
SBPAH (AOR 5.16, CI 3.62 - 7.36), GSH (AOR 2.08, 1.35 - 3.21), TH (AOR 3.02, 2.04 - 
4.47) were significantly associated with antibiotic resistance among P. aeruginosa isolates. 
At UH, PA isolates were 60% more likely to be resistant to antimicrobials; however this was 
not statistically significant (AOR 1.60, CI 0.91 - 2.79). Even though PA isolates reported in 
2008 and 2009 were more likely to be resistant to antimicrobials, the association was not 
statistically significant. (Table 5.5) 
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Table 5.5 Univariate and multivariate analysis of factors associated with antimicrobial drug resistance among 
selected blood culture infections 
 
 Staphylococcus aureus
 
Klebsiella pneumonia Pseudomonas aeruginosa 
Characteristic UOR (95% CI) AOR (95% CI) UOR (95% CI) AOR (95% CI) UOR (95% CI) AOR (95%CI) 
Age        
<5 1.01(0.79-1.27) 1.74(1.33-2.28) 1.51(1.21-1.88) 1.49(1.19-1.87) 0.87(0.63-1.20) 0.83(0.58-1.19) 
5-9 0.52(0.29-0.93) 0.66(0.35-1.26) 1.70(0.93-3.12) 1.58(0.86- 2.91) 1.19(0.58- 2.44) 1.28(0.60-2.74) 
10-19 0.79(0.56-1.11) 0.84(0.56-1.25) 1.01(0.71-1.42) 0.94(0.66-1.34) 0.96(0.56- 1.67) 0.95(0.53-1.70) 
20-29 1 (0.79-1.27) 1 1 1 1 1 
30-39 1.19(0.96-1.48) 1.25(0.94-1.67) 1.17(0.905-1.50) 1.15(0.89-1.48) 1.26(0.87-1.82) 1.25(0.85-1.85) 
40-49 0.90(0.70-1.15) 0.93(0.68-1.27) 0.89(0.68- 1.16) 0.89(0.68- 1.16) 0.92(0.62-1.36) 0.91(0.60-1.38) 
50-59 0.82(0.62-1.09) 0.80(0.56-1.13) 0.90(0.68-1.18) 0.88(0.66-1.16) 1.00(0.66-1.51) 0.97(0.62-1.50) 
60-69 0.93(0.68-1.27) 0.96(0.66-1.39) 0.95(0.71-1.27) 0.92(0.69-1.23) 1.08(0.70-1.67) 1.08(0.67-1.72) 
≥70 0.68(0.46-1.00) 0.78(0.50-1.23) 0.82(0.60-1.11) 0.78(0.57    -1.07) 1.02(0.63-1.66) 1.01(0.61-1.70) 
Gender       
Male 1 1 1 1 1 1 
Female 0.99(0.85-1.15) 0.97(0.82-1.14) 1.17(1.03-1.33) 1.13(1.00-1.29) 1.03(0.84-1.27) 0.99(0.80-1.24) 
Hospital**       
CMaxeke JAH 1 1 1 1 1 1 
CHani Bara 0.41(0.31-0.55) 0.41(0.30-0.56) 1.22(1.01-1.48) 1.08(0.89-1.32) 1.92(1.40-2.62) 1.87(1.34-2.62) 
Helen Joseph 0.95(0.68-1.33) 1.26(0.88-1.80) 1.09(0.81-1.46) 1.23(0.91-1.67) 1.66(1.05-2.65) 1.48(0.91- 2.39) 
SBPAcademic 0.83(0.60-1.15) 1.00(0.72-1.41) 0.95(0.77-1.18) 0.95(0.76-1.18) 5.43(3.84-7.68) 5.16(3.62-7.36) 
Universitas 2.55(1.76-3.70) 3.08(2.10-4.52) 1.56(1.14-2.134) 1.39(1.01-1.91) 1.80(1.04-3.11) 1.60(0.91-2.79) 
Groote Schuur 2.98(2.29- 3.89) 3.78(2.85-5.01) 1.04(0.82-1.31) 1.10(0.86-1.39) 2.33(1.53- 3.55) 2.08(1.35-3.21) 
Tygerberg  4.10(3.18-5.29) 4.75(3.6- 6.20) 1.25(0.99-1.58) 1.12(0.88-1.42) 3.20(2.18-4.70) 3.02(2.04-4.47) 
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Province       
Gauteng 1  1 --- 1 --- 
Free State 3.69(2.65-5.12) --- 1.44(1.09-1.90) --- 0.85(0.51-1.40) --- 
Western Cape 5.13(4.37- 6.02) --- 1.05(0.91-1.21) --- 1.32(1.03-1.69) --- 
Year       
2005 1 1 1 1 1 1 
2006 0.82(0.63-1.07) 0.72(0.54-0.97) 0.93(0.72-1.20) 0.90(0.69-1.17) 0.48(0.32-0.72) 0.52(0.33-0.80) 
2007 0.67(0.51-0.89) 0.61(0.45-0.82) 0.88(0.68-1.13) 0.87(0.67-1.13) 0.84(0.56-1.25) 0.79(0.51-1.21) 
2008 0.56(0.43-0.74) 0.48(0.35-0.65) 1.27(0.99-1.64) 1.29(0.99-1.68) 1.21(0.81-1.80) 1.20(0.78-1.84) 
2009 0.44(0.33-0.58) 0.39(0.28-0.53) 1.27(0.99-1.65) 1.27(0.98-1.66) 1.13(0.76-1.68) 1.11(0.72-1.70) 
 
CI, confidence interval; UOR, unadjusted odds ratio; AOR, adjusted odds ratio ** CMaxeke JAH: The reference hospital  
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5.4. Discussion 
This study led to a detailed and systematic data analysis of the LIS in reporting antimicrobial 
susceptibility of isolates from blood culture over a 5 year period, to assess possibility for 
reporting of trends and patterns of resistance from all isolates in public tertiary hospitals in 
South Africa. A total of 9969 isolates were identified belonging to S. aureus, K. pneumoniae 
and P. aeruginosa had drug susceptibility results reported on by the NHLS between July 1, 
2005 and December 31, 2009. The numbers of isolates of all three pathogens for 2005 (first 
year of CDW-based surveillance) were substantially smaller than the other years, as the 
surveillance system started half way through that year.  
 
S. aureus and K. pneumoniae were the most common pathogens and contributed 84.3% of the 
total magnitude of blood stream infections among the three selected pathogens reported 
within this period. This is in keeping with previous studies that have shown S. aureus to be 
the predominant cause of blood stream infections. (115, 116, 124) More isolates of these 
pathogens were reported from males and children below the age of 5 years. The relationship 
of higher incidence of blood stream infections among males has been documented in previous 
studies. (115, 125) As much as this study found higher incidence of blood stream infections 
among children, other studies in Canada and the USA have found smaller proportion of 
isolates from children. (126) There were more isolates reported from Chris Hani 
Baragwanath Hospital, which is the largest hospital in the country and services a historically 
disadvantaged population of Soweto. Antimicrobial susceptibility was done to assess rates of 
resistance to various antibiotics amongst the three common pathogens associated with in-
hospital acquisition.  
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The proportion of K. pneumoniae resistant isolates (defined as isolates resistant to one or 
more antibiotics) was higher among females while S. aureus and P. aeruginosa rates were 
similar. The proportion of S. aureus resistant isolates was highest at Tygerberg Hospital, K. 
pneumoniae was highest at Universitas Hospital and P. aeruginosa was highest at Steve Biko 
Pretoria Academic Hospital. There were more resistant isolates of S. aureus and P. 
aeruginosa reported from the Western Cape and more resistant isolates for K. pneumoniae 
reported from Free State province. The proportion of S. aureus resistant isolates was higher in 
2005; K. pneumoniae and P. aeruginosa were higher in 2008. 
 
No recent studies in South Africa on the frequency of bacteraemic pathogens have 
documented comparable information. This study used blood culture data that represent 
invasive pathogens and therefore excludes organisms that merely colonize non-sterile sites 
and may be present in specimens such as pus swabs. Such data could serve to guide 
prescription habits and form the basis of a robust national surveillance monitoring system 
able to regularly document similarities and differences in antimicrobial resistance between 
different hospitals both locally and internationally.  
 
Antibiotics with the broadest spectrum against S. aureus were vancomycin and linezolid. 
Vancomycin was still active against nearly all S. aureus isolates with resistance rate showing 
<0.1% across all the 7 hospitals. This is consistent with previous data which reported that 
vancomycin was still an active agent against S. aureus including MRSA.(31, 127-130) 
Frequencies of clindamycin resistance (72%), erythromycin resistance (44.1%) and 
rifampicin (60.7%) among S.aureus isolates at TH are relatively high. These might be linked 
to macrolide or as a result of inducible clindamycin resistance among erythromycin resistant 
strains. Simultaneous resistance to erythromycin and clindamycin among S.aureus isolates 
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could be a result of erythromycin resistance methylase genes (erm genes), while 
erythromycin resistance not crossed to clindamycin is consistent with the presence of msrA 
gene. The variation in susceptibility of erythromycin-resistant S.aureus to clindamycin as 
observed in this study among the seven tertiary public hospitals might be an indication of 
epidemiological variation in the two mechanisms of resistance that was mentioned above. 
(131, 132) 
 
The highest rates of MRSA were observed at Tygerberg and Groote Schuur hospitals in the 
Western Cape as opposed to Universitas hospital in the Free State province. In Gauteng 
province hospitals, MRSA rates of 0.4% - 4.5% were observed, questioning the reliability of 
such findings and this made it difficult in this study to make any meaningful comparison of 
resistance rates with other sites. It may also be because there is a bias in culturing more 
community acquired infections than hospital acquired. The variation in rates of MRSA 
observed is consistent with previous EARSS reports(125) that showed marked geographical 
variation in prevalence of MRSA. In the current setting, the plausible explanation for this 
variation might be due to differences in specimen collection, carriage rates or hospital 
infection control policies and practices as well as prescription policies between different 
hospitals and provincial Departments of Health. (115)  
 
The other reason might relate to differences in laboratory practices between different sites, 
with NHLS laboratories in Gauteng province failing to report cloxacillin resistant isolates, 
as opposed to NHLS laboratories in Western Cape and Free State. However, despite the 
geographical differences in MRSA and the observed systematic error in MRSA reporting in 
Gauteng hospitals, overall there was an apparent decline in MRSA in this province which on 
calculation was statistically significant (from 22.2 % (74/334) in 2005 to 10.5% (91/869) in 
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2009, p<0.042. However, without clinical information, this observed trend may be assumed 
to flawed, hence not real. On the other hand this finding is consistent with the EARSS report 
that documented that more countries within the Pan-European antimicrobial resistance 
surveillance showed decreasing MRSA proportions even though the rates still remained at 
>25% in almost one third of the countries. (125) In the UK, a national surveillance scheme 
run by the HPA, observed decreasing rates of MRSA from 31% in 2007 to 19.3% 2009 
(133). In addition, a similar trend was observed in Canadian hospitals, where Adam et al 
reported a drop in MRSA rates from 26.7% in 2007 to 18.9% in 2006. (115) Based on 
available evidence highlighted earlier, the observed trend of MRSA decline appears to be 
consistent with observed global trends. This correlates well with initiatives from 
Departments of Health to introduce strict infection control measures and mandatory 
surveillance for MRSA. 
 
In light of these findings, the reliability of routine laboratory data generated by the LIS for 
monitoring antimicrobial resistance requires further interrogation, as it remains unclear if the 
observed rates of antimicrobial resistance are realistic and not due to selection bias. On a 
different note, it is worthwhile to reassess and scrutinize the validity of the observed finding. 
Such differences might have been due to multiple factors, among them strengthening of 
hospital infection control policies and antimicrobial stewardship; training and implementation 
of hand-washing hygiene or changing epidemiology of MRSA in South Africa over the study 
period.  
 
The most active antibiotics against K. pneumoniae in this study were the carbapenems. These 
data are similar to those shown by Zhanel et al. (130) Cephalosporin, flouroquinolones and 
aminoglycosides showed high resistance across all sites. β-lactams, excluding carbapenems 
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were the least active antibiotics over the 4.5-year study period with resistance rate increasing 
in all sites and in keeping with previous review findings done in South Africa. (31) Low 
levels of carbapenem resistance, shows that there is evidence of emergence of 
carbapenemase-mediated resistance among KP isolates. Nordmann et al reported that K. 
pneumoniae that produces K.pneumoniae carbapenemase (KPC) have globally spread across 
hospitals. (134) However, it is a growing concern to note emerging colistin resistant KP. 
Bogdanovich et al, reported cases of KP-carbapenemase producing isolate that showed 
emerging resistance to colistin. (135) This is a worrying development as colistin is the last 
line of defence; it is reserved for treatment of severe Gram negative sepsis that has resulted 
from failed treatment with carbapenems. This is reassuring, as carbapenems have been shown 
in a multicentre study to have the most favourable outcomes in the treatment of bacteraemic 
ESBL-producing KP infections. (136) There was a significant trend of KP resistance to 
ciprofloxacin and cotrimoxazole, while meropenem showed a significant increasing trend of 
resistance from 2006 to 2009 - no particular resistance trend was observed for other 
antibiotics. (127) 
 
P. aeruginosa resistance was evident across most of the drug classes, showing high resistance 
to carbapenems, cephalosporin, flouroquinolones and aminoglycosides. Carbapenem 
resistance in P. aeruginosa is often mediated through genetic down regulation of outer 
membrane protein D. Even though Adam et al., in a study done among Canadian hospitals 
reported that resistance was encroaching to these drug classes, the resistance rate shown in 
this study, is far higher compared to the findings of Adam et al. This is a significant finding 
denoting that geographical location does play a role in development of antimicrobial 
resistance, and therefore might mean that due to rapid increase and high level of 
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intercontinental mobility, resistant clones are bound to spread across different countries and 
regions. (115, 127, 137) 
The rates of aminoglycoside resistance among P. aeruginosa and K. pneumoniae isolates was 
varied with amikiacin showing low resistance and tobramycin showing higher resistance. As 
shown above, among K.pneumoniae isolates, the mean resistance for amikacin was 26.4%, 
gentamicin 58.7% and tobramycin 80.4%, whereas P. Aeruginosa, the mean resistance for 
amikacin, gentamicin and tobramycin were 29.4%, 34.3% and 48.2% respectively. Such 
observed differences in resistance patterns could be due to differences in aminoglycoside 
modifying enzymes; prescription patterns or variation in quality of infection control practices 
in these hospitals, although geographical differences in the occurrence of individual 
aminoglycoside resistance determinants might also play a role. This emphasizes the fact that 
the prudent use of aminoglycosides as well as implementation of effective infection control 
practices are essential in limiting the development and continued spread of aminoglycoside 
resistance among these pathogens. (138) The only consistently active antibiotic against P. 
aeruginosa for the study period was colistin, which had resistance rate of 1.9%. This is 
similar to findings of previous studies that also showed a similar pattern of high activity of 
colistin against P. aeruginosa. (127, 139) 
Several demographic factors were found to be significantly associated with antimicrobial 
resistance. For SA, factors were: age-group <5 years; hospital location (UH, TH, GSH) and 
year of infection. Factors associated with KP resistance were age-group <5 years, female 
gender and hospital location (UH). The only factor significantly associated with PA 
resistance was hospital location (CHB, SBPAH, GSH and TH). There was however no data 
from our study that could explain such underlying associations despite the fact that 
environmental reservoirs and magnitude of burns of patients in hospitals are among the 
known drivers of P. aeruginosa resistance 
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5. 5 Limitations of the study 
This study had several limitations which are related to the analysis of routine laboratory data. 
No clinical data were available; hence any determination of the impact of antimicrobial 
resistance on clinical outcomes could not be made. Such data are essential as their availability 
would help in making detailed risk factor analysis, evaluating the potential impact of 
inappropriate antimicrobial therapy on outcome of patients with bacteraemia episode caused 
by the three selected pathogens.  
 
Secondly, the magnitude of blood stream infection caused by the selected pathogens was not 
determined. Such data would be useful to give precise estimates of the magnitude of blood 
stream infection caused by such organisms, as this would help direct strategic planning of 
service delivery, medication procurement as well as intensity of hospital infection control 
procedures.  
 
Thirdly susceptibility testing methods for individual antibiotics varied across sites for 
individual pathogens, with other NHLS laboratories testing certain specific agents more than 
other sites, which might have led to differences in estimation of resistance rates among those 
agents. Fourthly while using the first specimen only is one approach to surveillance, a 
limitation of such an approach is the possibility of missing the occurrence of acquired 
resistance during the illness. This may not be captured by the surveillance system. In addition 
although susceptibility testing figures were used to assess rates of resistance among the three 
pathogens associated with hospital acquisition, our results do not differentiate between 
community and hospital acquired infections and there is therefore the potential for 
underestimation of resistance rates in general. 
 
P a g e  |152 
 
  
Another important limitation is that no data was available on admission date for each patient 
and specimen collection hence no accurate description of community versus nosocomial 
acquired bacteraemia could be made. Lastly the use of ‘resistance to any antimicrobial agent’ 
tested as a method of estimating overall resistance rate. This method might have led to 
erroneous estimation of resistance among the antibiotics tested as shown in Table 5.5. 
 
5.6 Conclusion 
There are problems in retrieving information on AST from the current LIS. Estimated rates of 
antimicrobial resistance observed in this study, are a matter of grave concern, especially with 
regard to PA and KP. It was encouraging to see that other antimicrobial agents are still very 
active against the selected pathogens.  
Firstly, the rate of vancomycin resistance is almost negligible (0.1%, only 1 of 865 isolates-
one case at Tygerberg hospital in 2006) and linezolid resistance among S. aureus isolates was 
not detected in this study. Secondly, carbapenems (ertapenem, imipenem and meropenem) 
and colistin remains highly active against K. pneumoniae and thirdly, that colistin is highly 
active against P. aeruginosa. The extent of antimicrobial resistance in PA is alarming and is 
aggravated by the fact that colistin is both oto- and nephrotoxic. 
Therefore ongoing structured prospective surveillance to monitor the burden of bloodstream 
infections and their resistance profile is essential to better monitor trends and patterns of 
resistance to nosocomial infections at national level. Such data would enhance the knowledge 
of the magnitude of the problem regarding antimicrobial resistance and will form evidence 
upon which policies and practice aimed at containing antimicrobial resistance can be 
generated. In addition the analysis presented in this chapter provides the type of assessment 
that has to be used to develop empirical treatment guidelines.  
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Chapter 6 Distribution and risk factors of antimicrobial 
resistance of invasive Staphylococcus aureus and 
Klebsiella pneumoniae blood culture isolates from seven 
academic hospitals in South Africa-a prospective study 
 
This chapter provides findings of prospective analysis of antimicrobial resistance data of 
clinical isolates of Staphylococcus aureus and Klebsiella pneumoniae cultured from blood of 
patients presenting to hospital with bacteraemia episodes. The aim was to compare rates of 
resistance from prospective data with rates obtained from retrospective data with the view of 
finding out reliability of the LIS as a tool for monitoring antimicrobial resistance patterns in 
tertiary public hospitals in South Africa. 
 
6.0 Abstract 
Aim: To describe antimicrobial resistance profiles and risk factors of blood culture isolates of 
Staphylococcus aureus (SA) and Klebsiella pneumoniae (KP) from seven academic hospitals 
in South Africa, using data of bacterial isolates collected prospectively through an active 
national antimicrobial resistance surveillance system. 
 
Methods: Blood-culture isolates of SA and KP were detected and identified by automated 
MicroScan, Vitek 2 systems or standard biochemical tests. Antimicrobial susceptibility 
testing was done following manufacturers’ instructions and interpreted using the Clinical 
Laboratory Standards Institute (CLSI) guidelines. The identified blood culture isolates were 
systematically investigated for resistance against clinically relevant antimicrobials. 
 
P a g e  |154 
 
  
Results: There were 3026 isolates reported between July 2010 and June 2011; of these 1494 
(49.4%) were SA and 1532 (50.6%) were KP. Of the SA and KP isolates 68.0% and 71.1% 
respectively were from Gauteng province. The rate of SA resistance to methicillin (MRSA) 
was 558/1032 (54.1%) but it was higher (63.3%) in the <5 years age-group, and significantly 
different across all hospitals ranging between 31.8%-63.3% (p=<0.001). The highest rates of 
MRSA (243/292, 83.2%) were observed at Chris Hani Baragwanath (CHB) hospital, Gauteng 
province. SA resistance rates among fusidic acid, vancomycin among others were on average 
<1.5%, suggesting an infiltration development of resistance to these antimicrobial agents.  
 
There were (742/1045, 71.0%) extended spectrum beta-lactamase producing KP (ESBLs-KP) 
isolates. The <5 years age-group had the largest number of ESBL-KP isolates (266/340, 
78.2%) and there were significant differences in ESBL production between different age-
groups, p = 0.003. KP resistance to carbapenems, ranged from 1.3 - 3.4% and to other 
extended spectrum cephalosporins such as cefepime, resistance was high at 70.4% which is in 
accordance with the high proportions of ESBL-producing isolates recorded in this study. For 
betalactams i.e. amoxicillin/clavulanic acid, resistance ranged from 50.0 - 69.9% (p=0.007) 
across all hospitals. ESBL-KP was lowest at Steve Biko Pretoria Academic Hospital 
(SBPAH) and highest at Universitas Hospital (61.9 - 79.7%, P = 0.012). Overall there were 
significantly lower rates of MRSA (p = <0.001) and ESBLs (p = 0.021) at SBPAH compared 
to all other hospitals. 
 
Conclusions: This study describes high rates of antimicrobial resistance among blood culture 
isolates of SA and KP from academic hospitals in South Africa. Continued surveillance of 
antimicrobial resistance would provide useful data for guidance to physicians initiating 
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empiric therapy, and for the formulation of antimicrobial prescription policies in South 
Africa. 
 
6.1 Introduction 
Antimicrobial resistance (AMR) amongst hospital and community-acquired bacterial 
infections is an important clinical and public health challenge globally. (140-142) Several 
factors have been attributed to the increasing frequency of resistance to antimicrobials. 
Among these are natural characteristics of microbes, selective pressure due to intensive 
antimicrobial use and an increase in globalization due to advances in transportation and 
telecommunications infrastructure, some of which facilitate the transmission of resistant 
bacteria. (140, 143) Blood stream infections, commonly hospital-associated, are frequently 
caused by Staphylococcus aureus (SA) and Klebsiella pneumonia (KP). This frequency of 
bacteraemic episodes caused by these two organisms can serve as a guide to the magnitude of 
nosocomial infections in different settings. (122, 140, 144) 
 
The challenges encountered in managing nosocomial bacteraemia which are often severe 
infections in both developed and developing countries are complex and daunting. Increasing 
resistance to a wide array of conventional antibiotics often leads to increased morbidity and 
mortality due to the therapeutic failure of empirical treatment. (122, 145) Clinicians are not 
always aware of resistance patterns to common pathogens in their hospitals and patient 
treatment environment. Subsequent wrong treatment choices may lead to longer hospital stay, 
initiation of costly second-line antibiotic regimens and escalating medical expenditure. (122, 
140, 146) Useful and reliable measurement of the burden of antimicrobial resistance has often 
been impeded by the lack of an organized system of blood culture data collection, different 
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strategies for taking of blood cultures and varying levels of resistance associated with 
different health care facilities. (144) 
 
Surveillance of antimicrobial resistance provides objective information on the burden of 
resistance among bacterial pathogens such as SA and KP. However limitations of a passive 
system need to be taken into account when interpreting surveillance findings. Surveillance 
data accessible to key hospital personnel including molecular epidemiological investigation 
would assist in the prioritization and strategic planning of infection prevention interventions 
coupled with policy guidance on antimicrobial prescription. (16, 143, 147) This study aimed 
to describe the frequency, distribution and risk factors associated with resistance among SA 
and KP blood culture isolates in South Africa using, for the first time, data from an enhanced 
national antimicrobial resistance surveillance system that collects blood culture data in the 
designated surveillance sites in South Africa.  
 
6.2 Methodology 
 
6.2.1 Invasive Disease Surveillance 
The Group for Enteric Respiratory and Meningeal pathogens Surveillance in South Africa 
(GERMS-SA) has since 2003 been running enhanced invasive disease surveillance in all 9 
provinces of South Africa. (148) GERMS-SA conducts disease surveillance of invasive 
respiratory, meningeal, and enteric infections. In 2010, GERM-SA added an additional 
component to the surveillance system to look at antimicrobial resistance among nosocomial 
pathogens.  
P a g e  |157 
 
  
The Antimicrobial Resistance Surveillance and Research (ARSR) within the Centre for 
Opportunistic, Tropical and Hospital Infections at the National Institute of Communicable 
Diseases (NICD) collected blood culture isolates of SA and KP in 7 tertiary public hospitals 
associated with academic institutions from three provinces in South Africa. Details of 
participating sites included in this study have been reported in Chapter 5, section 5.2.2. (31) 
Isolates of SA and KP were transported to ARSR laboratory from each participating site on 
Dorset egg transport media and stored at -70
0 
C until pathogen identification and 
determination of minimum inhibitory concentrations (MIC) were done. (149) 
 
6.2.2 Study Design 
Data and clinical isolates of the two above mentioned blood stream pathogens were collected 
prospectively and tested for antimicrobial resistance. All non-duplicate isolates of SA and KP 
were prospectively sent by the microbiology laboratories of the participating sentinel sites to 
the Antimicrobial Resistance Surveillance and Research (ARSR) unit on an ongoing basis for 
confirmation and further characterization. The present study focused mainly on clinically 
relevant blood stream infections that are commonly associated with stay in hospital. (150) 
These isolates were identified at each participating hospital laboratory through routine blood 
culture investigation and sent to the antimicrobial reference laboratory at NICD where further 
testing was done. The study was approved by the Human Research Ethics Committee, 
University of the Witwatersrand, approval number M10625 (Appendix 12.3.8). 
 
6.2.3 Data collection 
Clinical Isolates of SA and KP were confirmed at ARSR using the automated MicroScan 
system. Due to the volume of the isolates sent from the participating sentinel sites, isolates 
P a g e  |158 
 
  
were stored for a median time of 6 - 8 weeks before being processed. All data originating 
from processing of the isolates, confirmation of pathogens and antimicrobial susceptibility 
testing as well as molecular characterizations were double entered into an MS access 
database at ARSR, NICD, Sandringham. Additional data collected included patients’ 
demographics (age and gender), hospital location, hospital ward, hospital name, province and 
year of collection. This study used data of SA and KP isolates collected between July 2010 
and June 2011. 
 
6.2.4 Susceptibility Testing 
Antimicrobial susceptibility testing of the isolates was carried out using the broth 
microdilution method as described by the Clinical Laboratory Standards Institute 
(CLSI).(151) Microdilution assays were obtained from MicroScan (Sacramento, California) 
and Media Laboratories (Tualantin, Oregon). Antibiotics tested were ciprofloxacin (SA and 
KP), clindamycin (SA), erythromycin (SA), fusidic acid (SA), gentamicin (SA and KP), 
rifampicin (SA), vancomycin (SA), oxacillin (SA), trimethoprim/sulfamethaxazole (SA and 
KP), ampicillin (SA and KP), cefazolin (SA and KP), cefuroxime (SA and KP), ertapenem 
(SA and KP), gentamicin (SA and KP), imipinem (SAand KP), meropenem (SA and KP), 
levofloxacin (SAand KP), tobramycin (SA and KP), amikacin (KP), cefepime (SA and KP), 
cefotaxime (KP), cefuroxime (KP), ceftazidime (KP), amoxicillin-clavulanate (SA and KP), 
piperacillin-tazobactam (KP), linezolid (SA), tetracycline (SA and KP), and tigercycline 
(KP). (113, 152) 
6.2.5 Quality Control 
The quality control of reagents used for the purpose of susceptibility test of isolates submitted 
from participating sentinel sites was evaluated by confirmatory testing carried out by the 
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ARSR laboratory using ATCC QC organisms: SA ATCC 29213 and KP 700603 routinely as 
control organisms. (113, 127) Interpretation of MICs breakpoints for each antibiotic tested 
was defined according to the CLSI guidelines. (151) 
 
6.2.6 Statistical analysis 
“Intermediate” and “resistant” isolates were grouped together into a “non-susceptible” 
category to create a binary variable called ‘non-susceptible’ indicating the presence or 
absence of antimicrobial resistance. Exposure variables included in the analysis were age, 
gender, hospital name, year of infection and province. The prevalence of resistance was 
estimated using percentages. Associations between resistance and various exposures were 
assessed using chi-squared test for independence. Missing data were excluded from further 
bivariate analysis. All analyses were done using Stata version 12 software (StataCorp 
Limited, College Station, Texas, USA).  
 
6.3 Results 
 
6.3.1 Distribution of S. aureus and K. pneumoniae isolates 
A total of 1494 SA and 1532 KP isolates were analyzed for the period July 2010 to June 
2011. Thirty point four percent of SA isolates and 32.3% of KP isolates were from patients 
under the age of five, 12.1% of SA isolates were from patients in the 30 - 39 years age-group 
and 11.8% of the KP isolates were from patients in the 50 - 59 years age-group; 11.3% of SA 
and 8.8% of KP isolates had missing data on age.  
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The proportion of isolates recorded from male patients was higher than females (50.0% vs. 
42.6% for SA (7.4% missing) and 52.0% vs. 41.5% for KP (6.6% missing)). By institution, 
there were more SA and KP isolates reported from CHB (29.3% SA and 29.9% KP). Overall 
67.9% and 71.0% of the SA and KP isolates respectively were from Gauteng province. 
Slightly more isolates were reported in 2010 and 2011 (SA 51.5% and KP 50.1% 
respectively. The proportion of missing data was observed among age and gender factor 
being higher amongst the age than gender factor. (Table 6.1) 
 
Table 6.1 Distribution of Staphylococcus aureus and Klebsiella pneumonia isolates 
according to age, gender, hospital, province and year during prospective period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHB - Chris Hani Baragwanath Hospital; CMJAH - Charlotte Maxeke Johannesburg Academic Hospital; GSH 
- Groote Schuur Hospital, HJH - Helen Joseph Hospital, SBPAH - Steve Biko Pretoria Academic Hospital, TH 
- Tygerberg Hospital, UH – Universitas Hospital.  
Characteristics S. aureus K. pneumoniae 
 Frequency 
(N=1494)(%) 
Frequency 
(N=1532)(%)  
Age-group   
<5 454 (30.4) 494 (32.3) 
5-9 32 (2.1) 14 (0.9) 
10-19 61 (4.1) 53 (3.5) 
20-29 145 (9.7) 128 (8.4) 
30-39 180 (12.1) 169 (11.0) 
40-49 141 (9.4) 147 (9.6) 
50-59 135 (9.0) 181 (11.8) 
60-69 97 (6.5) 128 (8.4) 
>=70 80 (5.4) 84 (5.5) 
Missing 169 (11.3) 134 (8.8) 
Gender   
Male 747 (50.0) 796 (52.0) 
Female 637 (42.6) 635 (41.5) 
Missing 110 (7.4) 101 (6.6) 
Hospital   
CHB 437 (29.3) 458 (29.9) 
CMJAH 205 (13.7) 285 (18.6) 
GSH 236 (15.8) 197 (12.9) 
HJH 146 (9.8) 93 (6.1) 
SBPAH 227 (15.2) 252 (16.5) 
TH 143 (9.6) 137 (8.9) 
UH 100 (6.7) 110 (7.2) 
Province   
Free State 100 (6.7) 110 (7.2) 
Gauteng 1015 (67.9) 1088 (71.0) 
Western Cape 379 (25.4) 334 (21.8) 
Year   
2010 770 (51.5) 764 (49.9) 
2011 724 (48.5) 768 (50.1) 
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6.3.2 Antimicrobial resistance pattern of SA and KP isolates 
More than 50.0% of SA isolates were resistant to anti-staphylococcal beta-lactams 
(amoxicilin-clavulanate 54.6%, oxacillin 54.1%), carbapenems (imipenem 54.8%, ertapenem 
54.9%, meropenem 55.0%) and cephalosporins (cefepime 54.5%). However, less than 1.5% 
of SA isolates were resistant to fusidic acid, synercid, teicoplanin and vancomycin. No 
isolates resistant to daptomycin or linezolid were identified. (Figure 6.1)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Profile of antimicrobial resistance of S.aureus 
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The proportion of KP isolates resistant to beta-lactams ranged between (30.1% and 79.3%): 
piperacillin-tazobactam 30.1%, amoxicilin-clavulanate 64.4%, and piperacillin 79.3%; 
resistance to carbapenems ranged between 1.3 - 3.4% and 70% of isolates were resistant to 
cephalosporins (cefepime 70.6%, cefotaxime 70.4%). Low resistance rates among KP isolates 
were observed to amikacin 4.5%, tigercycline 7.9 % and fosfomycin 8.8%. (Figure 6.2) 
 
Figure 6.2 Profile of antimicrobial resistance of K.pneumoniae 
 
6.3.3 Patterns of antimicrobial resistance rate by gender 
Consistently higher proportions of SA isolates were resistant to various antibiotics among 
females compared to males and these differences were mostly statistically significant. 
Resistance rates were (females vs. males): beta-lactams (amoxicilin-clavulanate 56.9% vs. 
49.8%, p = 0.030; oxacillin 56.7% vs. 49.0%, p = 0.019); carbapenems (imipenem 57.4% 
vs.50.0%, p = 0.024; ertapenem 57.2% vs.50.2%, p = 0.034; meropenem 57.2% vs. 50.6%, p 
= 0.045) and cephalosporins (cefepime 56.9% p = 0.026). For KP isolates, there was no 
consistent pattern in the proportions of resistant isolates to various antibiotics among females 
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compared to males. Resistance rates were: beta-lactams (piperacillin-tazobactam 34.4% vs. 
27.4%, p = 0.021; amoxicilin-clavulanate 66.6% vs.62.9%, p = 0.233; piperacillin 78.9% 
vs.78.5%, p = 0.871); carbapenems (ertapenem 2.6% vs. 2.9%, p = 0.815; imipenem 2.8% vs. 
3.4%, p = 0.609; meropenem 1.7% vs. 0.7%, p = 0.170) and cephalosporins (cefepime 69.0% 
vs. 70.3%, p = 0.658; cefuroxime 71.8% vs.72.4%, p = 0.843). None of the differences in 
rates of resistance were statistically significant except for piperacillin-tazobactam (p = 0.021) 
and levofloxacin (30.8 vs. 22.9, p = 0.006). (Table 6.2) 
 
Table 6.2 Univariate analysis results of S. aureus and K. pneumoniae resistance to 
specific antibiotics by gender 
 
S.aureus K.pneumoniae 
Antibiotic 
Males  Females 
p-value Antibiotic 
Males 
n=525(%) 
Females 
n=422(%) 
p-value 
n=399(%) n=328(%) 
Ampicillin 472 (93.7) 405(95.3) 0.278 Mezlocillin 430(81.9) 342(81.0) 0.734 
Amoxiclav*** 251 (49.8) 242(56.9)  0.030 Ampicillin/sulbactam 391(74.5) 322(76.3) 0.517 
Oxacillin 247 (49.0) 241(56.7) 0.901 Amoxclav 330(62.9) 281(66.6) 0.233 
Penicillin 471(93.5) 405(95.3) 0.019 Imipenem 18(3.4) 12(2.8) 0.609 
Imipenem 252 (50.0) 244(57.4)  0.024 Meropenem 9(1.7) 3(0.7) 0.170 
Meropenem 255 (50.6) 243(57.2) 0.045 Ertapenem 15(2.9) 11(2.6) 0.815 
Ertapenem 253 (50.2)  243(57.2) 0.034 Cefazolin 377(71.8) 306(72.5) 0.811 
Cefoxitin  260 (51.6) 190(44.7) 0.037 Ceftazidime 370(70.5) 292(69.2) 0.669 
Cefepime 250 (49.6) 242(56.9) 0.026 Cefuroxime 380(72.4) 303(71.8) 0.843 
Gentamicin 256 (50.8) 242(56.9) 0.061 Cefotaxime 368(70.1) 290(68.7) 0.648 
Tobramycin 254(50.4)  248(58.4) 0.015 Cefoxitin 69(13.1) 57(13.5) 0.870 
Clindamycin 186 (36.9) 183(43.1) 0.056 Cefepime 369(70.3) 291(69.0) 0.658 
Erythromycin 230 (45.6) 217(51.1) 0.099 Piperacillin 412(78.5) 333(78.9) 0.871 
Azithromycin 227 (45.0) 214(50.4) 0.106 Pip_Tazo* 144(27.4) 145(34.4) 0.021 
Ciprofloxacin 232 (46.0) 211(49.7) 0.272 Aztreonam 370(70.5) 294(69.7) 0.787 
Levofloxacin 223 (44.3) 185(43.5) 0.826 Gentamycin 328(62.5) 258(61.1) 0.673 
Moxifloxacin 221 (43.9)  184(43.3) 0.865 Tobramycin 342(65.1) 283(67.1) 0.536 
Trim-Sulfameth** 198(39.3)  190(44.8) 0.089 Amikacin 23(4.4) 20(4.7) 0.792 
Tetracyclin 249(49.4) 233(54.8) 0.100 Ciprofloxacin 224(42.7) 203(48.1) 0.095 
Vancomycin 6(1.2)  3(0.7)  0.453 Levofloxacin 120(22.9) 130(30.8) 0.006 
Fosfomycin 3 (0.6) 1(0.2) 0.404 Moxifloxacin 241(45.9) 218(51.7) 0.078 
Rifampin 83(16.5) 91(21.4) 0.228 Chlorampenicol 248(47.2) 209(49.5) 0.484 
Fusidic Acid 7 (1.4) 4(0.9) 0.530 Trim-Sulfameth 373(71.1) 304(72.0) 0.737 
Synercid 6(1.2) 4(0.9) 0.054 Tetracycline 240(45.7) 205(48.6) 0.380 
Teicoplanin 2(0.4) 2(0.5) 0.864 Tigecycline 38(7.2) 40(9.5) 0.213 
    
Fosfomycin 42(8.0) 44(10.4) 0.196 
* Piperacillin-Tazobactam; ** Trimethoprim-Sulfamethaxazole, ***Amoxicillin-Clavulanate 
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6.3.4 Patterns of antimicrobial resistance rate by province 
The proportions of SA resistant isolates varied by geographical location and were 
consistently higher among isolates from Gauteng province as compared to Free State and the 
Western Cape provinces. For example, significant differences were found in the proportion of 
isolates resistant to the beta-lactams ((oxacillin 48.9% vs. 61.9% vs. 39.5%, p = <0.001) 
carbapenems (etrapenem (51.1% vs. 62.8 vs. 40.1%, p = <0.001), cephalosporins (cefepime 
48.9% vs. 62.5% vs. 39.5%, p = <0.001)) and fluoroquinolone (ciprofloxacin 42.6% vs 
60.7% vs 26.7%, p = <0.001), among others. There were statistically significant differences 
in the distribution of SA isolates resistant to most of the antibiotics tested between the three 
provinces except for fosfomycin, synercid, fusidic acid, and vancomycin, p = >0.05. There 
were only 4 isolates resistant to teicoplanin and only 9 isolates resistant to vancomycin, all 
were reported from Gauteng province. (Table 6.3) The proportions of KP resistant isolates 
were higher in the Free State province for a number of antibiotics except amoxicillin-
clavulanate, fosfomycin, levofloxacin, piperacillin-tazobactam and tigercycline. There were 
statistically significant differences among three provinces (Free State, Gauteng and Western 
Cape respectively) in the proportion of KP isolates resistant to beta-lactams ((amoxycillin–
clavulante (50.0% vs. 67.9% vs. 58.7%, p = 0.001); piperacillin-tazobactam (20.3% vs. 
34.2% vs. 22.1%, p = <0.001)), and fluoroquinolones ((ciprofloxacin (50.0% vs. 47. 1% vs. 
37.3%, p = 0.015); levofloxacin (25.0% vs. 28.8% vs. 18.5%, p = 0.004)) among others. 
(Table 6.3) 
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Table 6.3 Univariate analysis results of S. aureus and K. pneumoniae resistance to 
selected antibiotics by province 
S. aureus K. pneumonia 
Antibiotic 
*FS GA WC 
p-value Antibiotic 
FS GA WC 
p-value 
n=47(%) n=651(%) n=334(%)  n=64(%)  n=705(%) n=276(%) 
Ampicillin 42 (89.4) 623(95.7) 312(93.4) 0.081 Mezlocillin 56 (87.5) 583 (82.7) 220(79.7) 0.284 
Amoxiclav 23 (48.9) 408(62.7) 132(39.5) <0.001 
<0.001 
Ampicillin/Sulbactam 51 (80.0) 539 (76.5) 202(73.2) 0.424 
Oxacillin 23(48.9) 403(61.9) 132(39.5) Amoxclav 32 (50.0) 479 (67.9) 162(58.7) 0.001 
Penicillin 42(89.4) 623(95.7) 311(93.1) <0.001 Imipenem 3(4.7) 21(3.0) 12(4.4) 0.488 
Imipenem 23(48.9) 409(62.8) 134(40.1) <0.001 Meropenem 2(3.1) 8(1.1) 4(1.5) 0.408 
Meropenem 23(48.9) 409(62.8) 136(40.7) <0.001 Ertapenem 4 (6.3) 20 (2.8) 6(2.2) 0.212 
Ertapenem 24 (51.1) 409(62.8) 134(40.1) <0.001 Cefazolin 52 (81.3) 516 (73.2) 193(69.9) 0.173 
Cefoxitin 25 (53.2) 256(39.3) 204(61.1) <0.001 Ceftazidime 51(79.7) 503(71.4) 186(67.4) 0.129 
Cefepime 23 (48.9) 407(62.5) 132(39.5) <0.001 Cefuroxime 53 (82.8) 515 (73.1) 193(69.9) 0.110 
Gentamicin 23(48.9) 417(64.1) 129(38.6) 0.225 Cefotaxime, 51(79.7) 500(70.9) 185(67.0) 0.120 
Tobramycin 25(53.2) 419(64.4) 126(37.7) <0.001 Cefoxitin 4 (6.3) 99 (14.0) 30(10.9) 0.112 
Clindamycin 19 (40.4) 305(46.9) 102(30.5) <0.001 Cefepime 52 (81.3) 501 (71.1) 185(67.0) 0.072 
Erythromycin 22 (46.8) 376(57.8) 115(34.4) <0.001 Piperracillin 55 (85.9) 565 (80.1) 209(75.7) 0.124 
Azithromycin 20 (42.6) 373(57.3) 114(34.1) <0.001 Pip-Tazo 13 (20.3) 241 (34.2) 61(22.1) <0.001 
Ciprofloxacin 20 (42.6) 395(60.7) 89(26.7) <0.001 Aztreonam, 52(81.3) 502(71.2) 188(68.1) 0.111 
Levofloxacin 16(34.0) 379(58.2) 74(22.2) <0.001 Gentamycin 48 (75.0) 433 (61.4) 175(63.4) 0.096 
Moxifloxacin 15(31.9) 374(57.5) 76(22.8) <0.001 Tobramycin 45 (70.3) 483 (68.5) 168(60.9) 0.060 
Trim-Sulfameth 13(27.7) 369(56.8) 70(21.0) <0.001 Amikacin 5 (7.8) 36(5.1) 6(2.2) 0.057 
Tetracyclin 15(31.9) 426(65.4) 108(32.3) 0.309 Ciprofloxacin 32 (50.0) 332 (47.1) 103(37.3) 0.015 
Vancomycin 0(0.0) 9(1.4) 0(0.0) 0.070 Levofloxacin 16 (25.0) 203 (28.8) 51(18.5) 0.004 
Fosfomycin 1(2.1) 2(0.3) 1(0.3) 0.100 Moxifloxacin 32 (50.0) 346 (49.1) 121(43.8) 0.314 
Rifampicin 10(21.3) 137(21.0) 47(14.1) 0.065 Chloramphenicol 42 (65.6) 378 (53.6) 96(34.8) <0.001 
Fusidic acid 1(2.1) 9(1.4) 1(0.3) 0.145 Trim-Sulfameth 51 (79.7) 517 (73.3) 185(67.0) 0.053 
Synercid 2(4.3) 10(1.5) 2(0.6) 0.027 Tetracycline 34 (53.1) 336 (47.7) 113(40.9) 0.086 
Teicoplanin 0(0.0) 4(0.6) 0(0.0) 0.103 Tigecycline 2 (3.1) 55 (7.8) 26(9.4) 0.238 
     
Fosfomycin 4 (6.3) 74 (10.5) 14(5.1) 0.020 
 
*FS ‘Free State’; GA ‘Gauteng’; WC ‘Western Cape’,  
6.3.5 Patterns of antimicrobial resistance rate over time 
Higher proportions of SA isolates reported between July and December in 2010 were 
resistant to various antibiotics compared with those reported between January and June in 
2011. For oxacillin (57.1% vs. 51.1%, p = 0.052) and for vancomycin out of the 9 resistant 
isolates reported, 5 were from 2010 and 4 from 2011 (1.0% vs. 0.8%, p = 0.733). The 
observed variation in the proportions of SA resistance was not significantly different for most 
antibiotics except for amoxicillin-clavulanate (57.9% vs. 51.3%, p = 0.033); ertapenem 
(58.1% vs. 51.8%, p = 0.045) and cefepime (57.7% vs. 51.3%, p = 0.039). 
 
For KP, a similar pattern of resistance was observed. However, the proportion of antibiotic 
resistance was higher in the 2011 period of the study compared to the 2010 period with some 
insignificant exceptions: amikacin, ertapenem and tigercycline showed slightly higher rates 
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of KP resistance during the first 6 months of the study compared with the last 6 months of the 
study. There were variations in the proportions of resistant isolates between the two 6 
month’s periods of July – December 2010 and January to June 2011. Although this variation 
was not significantly different for most antibiotics, significant differences were observed for 
the following antibiotics: ampicillin/salbactum (73.0% vs. 78.4%, p = 0.044), fosfomycin 
(10.6% vs. 7.2%, p = 0.050) and mezlocilin (79.4% vs. 84.8%, p = 0.023). (Table 6.4) The 
findings for SA are consistent with the winter respiratory infection season, and the findings 
for KP are typical for the summer gastrointestinal infection season in the southern 
hemisphere. Respiratory infections are known to be more common in winter. This 
corresponds to SA isolations which were more commonly isolated in 2010, representing the 
colder months of the year. Shedding of SA from the nasal carriage site is likely to be more 
common in winter due to respiratory infections. In contrast, diarrhoeal infections are more 
common in summer and KP commonly colonize the intestinal tract and is therefore more 
likely to cause bacteraemia associated with diarrhea during the summer months.  
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Table 6.4 Univariate analysis results of S. aureus and K. pneumoniae resistance of each 
antibiotic by year 
 
S. aureus K. pneumoniae  
Antibiotic 
2010 2011 
p-value Antibiotic 
2010 2011 
p-value 
n=515 (%) n=517(%) n=500(%) n=545(%) 
Ampicillin 482 (93.6) 495(95.7) 0.124 Mezlocillin 397(79.4) 462(84.8) 0.023 
Amoxiclav 298 (57.9) 265(51.3) 0.033 Ampicillin/Sulbactam 365(73.0) 427(78.4) 0.044 
Oxacillin 294(57.1) 264(51.1) 0.052 Amoxiclav  311(62.2) 362(66.4) 0.154 
Imipenem 297 (57.7) 269(52.0) 0.069 Imipenem 14(2.8) 22(4.0) 0.274 
Meropenem 297 (57.7) 271(52.4) 0.090 Meropenem 10(2.0) 4(0.7) 0.075 
Ertapenem 299 (58.1) 268(51.8) 0.045 Ertapenem 19(3.8) 11 (2.0) 0.085 
Cefoxitin 228 (44.3) 257(49.7) 0.080 Cefazolin 357(71.4) 404(74.1) 0.322 
Cefepime 297 (57.7) 265(51.3) 0.039 Ceftazidime 349(69.8) 391(71.7) 0.490 
Gentamicin 293 (56.9) 276(53.4) 0.257 Cefuroxime 359(71.8) 402(73.8) 0.476 
Tobramycin 292(56.7) 278(53.8) 0.344 Cefotaxime 348(69.6) 388(71.2) 0.573 
Clindamycin 226 (43.9) 200(38.7) 0.090 Cefoxitin 62(12.4) 71(13.0) 0.761 
Erythromycin 274 (53.2) 239(46.2) 0.025 Cefepime 349(69.8) 389(71.4) 0.576 
Azithromycin 269 (52.2) 238(46.0) 0.046 Piperracillin 386(77.2) 443(81.3) 0.103 
Ciprofloxacin 258 (50.1) 246(47.6) 0.419 Pip- Tazo* 154(30.8) 161(29.5) 0.658 
Levofloxacin 238 (46.2) 231(44.7) 0.621 Aztreonam 350(70.0) 392(71.9) 0.493 
Moxifloxacin 240(46.6) 225(43.5) 0.320 Gentamycin 307(61.4) 349(64.0) 0.378 
Trim-Sulfameth 226(44.0) 226(43.7) 0.934 Tobramycin 328(65.6) 368(67.5) 0.510 
Tetracyclin 272(52.8) 277(53.6) 0.806 Amikacin 27(5.4) 20(3.7) 0.178 
Vancomycin 5(1.0) 4(0.8) 0.733 Ciprofloxacin 211(42.2) 256(47.0) 0.121 
Fosfomycin 2 (0.4) 2(0.4) 0. 997 Levofloxacin 122(24.4) 148(27.2) 0.309 
Rifampin 105(20.4) 89(17.2) 0.192 Moxifloxacin 226(45.2) 273(50.1) 0.114 
Fusidic Acid 6 (1.2) 5(1.0) 0.757 Chlorampenicol 253(50.6) 263(48.3) 0.449 
Synercid 10(1.9) 4(0.8) 0.105 Trim-Sulfameth 362(72.4) 391(71.7) 0.813 
Teicoplanin 2(0.4) 2(0.4) 0.997 Tetracycline 230(46.0) 253(46.4) 0.891 
    
Tigecycline 40(8.0) 43(7.9) 0.948 
        Fosfomycin 53(10.6) 39(7.2) 0.050 
 
6.3.6 Age related distribution of patterns of S aureus resistance 
The pattern of SA resistance by age was varied. From Table 6.5, the highest rates of 
resistance were in the under 5 year’s age-group. Resistance to cefepime, a 4th generation 
cephalosporin in the under 5 years was >60%. Significant differences existed in the rates of 
resistance by the different age - groups (p < 0.001). The proportion of MRSA was 63.3% in 
the <5 year age-group, indicating that there were significant differences in the rates of 
resistance between the different age - groups (p = <0.001). There were 9 isolates resistant to 
vancomycin, 4 (4/324) isolates in the under 5 years age-group, a single isolate (1/91) in the 
40 - 49 years age-group and the remaining 4 isolates had no data on age. Only a single isolate 
(1/324), resistant to teicoplanin was reported and was identified in the under 5 years age-
group. For other antibiotics such as fusidic acid, 3 (3/324) resistant isolates were identified in 
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the under 5 year’s age-group, 1(1/121) in the 30 - 39 years age-group, 1 (1/91) in the 40 - 49 
year age-group and 1 (1/48) in the >70 years age group; for synercid there were 7 (7/324) 
resistant isolates in the <5 years age-group, 1 (1/121) in the 30-39 years age-group and 1 
(1/48) in the >70 years age group. Comparatively, the 20 - 29 years age-group had lower rates 
of resistance amongst the different age-groups and there was no identified isolate resistant to 
vancomycin, linezolid and fusidic acid.(Table 6.5) 
 
Table 6.5 Univariate analysis results of S. aureus resistance to each antibiotic by age 
group 
 
                                                     Age group 
Antibiotic <5 
n=324(%) 
5-9 
n=22(%) 
10-19 
n=31(%) 
20-29 
n=88(%) 
30-39 
n=121(%) 
40-49 
n=91(%) 
50-59 
n=82(%) 
60-69 
n=71(%) 
>70 
n=48(%) 
p-value 
Amoxiclav 208(64.2) 7(31.8) 14(45.2) 32(36.4) 62(51.2) 46(50.6) 34(41.5) 26(36.6) 20(41.7) <0.001 
Ampicillin 315(97.2) 20(90.9) 28(90.3) 79(89.8) 114(94.2) 84(92.3) 77(93.9) 65(91.6) 44(91.7) 0.165 
Azithromycin 202(62.4) 9(40.9) 14(45.2) 25(28.4) 49(40.5) 36(39.6) 30(36.6) 24(33.8) 19(39.6) <0.001 
Cefepime 208(64.2) 7(31.8) 14(45.2) 32(36.4) 60(49.6) 47(51.7) 34(41.5) 26(36.6) 20(41.7) <0.001 
Cefoxitin 124(38.3) 15(68.2) 17(54.8) 57(64.8) 61(50.4) 46(50.6) 48(58.5) 45(63.4) 28(58.3) <0.001 
Ciprofloxacin 166(51.2) 9(40.9) 10(32.3) 32(36.4) 52(43.0) 43(47.3) 35(42.7) 27(38.0) 22(45.8) 0.156 
Clindamycin 163(50.3) 7(31.8) 13(41.9) 20(22.7) 45(37.2) 34(37.4) 27(32.9) 22(31.0) 16(33.3) <0.001 
Ertapenem 211(65.1) 8(36.4) 14(45.2) 32(36.4) 61(50.4) 46(50.6) 35(42.7) 26(36.6) 20(41.7) <0.001 
Erythromycin 201(62.0) 10(45.5) 14(45.2) 26(29.6) 49(40.5) 38(41.8) 30(36.6) 24(33.8) 20(41.7) <0.001 
Fosfomycin 2(0.6) 1(4.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0(0.0) 1(1.4) 0(0.0) 0.159 
Fusidic Acid 3(0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1(0.8) 1(1.1) 0 (0.0) 0 (0.0) 1(2.1) 0.861 
Gentamicin 213(65.7) 12(54.6) 13(41.9) 36(40.9) 58(47.9) 46(50.6) 30(36.6) 20(28.2) 22(45.8) <0.001 
Imipenem 209(64.5) 8(36.4) 14(45.2) 32(36.4) 61(50.4) 46(50.6) 35(42.7) 26(36.6) 21(43.8) <0.001 
Levofloxacin 154(47.5) 7(31.8) 11(35.5) 27(30.7) 51(42.2) 41(45.1) 30(36.6) 25(35.2) 19(39.6) 0.114) 
Meropenem 209(64.5) 9(40.9) 14(45.2) 32(36.4) 62(51.2) 46(50.6) 35(42.7) 27(38.0) 20(41.7) <0.001 
Moxifloxacin 154(47.5) 6(27.3) 12(38.7) 28(31.8) 50(41.3) 39(42.9) 30(36.6) 24(33.8) 19(39.6) 0.116 
Oxacillin 205(63.3) 7(31.8) 14(45.2) 32(36.4) 60(49.6) 46(50.6) 34(41.5) 26(36.6) 20(41.7) <0.001 
Penicillin 315(97.2) 20(90.9) 28(90.3) 79(89.8) 114(94.2) 84(92.3) 77(93.9) 65(91.6) 43(89.6) 0.123 
Rifampin 47(14.5) 6(27.3) 6(19.4) 17(19.3) 26(21.5) 27(29.7) 14(17.1) 8(11.3) 8(16.7) 0.047 
Synercid 7(2.2) 0 (0.0) 0(0.0) 0 (0.0) 1(0.8) 0 (0.0) 0 (0.0) 0 (0.0) 1(2.1) 0.370 
Teicoplanin 1(0.3) 0 (0.00) 0 (0.00) 0 (0.0) 0 (0.0) 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.989 
Tetracyclin 189(58.3) 9(40.9) 13(41.9) 40(45.5) 55(45.5) 45(49.5) 32(39.0) 25(35.2) 20(41.7) 0.003 
Tobramycin 203(62.7) 12(54.6) 16(51.6) 37(42.1) 60(49.6) 46(50.6) 32(39.0) 26(36.6) 23(47.9) <0.001 
Sulfamethoxazole 160(49.5) 8(36.4) 8(25.8) 27(30.7) 51(42.2) 41(45.1) 22(26.8) 19(26.8) 12(25.0) <0.001 
Vancomycin 4(1.2) 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1(1.1) 0 (0.0) 0 (0.0) 0(0.0) 0.628 
 
6.3.7 Age related distribution of patterns of K. pneumoniae resistance 
There was wide variation in KP resistance by age-group with significant differences observed 
amongst the following antibiotics: cephalosporins (cefazolin, cefepime, cefotaxime, 
ceftazidime); fluoroquinolones (ciprofloxacin, levofloxacin) (p < 0.05). Beta-lactams i.e. 
amoxicillin-clavulanate, piperacillin-tazobactam and carbapenems (imipenem, etrapenem), 
showed no significant differences in resistance rates between different age-groups (p≥0.05). 
Even though differences in rates of antibiotic resistance were observed amongst some 
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aminoglycoside (amikacin, tobramycin), such differences were not statistically significant (p 
≥ 0.05) except gentamicin (p = 0.007). The lowest number of resistant isolates was from the 5 
- 9 years age-group with no resistant isolate identified to levofloxacin and tigercycline 
reported in this age-group. Higher rates of KP resistant isolates were in the < 5 years age-
group. Resistance to cefotaxime ranged from 57.6% - 81.8%, (p = 0.003), showing high rates 
of ESBL presence across all age-groups. (Table 6.6) 
 
Table 6.6 Univariate analysis results of K. pneumoniae resistance to each antibiotic by 
age group 
 
 
6.3.8 Hospital related distribution of patterns of S.aureus resistance 
The rate of SA resistance across hospitals was widely varied, showing significant differences 
amongst most antibiotics such as amoxicillin-clavulanate, oxacillin, imipenem, meropenem, 
cefepime among others (p ≤ 0.001). The rates of SA resistance to oxacillin, a marker for 
Age group 
Antibiotic 
<5  
n=340(%) 
 5-9  
n=11(%) 
10-19 
n=33(%) 
20-29 
n=80(%) 
30-39 
n=112(%) 
40-49 
n=92(%) 
50-59 
n=118(%) 
60-69 
n=88(%) 
>=70  
n=59(%) 
p-value 
Amikacin 16(4.7) 1(9.1) 1(3.0) 3(3.8) 6(5.4) 2(2.2) 4(3.4) 7(8.0) 2(3.4) 0.742 
Amoxiclav 230(67.7) 7(63.6) 22(66.7) 54(67.5) 75(67.0) 51(55.4) 75(63.6) 54(61.4) 32(54.2) 0.381 
Ampicillin/Sulbactam 279(82.1) 8(72.7) 27(81.8) 59(73.8) 87(77.7) 66(71.7) 84(71.2) 65(73.9) 39(66.1) 0.088 
Aztreonam 269(79.1) 8(72.7) 26(78.8) 51(63.8) 82(73.2) 60(65.2 78(66.1) 57(64.8) 34(57.6) 0.002 
Cefazolin 273(80.3) 8(72.7) 27(81.8) 55(68.8) 82(73.2) 62(67.4) 80(67.8) 60(68.2) 37(62.7) 0.017 
Cefepime 267(78.5) 8(72.7) 26(78.8) 51(63.8) 81(72.3) 60(65.2) 76(64.4) 58(65.9) 34(57.6) 0.004 
Cefotaxime 266(78.2) 8(72.7) 27(81.8) 51(63.8) 81(72.3) 60(65.2) 76(64.4) 57(64.8) 34(57.6) 0.003 
Cefoxitin 24(7.1) 1(9.1) 5(15.2) 13(16.3) 19(17.0) 10(10.9) 22(18.6) 17(19.3) 6(10.2) 0.007 
Ceftazidime 267(78.5) 8(72.7) 27(81.8) 52(65.0) 82(73.2) 60(65.2) 76(64.4) 57(64.8) 34(57.6) 0.003 
Cefuroxime 272(80.0) 8(72.7) 28(84.9) 53(66.3) 84(75.0) 63(68.5) 77(65.3) 61(69.3) 36(61.0) 0.004 
Chlorampenicol 152(44.7) 3(27.3) 21(63.6) 43(53.8) 59(52.7) 48(52.2) 57(48.3) 53(60.2) 25(42.4) 0.069 
Ciprofloxacin 119(35.0) 4(36.4) 18(54.6) 36(45.0) 63(56.3) 40(43.5) 62(52.5) 51(58.0) 30(50.9) <0.001 
Ertapenem 9(2.7) 1(9.1) 0(0.0) 3(3.8) 1(0.9) 1(1.1) 5(4.2) 6(6.8) 1(1.7) 0.184 
Fosfomycin 28(8.2) 1(9.1) 3(9.1) 2(2.5) 7(6.3) 5(5.4) 15(12.7) 6(6.8) 7(11.9) 0.289 
Gentamicin 244(71.8) 7(63.6) 23(69.7) 44(55.0) 70(62.5) 54(58.7) 66(55.9) 54(61.4) 30(50.9) 0.007 
Imipenem 14(4.1) 1(9.1) 2(6.1) 2(2.5) 2(1.8) 3(3.3) 2(1.7) 5(5.7) 2(3.4) 0.693 
Levofloxacin 42(12.4) 0(0.0) 12(36.4) 21(26.3) 45(40.2) 28(30.4) 43(36.4) 36(40.9) 20(33.9) <0.001 
Mezlocillin 297(87.4) 9(81.8) 31(93.9) 64(80.0) 92(82.1) 72(78.3) 91(77.1) 66(75.0) 43(72.9) 0.015 
Meropenem 6(1.8) 1(9.1) 0(0.0) 0(0.0) 0(0.0) 1(1.1) 2(1.7) 3(3.4) 0(0.0) 0.158 
Moxifloxacin 132(38.8) 4(36.4) 20(60.6) 39(48.8) 64(57.1) 42(45.7) 68(57.6) 50(56.8) 32(54.2) 0.001 
Piperracillin 290(85.3) 8(72.7) 31(93.9) 63(78.8) 89(79.5) 68(73.9) 89(75.4) 65(73.9) 41(69.5) 0.010 
Pip-tazobactam 95(27.9) 4(36.4) 10(30.3) 25(31.3) 38(33.9) 25(27.2) 40(33.9) 32(36.4) 20(33.9) 0.799 
Tetracycline 149(43.8) 4(36.4) 19(57.6) 32(40.0) 56(50.0) 42(45.7) 56(47.5) 52(59.1) 27(45.8) 0.225 
Tigecycline 26(7.7) 0(0.0) 5(15.2) 10(12.5) 10(8.9) 6(6.5) 9(7.6) 8(9.1) 2(3.4) 0.471 
Tobramycin 247(72.7) 7(63.6) 22(66.7) 49(61.3) 78(69.6) 56(60.9) 71(60.2) 57(64.8) 33(55.9) 0.087 
Trim-sulfam 258(75.9) 8(72.7) 27(81.8) 60(75.0) 82(73.2) 68(73.9) 83(70.3) 63(71.6) 31(52.5) 0.043 
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MRSA, was significantly different across the different hospitals; ranging from 36.3% - 83.2% 
(p ≤ 0.001) and highest rates being (243/292, 83.2%) at CHB hospital. Out of the 9 
vancomycin resistant isolates, 4 (1.4%) were from CHB, 1 (1.1%) was from CMJAH and 4 
(2.5%) were from SBPAH. For teicoplanin resistant isolates, 1 (1.1%) was from CMJAH, 1 
(0.3%) from CHB and 2 (1.3%) were from SBPAH. As for fusidic acid, 3 (1.0%) isolates 
were from CHB, 2 (2.3%) were from CMJAH, 1 (0.5%) was from GSH, 1 (2.1%) from UH 
and 4(2.5%) were from SBPAH. There were no resistant isolates to linezolid and daptomycin 
from any of the hospitals and rates of MRSA were generally lower at SBPAH compared to all 
other hospitals. (Table 6.7) 
 
Table 6.7 Univariate analysis of S. aureus resistance to each antibiotic by hospital 
 
Antibiotic 
CMJAH  CHB 
n=292(%) 
GSH HJH SBPAH TH UH 
p-value 
n=88(%) n=215(%) n=111(%) n=160(%) n=119(%) n=47(%) 
Ampicillin 85 (96.6) 286 (98.0) 201(93.5) 104(93.7) 148 (92.5) 111(93.3) 42(89.4) 0.057 
Amoxiclav 54 (61.4) 244 (83.6) 77(35.8) 49(44.1) 61(38.1) 55(46.2) 23(48.9) <0.001 
Oxacillin 53 (60.2) 243 (83.2) 77(35.8) 49 (44.1) 58(36.3) 55(46.2) 23(48.9) <0.001 
Imipenem 54(61.4) 244(83.6) 79(36.7) 50(45.1) 61(38.1) 55(46.2) 23(48.9) <0.001 
Meropenem 55(62.5) 244 (83.6) 79(36.7) 50 (45.1) 60 (37.5) 57(47.9) 23(48.9) <0.001 
Ertapenem 54 (61.4) 244 (83.6) 79(36.7) 50 (45.1) 61 (38.1) 55(46.2) 24(51.1) <0.001 
Cefoxitin 37(42.1) 54 (18.5) 139(64.7) 62(55.9) 103 (64.4) 65(54.6) 25(53.2) <0.001 
Cefepime 54 (61.4) 244 (83.6) 77(35.8) 49 (44.1) 60 (37.5) 55(46.2) 23(48.9) <0.001 
Gentamicin 52(59.1) 250(85.6) 72(33.5) 51(46.0) 64 40.0) 57(47.9) 23(48.9) <0.001 
Tobramycin 54(61.4) 245 (83.9) 70(32.6) 51 (46.0) 69 (43.1) 56(47.1) 25(53.2) <0.001 
Ciprofloxacin 52 (59.1) 236 (80.8) 48(22.3) 49 (44.1) 58 (36.3) 41(34.5) 20(42.6) <0.001 
Levofloxacin 49 (55.7) 227 (77.7) 37(17.2) 45 (40.5) 58 (36.3) 37(31.1) 16(34.0) <0.001 
Moxifloxacin 48 (54.6) 225 (77.1) 38(17.7) 44 (39.6) 57 (35.6) 38(31.9) 15(31.9) <0.001 
Clindamycin 47 (53.4) 167 (57.2) 61(28.4) 38 (34.2) 53 (33.1) 41(34.5) 19(40.4) <0.001 
Erythromycin 50 (56.8) 221 (75.7) 68(31.6) 45 (40.5) 60 (37.5) 47(39.5) 22(46.8) <0.001 
Azithromycin 50 (56.8) 218 (74.7) 66(30.7) 45(40.5) 60 (37.5) 48(40.3) 20(42.6) <0.001 
Trim-Sulfameth 50(56.8) 227(77.7) 37(17.2) 46(41.4) 46(28.9) 33(27.7) 13(27.7) <0.001 
Tetracyclin 54(61.4) 249 (85.3) 62(28.8) 59 (53.2) 64 (40.0) 46(38.7) 15(31.9) <0.001 
Vancomycin 1(1.1) 4(1.4) 0(0.0) 0(0.0) 4(2.5) 0(0.0) 0(0.0) 0.119 
Rifampin 22 (25.0) 65 (22.3) 35(16.3) 27 (24.3) 23(14.4) 12(10.1) 10 (21.3) 0.015 
Synercid 3 (3.4) 4 (1.4) 1(0.5) 0 (0.0) 3 (1.9) 1(0.8) 2(4.3) 0.169 
Fosfomycin 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.9) 0 (0.0) 1(0.8) 1 (2.1) 0.331 
Fusidic Acid 2 (2.3) 3 (1.0) 1(0.5) 0 (0.0) 4 (2.5) 0(0.0) 1(2.1) 0.234 
Teicoplanin 1 (1.1) 1 (0.3) 0(0.0) 0(0.0) 2 (1.3) 0(0.0) 0(0.0) 0.392 
 
6.3.9 Hospital related distribution of patterns of K. pneumoniae 
resistance 
The pattern of KP resistance for most antibiotics was not significantly different across 
different hospitals except for amikacin, cefotaxime, cefuroxime, cefepime, tobramycin and 
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piperacillin-tazobactam (p < 0.05). There was no KP resistant isolate reported from TH 
against ertapenem and only 1 resistant isolate to ertapenem was reported from CMJAH. A 
total of 36 isolates representing 3.4% (36/1045) were resistant to imipenem, and the range of 
resistance across hospitals was 2.0% - 8.1%, but the variation not statistically significant (p = 
0.236). KP resistance to piperacilin/tazobactam across all hospitals ranged from 19.3% - 
35.5% (p = 0.005) showing a statistically significant variation in rates of resistance across 
different hospitals. The proportion of ESBL-KP was lowest at SBPAH and highest at UH 
(61.4 - 79.7%, P = 0.012). It is evident that SBPAH generally had lower rates of ESBL-KP 
producing isolates compared to other hospitals. (Table 6.8) 
 
Table 6.8 Results of univariate analysis of K. pneumoniae resistance to each antibiotic 
by hospital 
 
Antibiotic 
CMJAH CHB GSH HJH SBPAH TH UH 
p-value 
n=97(%) n=349(%) n=166(%) n=62(%) n=197(%) n=110(%) n=64(%) 
Mezlocillin 81(83.5) 298(85.4) 133(80.1) 52(83.9) 152(77.2) 87(79.1) 56(87.5) 0.202 
Amp-Sulb 78(80.4) 272(77.9) 120(72.3) 50(80.7) 139(70.6) 82(74.6) 51(79.7) 0.279 
Amoxiclav 65(67.0) 244 (69.9) 102(61.5) 45(72.6) 125(63.5) 60(54.6) 32(50.0) 0.007 
Imipenem 4(4.1) 7(2.0) 8(4.8) 5(8.1) 5(2.5) 4(3.6) 3(4.7) 0.236 
Meropenem 1(1.0) 3(0.9) 4(2.4) 2(3.2) 2(1.0) 0(0.0) 2(3.1) 0.323 
Ertapenem 1(1.0) 9(2.6) 6(3.6) 3(4.8) 7(3.6) 0(0.0) 4(6.3) 0.193 
Cefazolin 74(76.3) 265(75.9) 119(71.7) 47(75.8) 130(66.0) 74(67.3) 52(81.3) 0.079 
Ceftazidime 72(74.2) 261(74.8) 113(68.1) 47(75.8) 123(62.4) 73(66.4) 51(79.7) 0.022 
Cefuroxime 72(74.2) 268(76.8) 117(70.5) 48(77.4) 127(64.5) 76(69.1) 53(82.8) 0.021 
Cefoxitin 10(10.3) 54(15.5) 21(12.7) 10(16.1) 25(12.7) 9(8.2) 4(6.3) 0.239 
Cefotaxime  72(74.2) 260(74.5) 113(68.1) 47(75.8) 121(61.4) 72(65.5) 51(79.7) 0.012 
Cefepime 72(74.2) 261(74.8) 113(68.1) 46(74.2) 122(61.9) 72(65.5) 52(81.3) 0.011 
Piperracillin 81(83.5) 286(82.0) 124(74.7) 51(82.3) 147(74.6) 85(77.3) 55(85.9) 0.141 
Pip-Tazo* 34(35.1) 116(33.2) 32(19.3) 22(35.5) 69(35.0) 29(26.4) 13(20.3) 0.005 
Aztreonam 72(74.2) 261(74.8) 115(69.3) 46(74.2) 123(62.4) 73(66.4) 52(81.3) 0.021 
Gentamicin 60(61.9) 223(63.9) 108(65.1) 43(69.4) 107(54.3) 67(60.9) 48(75.0) 0.061 
Tobramycin 66(68.0) 253(72.5) 105(63.3) 45(72.6) 119(60.4) 63(57.3) 45(70.3) 0. 017 
Amikacin 2(2.1) 14(4.0) 6(3.6) 2(3.2) 18(9.1) 0(0.0) 5(7.8) 0.005 
Ciprofloxacin 40(41.2) 162(46.4) 68(41.0) 37(59.7) 93(47.2) 35(31.8) 32(50.0) 0.013 
Levofloxacin 21(21.7) 99(28.4) 32(19.3) 25(40.3) 58(29.4) 19(17.3) 16(25.0) 0.006 
Moxifloxacin 46(47.4) 170(48.7) 80(48.2) 35(56.5) 95(48.2) 41(37.3) 32(50.0) 0.319 
Chlorampenicol 57(58.8) 193(55.3) 54(32.5) 37(60.0) 91(46.2) 42(38.2) 42(65.6) <0.001 
Trim-Sulfameth 71(73.2) 257(73.6) 111(66.9) 49(79.0) 140(71.1) 74(67.3) 51(79.7) 0.284 
Tetracyclin 41(42.3) 162(46.4) 72(43.4) 29(46.8) 104(52.8) 41(37.3) 34(53.1) 0.154 
Tigecycline 12(12.4) 27(7.7) 17(10.2) 3(4.8) 13(6.6) 9(8.2) 2(3.1) 0.306 
Fosfomycin 8(8.3) 37(10.6) 8(4.8) 6(9.7) 23(11.7) 6(5.5) 4(6.3) 0.181 
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6.3.10 Analysis of factors associated with methicillin resistance to S. 
aureus 
In the analysis of factors associated with MRSA, males with SA bacteraemia were 
significantly less likely to have MRSA (adjusted odds ratio (AOR) 0.63, confidence interval 
(CI) 0.46 - 0.86, p = 0.003) compared with females. Among children of <5 years, those above 
the age of 5 years were significantly less likely to have MRSA; this was true for children of 5 
- 9 years and adults 20 - 29 years and ≥60 years. Using CMJAH as a reference, SA isolates 
from other hospitals, except CHB, were less likely to be methicillin resistant. Findings 
showing statistically significant less likelihood of MRSA isolates were observed from the 
GHS, HJ, and SBPAH, while SA isolates from CHB were nearly 3 times more likely to be 
methicillin resistant (AOR 2.91, CI 1.40 - 6.06, p = 0.004). (Table 6.9) 
 
Table 6.9 Risk factors associated with methicillin-resistant S. aureus (MRSA) blood 
stream infections 
 
  Univariate Analysis Multivariate Analysis 
Characteristic Positive MRSA (%) Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value 
Sex      
Female 231/425(54) 1  1  
Male 231/504(45) 0.71(0.55-0.92) 0.010 0.63(0.46-0.86) 0.003 
Age      
<5 192/324(59) 1  1  
5-9 6/22(27) 0.26(0.10-0.68) 0.006 0.23(0.08-0.72) 0.011 
10-19 13/31(42) 0.50(0.24-1.05) 0.066 0.76(0.34-1.71) 0.506 
20-29 30/88(34) 0.36(0.22-0.58) <0.0001 0.40(0.23-0.71) 0.002 
30-39 58/121(48) 0.63(0.42-1.07) 0.033 0.63(0.39-1.02) 0.062 
40-49 45/91(49) 0.67(0.42-1.07) 0.096 0.92(0.55-1.55) 0.766 
50-59 32/82(39) 0.44(0.27-0.72) 0.001 0.61(0.35-1.04) 0.070 
60-69 24/71(34) 0.35(0.20-0.60) <0.0001 0.40(0.22-0.73) 0.003 
>70  0.45(0.24-0.84) 0.012 0.43(0.21-0.89) 0.023 
Hospital      
Charlotte Maxeke Academic 47/88(53) 1  1  
Chris Hani Baragwanath 235/292(80) 3.60(2.16-5.98) <0.0001 2.91(1.40-6.06) 0.004 
GSH 70/215(33) 0.42(0.25-0.70) 0.001 0.32(0.16-0.63) 0.001 
Helen Joseph 48/111(43) 0.66(0.38-1.17) 0.155 0.41(0.20-0.84) 0.016 
Steve Biko Academic 55/160(34) 0.46(0.27-0.78) 0.004 0.32(0.16-0.65) 0.002 
Tygerberg 52/119(44) 0.68(0.39-1.18) 0.167 0.55(0.27-1.12) 0.097 
Universitas 22/47(47) 0.77(0.38-1.56) 0.465 0.89(0.36-2.15) 0.788 
Province      
Free State 22/47(47) 1  - - 
Gauteng 385/651(59) 1.64(0.91-2.98) 0.101 - - 
Western Cape 122/334(37) 0.65(0.35-1.21) 0.176 - - 
Year       
2010 278/515(54) 1  1  
2011 251/517(49) 0.80(0.63-1.03) 0.081 0.79(0.58-1.08) 0.139 
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6.3.11 Analysis of factors associated with ESBL K. pneumoniae 
Among KP isolates, there was no significant association observed between gender and 
ESBL-KP. Except for age-group less than 20 years, KP isolates from patients of age ≥20 
years were significantly less likely to be ESBL producers. The analysis showed an inverse 
relationship, the higher the age the less the likelihood of ESBL production, e.g. patients >70 
years were less likely to have ESBL-KP isolates (AOR 0.31, CI 0.17 – 0.57, p = <0.0001). 
In multivariate models, with CMJAH as the reference group, KP isolates from SBPAH were 
significantly less likely to be ESBL producers (AOR 0.49, CI 0.25 – 0.95, p = 0.036). The 
same pattern showing lower odds of ESBL-KP was observed from the other hospitals (CHB, 
GSH, HJ and UH). However, the association was not statistically significant. (Table 6.10) 
 
Table 6.10  Factors associated with extended spectrum beta-lactames (ESBLs) K. 
pneumoniae 
 
  Univariate Analysis Multivariate Analysis 
Characteristic Positive ESBL (%) Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value 
Sex      
Female 273/422(65) 1  1  
Male 354/525(67) 0.89(0.68-1.16) 0.376 0.85(0.63-1.14) 0.282 
Age      
<5 259/340(76) 1  1  
5-9 8/11(73) 0.83(0.22-3.22) 0.792 0.61(0.15-2.47) 0.491 
10-19 25/33(76) 0.98(0.42-2.25) 0.957 0.92(0.37-2.26) 0.854 
20-29 50/80(63) 0.52(0.31-0.87) 0.013 0.45(0.26-0.78) 0.005 
30-39 75/112(67) 0.63(0.40-1.01) 0.055 0.60(0.37-0.98) 0.042 
40-49 60/92(65) 0.59(0.36-0.96) 0.035 0.44(0.26-0.74) 0.002 
50-59 72/118(61) 0.49(0.31-0.76) 0.002 0.42(0.26-0.68) <0.0001 
60-69 51/88(58) 0.43(0.26-0.70) 0.001 0.36(0.21-0.61) <0.0001 
>70 32/59(54) 0.37(0.21-0.66) 0.001 0.31(0.17-0.57) <0.0001 
Hospital      
Charlotte Maxeke Academic 69/97(71) 1  1  
Chris Hani Baragwanath 241/349(69) 0.91(0.55-1.48) 0.694 0.75(0.38-1.45) 0.389 
GSH 111/166(67) 0.82(0.47-1.41) 0.473 0.60(0.30-1.19) 0.141 
Helen Joseph 42/62(68) 0.85(0.43-1.70) 0.650 0.64(0.28-1.46) 0.288 
Steve Biko Academic 116/197(59) 0.58(0.34-0.98) 0.042 0.49(0.25-0.95) 0.036 
Tygerberg 72/110(65) 0.77(0.43-1.39) 0.382 0.50(0.24-1.04) 0.064 
Universitas 50/64(78) 1.45(0.69-3.03) 0.324 0.96(0.38-2.44) 0.930 
Province      
Free State 50/64(78) 1  - - 
Gauteng 468/705(66) 0.55(0.30-1.02) 0.058 - - 
Western Cape 183/276(66) 0.55(0.29-1.05) 0.069 - - 
Year       
2010 329/500(66) 1  1 - 
2011 372/545(68) 1.12(0.86-1.45) 0.399 1.17(0.87-1.58) 0.308 
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6.3.12 Analysis of S. aureus/ MRSA, and K. pneumoniae/ESBL from three 
Johannesburg hospitals  
 
In order to consider the possible role of race, which will also reflect socio-economic status, 
bacteraemic episodes and isolation from blood of S. aureus and MRSA; as well as K. 
pneumoniae and ESBL from CHB (predominantly black patients), CMJAH (all races, mainly 
white patients) and Helen Joseph Hospital (mainly white and coloured patients) were 
compared in Table 6.11. The proportion of MRSA from SA isolates was much higher at CHB 
(80%) representing predominantly black patients with relatively low socio-economic status, 
compared with the other two Johannesburg hospitals (proportion of MRSA isolates varying 
from 43% to 53%). The latter two hospitals accommodate mixed race patients with a small 
proportion of black patients originally coming from a higher socio-economic group than 
those at CHB. No obvious difference in the proportion of ESBL in KP among patients from 
the three hospitals was noted (proportions varied from 62% to 72%). The proportion of 
MRSA was significantly higher in females (54% vs 45%) however the proportions of ESBL 
in KP were very similar in females and in males (65% vs 67%). (Table 6.11)  
 
Table 6.11 Bacteraemia isolates of S. aureus/ MRSA, and K. pneumoniae/ESBL from 
three Johannesburg hospitals representing different racial/ socio-economic populations 
 
 Number of bacteraemic patients at three hospitals               
Hospitals   S.aureus MRSA (%) K.pneumoniae ESBL (%) 
All 929 462  (49.7) 947 627 (66.2) 
CHB 292 235  (80) 349 241 (69) 
CHJAH 88 47    (53) 97 69   (71) 
HJ 111 48    (43) 62 42   (68) 
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6.4 Discussion 
This study aimed to provide data on the burden of AMR in South Africa using a sentinel 
surveillance system of collecting data on SA and KP blood culture isolates that have 
undergone susceptibility testing of all clinically relevant antibiotics with strict quality control 
measures. Drug susceptibility testing was carried out in a single (reference) laboratory. The 
purpose of doing this work was to validate the previous LIS/CDW approach and add to the 
understanding of the epidemiology of antimicrobial resistance in hospitals and provide a 
platform for policy change regarding antimicrobial use, regular surveillance of resistance 
patterns and hospital infection control.  
 
6.4.1 Distribution of S. aureus and K. pneumoniae isolates 
There were more isolates of SA and KP in the <5 years age-group, and more KP isolates in 
the 50 - 59 years age-group. It is not uncommon to find a high prevalence of bacteremia in 
children less than five years of age. However, among the 50 - 59 years age-group, it is 
assumed that the reason for high proportion of bacteremia, is likely to be a result of 
increasing colonization of KP in the communities. More isolates were reported from Gauteng 
province since more hospitals from this province were included in the study, and they were 
the largest hospitals and the volume of blood cultures from these 4 Gauteng hospitals might 
be higher than for the Western Cape and Free State provinces. Bias towards Gauteng 
sampling poses a major confounder when trends of resistance in provinces are considered. 
Rates of resistance observed from this province should therefore have been assessed 
separately. Despite this over representation there was insignificant variation in rates of 
resistance across hospitals. (Table 6.8) 
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Although it is still unclear why there is such variation in the type of isolates identified at HJH 
hospital and CMJAH, a possible reason might be the differences in infection control policies 
or dynamics of patient population i.e. differences in socioeconomic status. These two 
hospitals support patients from traditionally different population groups (HJH predominantly 
served patients from the south west of Johannesburg while CMJAH patients were mostly 
patients from the northern side of Johannesburg, meaning the overall prevalence of SA and 
KP might be different in the two geographical areas. More SA and KP isolates were reported 
among males compared to females showing preponderance for such infections among the 
male population. Again, the reason for the difference is unclear but, it might be a reflection of 
differences in risk exposures between the two populations or declining immune function in 
the male population presumably, due to higher prevalence of HIV infection, making them 
vulnerable to opportunistic bacteraemic episodes. HIV infection, especially when associated 
with low CD4 cell counts renders patients susceptible to infection, including invasive disease 
caused by SA and KP. (153, 154) The age distribution of MRSA is interesting and the 
proportions were highest in infants and children <5 years of age (59%), and in the 30-50 year 
age group (48-49%; see table 6.9), coinciding with HIV/AIDS prevalence. With regard to 
KP, the proportions of ESBLs were highest in the <20 years age groups (73%-76%; see table 
6.10). The proportions of ESBL in the age groups 30 years to >70 years varied from 58-67%. 
 
6.4.2 Antimicrobial resistance pattern of SA and KP isolates 
The pattern of SA and KP resistance showed high proportion of resistant isolates to most of 
the conventional antibiotics, with β-lactam resistance of over 40% and MRSA crude rate of 
over 50%. This finding is consistent with previous studies that showed similar high rates of 
antibiotic resistance. (155, 156) 
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Resistance rates of SA to fusidic acid, synercid, teicoplanin and vancomycin were less than 
2%. No resistant isolates were identified to linezolid and daptomycin. Despite these low 
prevalence rates, ongoing surveillance of drug resistance to this group of anti-microbial 
agents is important, as an increasing trend in resistance could have significant consequences 
for patient management. (157, 158) Earlier studies have shown that antimicrobial resistance 
to reserved antibiotics such as vancomycin has slowly been increasing (159) and this is a 
worrying development considering that antimicrobial-resistant strains acquired in hospital, 
could be transmitted nosocomially and eventually spread to the community. (160) 
 
6.4.3 Patterns of antimicrobial resistance rate by gender 
Even though minor differences were seen in gender prevalence of MRSA, these were not 
statistical significant. The same was the case with fluoroquinolone resistance in SA isolates. 
In contrast, for KP, significantly more cases of fluoroquinolone resistance occurred in 
females. It is unlikely that this could be attributed to the use of fluoroquinolones for the 
treatment of sexually transmitted infections (STIs) such as gonococcal infections. As a result 
of the emergence of drug resistance, such infections are no longer treated with this group of 
agents and historically these infections, although treated with fluoroquinolones, were 
probably more commonly diagnosed in males than in females. (161-163) The preponderance 
of fluoroquinolone resistance among KP isolates in females is likely to be related to the 
selective pressure of fluoroquinolone treatment of Gram-negative urinary tract infections 
which are very common and much more frequently encountered in females. (164) 
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6.4.4 Patterns of antimicrobial resistance rate by province 
Four of the seven academic hospitals included in this study are in Gauteng Province, two in 
the Western Cape and one in the Free State. SA resistance rates to the various antimicrobial 
agents showed considerable variation e.g., resistance to β-lactams such as 
amoxicillin/clavulanate in the 4 Gauteng Province hospitals varied from 38.1% (SBPAH) to 
83.6% (CHB) with a mean resistance rate of 60.9%, while the figures for the Western Cape 
Province were 35.8% for GSH and 46.2% for TH and a mean of 41.0%. The Free State (UH) 
figure was 48.9%. Because of the wide variation in resistance in hospitals to most of the 
antibiotics featuring in this study, it would be more meaningful for future studies to only 
compare the frequency of resistance between the hospitals rather than by province. 
 
In a study by Bamford et al. performed on bacteraemic isolates from 7 academic hospitals, 
six of which featured in this present study, susceptibility of both SA and KP to selected 
antimicrobial agents was determined and analysed. Comparing the 2010 findings of Bamford 
et al. with those of this study, the respective resistance figures for SA are oxacillin (MRSA): 
45% vs. 54.1% and erythromycin: 46% vs. 49.7%. In the case of KP, the respective resistance 
figures are 19% vs. 4.5% for amikacin; 57% vs. 62.8% for gentamicin and 37% vs. 44.7% for 
ciprofloxacin (123) 
 
The proportions of KP resistant isolates to various antibiotics were higher in the Free State 
compared to Gauteng and Western Cape Provinces. We found that significant differences 
existed in the proportion of KP isolates resistant to antibiotics such as amoxicillin-clavulanate 
(50.0% vs. 67.9% vs. 58.7%, p = 0.001) and piperacillin-tazobactam (20.3% vs.34.2% vs. 
22.1%, p = <0.001). The resistance rates are comparable to what is previously known about 
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KP resistance. (165-167) It is not immediately apparent why such geographical difference 
exists but it again may be attributed to differences in population dynamics, in these different 
provinces. However, this finding warrants further investigation to understand the dynamics of 
the observed differences including exploring differences in antibiotic prescribing policies or 
hospital infection control programmes in these provinces.  
 
6.4.5 Patterns of antimicrobial resistance rate by year 
The pattern of SA resistance differed between July to December 2010 and January to June 
2011 with the 6 months period in 2010 showing higher proportions of resistant isolates than 
the 6 months period in 2011. It should be noted that in both years, data were gathered for half 
of the year (July 2010 to June 2011) as the Antimicrobial Resistance Surveillance and 
Research (ARSR) only started operating in July 2010. Caution should, therefore, be exercised 
in interpreting these findings as we would not know if this would have been different if data 
were to be collected for each complete calendar year.  
The variation in resistance of SA to antibiotics between the two years was wide and 
statistically significant for: amoxicillin-clavulanate, cefepime, ertapenem etc. This finding is 
similar to that of a previous study that reported on retrospective data of SA and KP over a 5 
year period. (168) For KP, we observed no significant differences in the variation of 
antibiotic resistance between the two time periods, for most of the antibiotics. The pattern 
favours an upward direction of resistance development, with higher rates of resistance in 
2011. However, 6 months data may not be robust enough to unravel such differences. (31, 
123, 165, 169) 
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6.4.6 Age related distribution of patterns of S. aureus resistance 
The pattern of SA resistance shown in this study is consistent with previous findings. 
Resistance was shown to be higher in the < 5 years age-group. (168) High levels of resistance 
to 4
th
 generation cephalosporins and MRSA rates of greater than 60% in this age-group poses 
a major clinical and public health challenge and is a worrisome development. (170) 
Vancomycin resistant SA isolates have been reported in previous studies done in Canada, UK 
and Japan.(115, 159, 171) Increasing magnitude of vancomycin resistant SA is of concern. 
(172) In our study, 9 vancomycin resistant isolates were found within this period.  
 
Development of glycopeptides resistance poses major challenges as this is still an antibiotic 
of choice for MRSA.(173, 174) Lower rates of resistance for most of the antibiotics were 
observed in the 5 - 9 years age group than across the other different age-groups, with no 
resistant isolates reported to vancomycin, synercid and fusidic Acid. A possible explanation 
for this observation is probably a lower exposure to antibiotics amongst this age-group.  
 
6.4.7 Age related distribution of patterns of K. pneumoniae resistance 
The study showed that the largest number of ESBL-KP isolates (266/340, 78.2%) were in the 
under 5 years age-group, with significant differences between the different age-groups, 
(p=0.003). The lowest number of ESBL-KP isolates was in the 5 - 9 years age-group. No 
resistant isolates to levofloxacin and tigercycline were reported in this age-group. KP 
resistance to cefepime, a 4
th
 generation cephalosporin, ranged from 56.7% to 78.8% 
(p=0.004) across all age-groups showing high resistance to extended spectrum 
cephalosporins. This study shows that antibiotic resistance in KP bacteraemia was high in the 
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younger age-group as opposed to the adult patients and this has been well documented in 
previous studies.  
 
6.4.8 Hospital related distribution of patterns of S. aureus resistance 
In a study by Bamford et al, susceptibility of both SA and KP to selected antimicrobial agents 
was determined and showed resistance rates that were comparable, with minimal degree of 
variation.(123) While the rates of SA resistance across hospitals varied widely, MRSA 
significantly differed across the hospitals (p=<0.001) and being highest at CHB hospital, 
similar to the finding that was previously reported. (123) This might be because of 
differences in infection prevention practices or prescribing policies between the different 
hospitals. The finding of high MRSA rates at CHB hospital is consistent with previous 
findings. (31) Of the 9 vancomycin resistant isolates, 4 were from CHB and 4 from SBPAH. 
This could be due to inadequate infection prevention measures at these hospitals. This is of 
concern as there is a danger of community spread of the resistant strain in the catchment area 
served by these hospitals.  
 
6.4.9 Hospital related distribution of patterns of K. pneumoniae 
resistance 
The study demonstrated a significant variation in the distribution of KP resistance across the 
different hospitals. The findings of this study are consistent with previous findings showing 
growing rates of resistance to the carbapenems ranging from 1% - 6.7%.(31, 123, 169) No 
KP isolate resistant to etrapenem and meropenem was reported from TH and only 1 resistant 
isolate was reported from CMJAH. It appears that none or lower number of isolates resistant 
to carbapenems were reported from HJH and UH. This could be due to low exposure of 
carbapenems as a result of differing prescription policies or practices between these hospitals 
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with the assumption that HJH and UH having restricted use of carbapenems compared to 
other hospitals. Another explanation could be different infection control protocols thereby 
leading to a reduction in risk for acquisition of hospital associated infections (HAIs).  
 
KP resistance to piperacilin-tazobactam was high (165) across all sites. The high rates of 
ESBL-KP are worrisome as they limit treatment choices in the management of KP 
bactereamia. Resistance showed to be relatively lower at SBPAH and it is not entirely clear 
why KP resistance is generally lower at SBPAH compared to other hospitals, it can only be 
assumed that the possible reason would be due to differences in prescription policy at these 
different hospitals or differences in blood culture practices. (123) 
 
6.4.10 Factors associated with MRSA and ESBL-KP 
Several demographic factors were found to be significantly associated with antimicrobial 
resistance. For SA factors associated with lower odds of MRSA were: male gender, age-
group <5 years and ≥60 years and hospital location (CHB, HJ, GSH and SBPAH). Factors 
significantly associated with lower odds ESBL-KP were older age ≥20 years and hospital 
location (SBPAH). Even though male gender had lower odds of ESBL-KP, the finding was 
not statistically significant. There is however no known reason that could explain such 
underlying associations. However, in European hospitals more males than females are treated 
at any moment in time. This is probably due to the more unhealthy lifestyles (more stress, 
more alcohol, more smoking) leading to earlier chronic disease in males than in females. In 
contrast, in the present study we had showed no significant variation in resistance pattern 
between males and females for ESBL in KP (male 67%, female 65%; p=0.282. Table 6.10) 
but MRSA was significantly more common in females (54%) compared with males (45%); 
table 6.9, p=0.0003), an indication that the situation may not be as observed in Europe. 
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The main limitation of this study is incompleteness of data, an inherent weakness of public 
health surveillance systems. Analysis of data stratified by the numbers of hospital beds of 
individual institutions was not done, constituting an important limitation of the study. In 
addition no data on admission date and occurrence of blood stream infection were available 
hence it was not possible to determine prevalence of nosocomial bactereamia. This being 
laboratory based surveillance therefore no data was available on clinical parameters and 
clinical outcomes and it was therefore not possible to ascertain the clinical impact of 
antimicrobial resistance on outcomes in these hospitals.  
 
6.5 Conclusion 
The rates of SA and KP resistance observed in this study are high. It is also of concern that 
there (i) is an increasing number of SA isolates resistant to vancomycin, (ii) are high rates of 
MRSA and (iii) is an emergence of carbapenemase-mediated resistance in KP which is rising 
above 3%.  
 
It has been shown that appropriate antibiotic treatment reduces the likelihood of infections 
caused by antibiotic resistant pathogens and ultimately leads to improved patient outcomes. 
As such, to promote improved clinical management of bacteraemia episodes, antibiotic 
treatment guidelines and stewardship programmes should be developed based on local 
patterns of antibiotic resistance. Such a surveillance program is essential as it will contribute 
to ascertaining the precise burden of antimicrobial resistance among nosocomial infections at 
local (hospital) and provincial levels. Such data could provide a landscape for the 
enhancement of basic infection control practices and antimicrobial stewardship to combat the 
development and spread of antibiotic resistant bacteria.  
P a g e  |184 
 
  
 
Since these findings may not entirely represent the average resistance rate from all hospitals 
in South Africa because the study only covered hospitals from 3 out of 9 provinces, further 
studies are needed to confirm these findings as resistance rates seem to vary by geographical 
and hospital location. 
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Chapter 7  Comparative assessment of patterns of 
antimicrobial resistance of Staphylococcus aureus & 
Klebsiella pneumoniae blood culture isolates from 
GERMS–SA and CDW databases 
 
This chapter presents comparative findings of patterns of antimicrobial resistance to various 
antimicrobial agents commonly used in hospitals. Comparative data presented here were from 
prospective (July 2010 to June 2011) and retrospective (July 2005 to December 2009) 
periods. The purpose was to ascertain validity and reliability of routine LIS data sources. 
 
7.1 Introduction 
A reliable antimicrobial surveillance system requires thorough assessment of data quality and 
control measures so as to ensure that blood culture data collected by the National Health 
Laboratory Service (NHLS) system through the Group for Enteric, Respiratory and 
Meningeal Disease Surveillance programme in South Africa (GERMS-SA) are reliable and 
representative of the South African population. 
 
GERMS-SA conducts national laboratory-based surveillance of communicable diseases of 
public health relevance in South Africa. The surveillance system has been ongoing since the 
early 2000s’. All participating laboratories are asked to regularly send isolates of the selected 
pathogens following the well-defined case definitions. Such isolates are sent to GERMS-SA 
for further microbiological testing which includes culture and susceptibility testing, 
molecular testing, genotyping and phenotyping of the isolates etc.  
 
To ensure appropriate data quality for the surveillance purposes, GERMS-SA endeavours to 
conduct data audits so as to evaluate the number of blood culture isolates received at the 
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reference laboratory compared with the number of blood culture isolates identified at the 
participating NHLS laboratories. The difference which can be expressed as a proportion can 
act as a proxy measure of how representative the GERMS surveillance network is in South 
Africa so that data aggregated and the results coming from such data can be generalized to 
the South African population with some degree of certainty. 
 
A comparative assessment was conducted of blood culture data for Staphylococcus aureus 
(SA) and Klebsiella pneumoniae (KA) isolated in seven tertiary academic hospitals in South 
Africa. The aim was to assess completeness and hence reliability of the blood culture data 
that were entered into the GERMS-SA database from the sentinel laboratories. Furthermore, 
to simultaneously assess the reliability of routine blood culture data generated from the 
Laboratory Information System (LIS) by comparing such data with data collected in a more 
systematic and controlled manner by the ARSR unit of GERMS-SA enhanced surveillance 
system.  
 
Antimicrobial susceptibility data from ARSR unit were uses as a gold standard comparator. It 
was assumed that GERMS-SA data are of more reliable quality since data are gathered 
through a rigorous research process following a specified standard protocol and subjected to 
error scrutiny. It was envisaged that such a comparative assessment would provide objective 
information on whether the data generated through the LIS despite its limitations would 
provide similar patterns of resistance, as that observed through analysis of blood culture data 
generated through the GERMS-SA surveillance system.  
 
This assessment was not intended to evaluate functionality and performance of laboratories 
across different geographical location nor investigate laboratory standards. SA and KP are 
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bacteria of interest that were selected for the antimicrobial resistance surveillance by the 
GERMS-SA. This provided a platform for comparing validity and reliability of the CDW 
blood culture data that are routinely aggregated through the LIS. 
 
7.2 Objectives 
The specific objectives of the comparative assessment were: 
 To ascertain that all blood culture isolates of selected pathogens under surveillance from 
the seven tertiary academic hospitals are reported to the GERMS-SA surveillance 
network. 
 To assess the quality of antimicrobial susceptibility data of blood culture isolates of S. 
aureus and K. pneumoniae that are reported to the CDW to ascertain representativeness of 
the GERMS-SA surveillance data. 
 To ascertain the proportion of missing data in order to determine the gravity of biased 
estimation of the prevalence of the blood stream infections caused by the S. aureus and K. 
pneumoniae. 
 
7.3 Methodology 
 
7.3.1 Study Setting 
The study compared data obtained by ARSR of the National Institute of Communicable 
Diseases (NICD). Blood culture isolates of SA and KP were collected in 7 tertiary public 
hospitals associated with academic institutions. Details of participating sites have been 
reported elsewhere in this thesis. (Chapter 5, section 5.2.2) 
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7.3.2 Data extraction from the CDW 
The procedure for data extraction from the Corporate Data Warehouse (CDW) of the NHLS 
followed the GERMS-SA protocol that is used when conducting data audits.  
Blood culture data were accessed through a password controlled portal 
(https://cdwmicrostrategy.nhls.ac.za/MicroStrategy/asp/main.aspx), through use of legitimate 
log in details (username and password) followed by a selection of the bacterial pathogens of 
interest. For this study the pathogens selected were S. aureus and K. pneumoniae which are 
bacterial pathogens of focus for the Centre for Opportunistic, Tropical and Hospital 
Infections at the National Institute for Communicable Diseases (NICD). Details of how data 
were extracted from the CDW are provided elsewhere in this thesis (2.5 Data Management, 
Section 2.5.1). 
 
7.3.3 Assessment of completeness of blood culture data from the CDW 
Database 
 
The procedure for conducting the data audit from the CDW database followed the standard 
protocol developed by GERMS-SA quality assurance team. The process was done by specific 
matching parameters of blood culture data found in the CDW database with similar 
parameters in the GERMS-SA database, in order to identify non-matching cases for further 
scrutiny. 
 
7.3.4 Matching of GERMS-SA Data to CDW data 
To be able to match data in the two databases and identify missing isolates which were 
termed ‘audits cases’, we performed an automated matching using the VLOOKUP function 
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of MS Excel. This matching allowed for quick identification of similar records in the two 
databases, i.e. the GERMS and the CDW databases. Blood cultures that were done after 21 
days from the date of the last blood culture were deemed to be a new bacteraemic episode, 
hence not regarded as duplicate records. 
 
The records that did not match were put under further interrogation by using the manual 
eyeballing technique. This made it possible to further identify matching blood culture records 
in the two different databases. This was done by creating a ‘Non-match’ CDW spreadsheet to 
look the same as that of the GERMS-SA spreadsheet. This was achieved by aligning the 
order of the column in the two different databases, and then combining the spreadsheets and 
sorting by Surname, First Name, Collect Date and Reference Organism etc. The Non-match 
CDW cases that did not match the GERMS-SA cases, were identified as 'audit cases' and 
were coded “a” under AUDIT column in the CDW spreadsheet.  
 
The list of all non-match cases which were called audit cases was then submitted to the unit 
laboratory manager for thorough checking of such cases on the DISAlab LIS. Once verified 
that such data were not duplicates, but were missing cases in the GERMS-SA database, data 
for such individual cases were entered onto the GERMS-SA antimicrobial resistance 
surveillance and research (ARSR) database. When all audit cases were identified and entered 
onto the database, a full quarterly surveillance statistical report was generated. 
 
7.4 Results 
7.4.1 Assessing data completeness 
Table 7.1 presents an assessment report for a complete 12 months calendar period. The table 
highlights audit cases identified during the process of the surveillance audit of SA and KP 
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isolates from the 7 academic hospitals’clinical microbiology laboratories. By definition, audit 
cases were blood culture isolates that were found on the CDW database, but were not present 
on the GERMS-SA database, which means that these clinical isolates were not reported in 
GERMS-SA by the different laboratories. By implication, without this audit process, 
GERMS-SA surveillance is prone to under reporting the occurrence of SA and KP 
bacteraemia.  
The distribution shows that the percentage of audit cases was highest at Charlotte Maxeke 
Johannesburg Academic hospital (29.3% and 36.4%, respectively) and lowest at Groote 
Schuur hospital (5.6% and 0.3%, respectively) for both SA and KP isolates. In general, there 
were fewer audit cases identified in the Western Cape Province clinical microbiology 
laboratories. 
 
Table 7.1 Frequency distribution of audit cases identified for the period 1st January-
31st December, 2011 
 
                                  Audit Cases  
Province Hospital Name 
Staphylococcus aureus 
             N=409* (%) 
Klebsiella pneumoniae 
               N=365* (%) 
Gauteng Charlotte Maxeke JAH 120 (29.3) 133 (36.4) 
  CH Baragwanath Hospital 66 (16.1) 119 (32.6) 
  Helen Joseph Hospital 45 (11.0) 35 (9.6) 
  Steve Biko PAH 57 (13.9) 5 (1.4) 
Free State Universitas Hospital 55 (13.4) 46 (12.6) 
Western Cape Groote Schuur Hospital 23 (5.6) 1 (0.3) 
  Tygerberg Hospital 
43 (10.5) 
26 (7.1) 
 
*N= total number audit cases identified 
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7.4.2 Comparison of Antimicrobial Resistance data from GERM-SA and 
CDW data bases 
 
We compared resistance patterns generated from the two data sources: 1) CDW which houses 
routine data and 2) GERMS-SA which houses data from reference laboratory where isolates 
from different NHLS laboratories are assessed and confirmed, and susceptibility testing 
undertaken in a more controlled research setting. Table 7.2 and 7.3 present the results of the 
comparative analyses of resistance patterns of the selected antibiotics for SA and KP. 
However it should be noted that differential sampling between the two study periods might 
have introduced selection bias in comparing resistance proportions estimating antimicrobial 
resistance. 
 
The cloxacillin mean resistance rate was 15.4% (range 0.4% - 43%) (Table 7.2). Gauteng 
province hospitals had very low resistance (range 0.4 - 5%), so when excluding data for 
cloxacillin from Gauteng Province hospitals, cloxacillin mean resistance rate was 39% (range 
30-43%). The mean resistance rate as well as the range of antimicrobial resistance has 
minimum variation from each other between the GERMS-SA and the CDW data sources. The 
table gives a picture of the pattern of antibiotic resistance among commonly used agents for 
treating S.aureus bactereamia. 
Table 7.2 Comparison of rates S. aureus resistance for periods 2005-2009 and 2010-2011 
Antibiotic CDW 2005-2009  GERMS-SA 2010-2011  
Ampicillin 95.7 (88.2%-96.5%) 94.7 (89.4%-98.0%)  
Cloxacillin* 15.4 [(30%-43% (UH & WC), 
^GA 0.4-5.0% )] 
54.1 (36.3%-83.2%) 
Clindamycin 32.4 (15%-72%) 41.3 (28.4%-57.2%) 
Erythromycin 34.5 (19%-44%) 49.7 (31.6%-75.7%) 
Gentamicin 51.8 (22.2%-66.7%) 55.1(33.5%-85.5%)  
 
*UH and Western Cape Province hospitals (resistance range 30.4-43.0%); ^Gauteng Province hospitals 
(resistance range 0.4%-5%) 
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In Table 7.3, the rates of antibiotic resistance between the GERMS-SA and the CDW data 
sources also shows very minimal variation amongst the tested antibiotics. Comparatively, 
more cases of carbapanemes resistance were identified during the 2010-2011 period: 
ertapenem 50 resistant isolates out of 2474 KP isolates tested; imipenem 4 out of 3059 
isolates tested; and meropenem 5 out of 3046 tested during the 2005-2009 period. While in 
the 2010-2011 period 30, 36, and 14 resistant isolates to etrapenem, imipenem, meropenem, 
respectively, were identified out of 1045 KP isolates tested.  
 
Data in the table7.3 suggests an increase in carbapanem resistance during the period 2010-
2011 which might have been as a result of an enhanced ability to accurately determine 
resistance in all isolates as compared to previous years. However, when one looks at the data 
on carbapenem resistance in table 7.3, it can be seen that the ranges presented for the 
GERMS-SA carbapenem resistance are much wider that those recorded in the CDW, 
suggesting the possibility of a technical or recording problem with the GERMS-SA (2010-
2011) over the one-year period. Despite this observed increasing resistance, the findings 
between the two databases show a minimal variation in terms of KP resistance pattern among 
these antibiotics. 
Table 7.3 Comparison of rates of K. pneumoniae antimicrobial resistance for periods 
2005-2009 and 2010-2011 
 
Antibiotic CDW 2005-2009  GERMS-SA 2010-2011  
Amoxclav 64.8 (52.7-73%) 64.4 (50.0-72.6%) 
Ciprofloxacin 51.8 (43-77%) 44.7 (31.8-59.7%)  
Ertapenem 2.0 (0.8-4.6%) 2.9 (0.0–6.3%) 
Gentamicin 58.7 (53-70%) 62.8 (54.3-75.0%) 
Imipenem 0.1 (0.0%–0.3%) 3.4 (2.0–8.1%) 
Meropenem 0.2 (0-0.2%) 1.3 (0.0–3.2%) 
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7.5 Discussion and Conclusion 
This comparative assessment of blood culture data showing rates of antimicrobial resistance 
was carried out in order to validate the effectiveness of the CDW data repository as a useful 
and effective tool that can be utilised to monitor antimicrobial resistance in South Africa. In 
conducting the audit, we were able to use the CDW as a proxy with which to assess the 
validity and reliability of the LIS as an effective system that gathers reliable blood culture 
data that can be systematically analysed to provide valid evidence of the existing patterns of 
antimicrobial resistance to nosocomial pathogens in tertiary public hospitals. For antibiotic 
resistance to be effectively controlled, an effective surveillance system that uses existing 
routine systems of blood culture data collection needs to be established. This system, if put to 
use would provide regular updates on trends and patterns on antibiotic resistance amongst 
nosocomial blood borne infections.  
 
In South Africa, the well established LIS that forms a network of NHLS laboratories serves 
as a solid platform on which to institute regular analysis of blood culture data gathered 
routinely from the network of public sector clinical microbiology laboratories. We, therefore, 
needed to assess the validity and reliability of blood culture data produced through the routine 
system and understand if such data provides similar results to that gathered in a systematic 
way through a rigorous research process. 
 
From the results provided above, it is clear that laboratories in the Western Cape Province are 
better able to report isolates of SA and KP as shown by few missing isolates, i.e. isolates 
identified by the routine laboratory procedures but not reported to GERMS-SA surveillance 
system. In addition to that, the results provides a comparative basis on the reliability of 
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routine data acquired through the CDW as mean rates of resistance for various antibiotics 
showed minimal variation. It was however questionable why MRSA resistance in Gauteng 
hospitals (0.4-5%) showed to be lower (as reported in Chapter 5, Table 5.3) than the mean 
estimated rate of resistance shown by the systematic review (33%),(31) and the prospective 
analysis (54.1%).(Chapter 6, Figure 6.1) The phenomenon of antibiotic suppression carried 
out by the clinical microbiology laboratories in Gauteng Province might be the plausible 
explanation for such a variation in the reporting of MRSA. The practice of “antibiotic 
suppression” is designed to guide clinicians on the choice of appropriate antimicrobials in 
accordance with hospital policies; therefore susceptibility status of bacterial isolates is much 
more likely to be reported on. However susceptibility test information relating to isolates that 
are resistant to other antimicrobials which are not only the preferred agent within an 
antibiotic class according to the prevailing policies are likely to be suppressed. 
 
From these findings, it can be concluded that clinical microbiology laboratories in the 
Western Cape and Free State Provinces might have employed more effective recording 
practices leading to fewer recording errors in their reporting of susceptibility results hence 
better reporting mechanism for nosocomial bacteria i.e. SA and KP isolates as opposed to 
laboratories in the Gauteng province. We can also conclude that the observed MRSA rates for 
Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Hospital, 
Helen Joseph Hospital and Steve Biko Pretoria Academic Hospitals (Chapter 5, Table 5.3), 
might be an indication of systematic error in the reporting of data by the laboratories, 
therefore might have been systematically underreported hence might not be reliable 
representation of MRSA rates in these hospitals. An in-depth inquiry might be essential to 
determine the validity of such data. 
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Chapter 8 Understanding Laboratory Methods and their 
impact on antimicrobial resistance surveillance in 
Muhimbili National Hospital, Dar es Salaam, Tanzania 
 
This chapter describes the findings of a laboratory audit of the procedures and practices of the 
microbiology laboratory at Muhimbili National Hospital. Critical assessment of the sequence 
of events pertaining to blood cultures from point of collection in the wards to the time results 
are released to the clinicians for viewing has been outlined. In addition blood culture data 
entry into the JEEVA LIS and challenges of manual data entry has been described. 
 
8.1 Introduction 
Muhimbili National Hospital’s (MNH) existence dates back to 1910 when it was known as 
Sewahaji. It is a 900 bed specialised National Referral and University Teaching Hospital 
(175) that provides tertiary health services to inhabitants of Dar es Salaam region, Tanzania, 
with an estimated population of 2.5 million people. (176) The hospital admits 1,000 to 1,200 
in-patients per day. Blood cultures at this hospital are not routinely conducted because 
clinical diagnosis of bacteraemia and empirical antibiotic therapy is the main approach to 
clinical management. Blood culture is only requested in special circumstances, mostly due to 
treatment of non-response or in neonatals due to non-specifity of clinical symptoms in this 
age group. The aim of this study was to describe in details laboratory methods and procedures 
relating to blood cultures and their potential impact on antimicrobial resistance surveillance 
among nosocomial bacteria. 
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8.1.1 The Central Pathology Laboratory 
The Medical Laboratory Services in Tanzania (called Tanganyika during the colonial era) 
were established in the late 19
th
 Century during the German administration. The first 
Government Health Laboratory was established in 1897, at Ocean Road in Dar es Salaam. 
Historically, this laboratory was the first site of a medical laboratory in Tanzania. The 
laboratory was often visited by Dr Robert Koch who worked in the laboratory on several 
occasions as he was investigating tropical diseases such as malaria, sleeping sickness etc, 
which were then a major health problem in the country. Laboratory services have grown and 
expanded country wide. The Ocean Road Laboratory became the Central Pathology 
Laboratory (CPL) in the early 1960s and is still operational under the Ministry of Health and 
Social Welfare. (177) The CPL, located at the MNH, is a key player in the provision of high 
quality laboratory services to all patients referred to and admitted at MNH or attended to as 
out-patients.  
 
8.1.2 Departments and Laboratory information system 
The CPL is the leading provider of diagnostic laboratory services in Tanzania. In addition, 
the CPL offers referral laboratory services for tests requests from other public and private 
hospitals within Dar es Salaam and surrounding regions. Among the services provided by the 
CPL are: microbiology, histopathology, parasitology, haematology and blood transfusion, 
clinical chemistry etc. The CPL uses a laboratory information system (LIS) fully interfaced 
with all automated diagnostic machines and hospital information management system 
(HIMS), the Jeeva system 2000. This was established as an attempt to improve turnaround 
time for laboratory results.  
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All clinical departments are computerised and interlinked to the LIS and the results are 
entered and posted on the Jeeva LIS for clinicians to access directly in the wards and other 
clinical departments through logging into the system with their username and password. The 
clinicians view the results online in the wards, and this expedites the clinical decision 
regarding treatment modalities for bacteraemia cases. Hard copies of the laboratory results 
are sent to the wards afterwards for purposes of filing in the patient’s files and cross 
referencing in case of a future episode of an illness. The microbiology unit at the CPL 
handles high volumes of laboratory results ranging from samples of blood, cerebral spinal 
fluids, pus swabs, urine specimens, stool etc. The microbiology unit does the following tests 
among others: bacterial identification, antibiotics susceptibility testing and serological tests. 
The LIS helps to ensure that results are captured in time and transmitted or released to the 
patients within acceptable time limits. (178) 
 
8.2 Methodology 
 
8.2.1 Design and study setting 
A systematic audit of blood culture procedures and practices was carried out in the 
department of microbiology of the Central Pathology Laboratory of Muhimbili National 
Hospital. The audit lasted 3 days and focussed on the procedures and practices carried out in 
the process of dealing with blood cultures i.e. tracing a pathway from receipt of blood culture 
specimen in the microbiology laboratory to processing the blood culture to communicating 
results to the clinicians in the wards and entering results on LIS. Our study focussed at blood 
culture from bacteraemia caused by Staphylococcus aureus (SA) and Klebsiella pneumonia 
(KP).  
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8.2.2 Data collection procedures 
We used a standard guide (Appendix 12.4) as we went through different sections of the 
microbiology department focussing on how blood cultures are performed and how data are 
gathered in the laboratory and utilised for surveillance. The audit involved i) a comprehensive 
orientation on the activities of the bacteriology section, to familiarise with standard routines 
and laboratory practice, ii) observation of how blood procedures are done in the laboratory 
and, iii) individual discussions with staff involved in technical procedures of blood culturing 
and data entry of blood culture results.  
 
8.3 Results 
 
8.3.1 Blood culture specimen flow 
We schematically describe in the chart below specimen flow of blood cultures and related 
procedures pertaining to blood cultures at MNH. 
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Figure 8.1 Blood culture data flow and interlinkage with the LIS at MNH microbiology 
laboratory 
 
Step 1: Two blood culture bottles are collected and sent to the laboratory. For children, only a 
single specimen is collected into a special blood culture bottle. Duplicate specimens in this 
laboratory are rare as blood cultures are collected on special request only not as a routine test. 
 
P a g e  |200 
 
  
Step 2: From the wards, all specimens are delivered to the laboratory reception area where 
they are sorted out based on the type of the specimen. 
 
Step 3: At the reception area, blood culture specimens are isolated from the pool of other 
specimens by the laboratory clerk responsible for all microbiology specimens. A serial 
number is allocated and pasted onto each of the blood culture specimen bottle. 
 
Step 4: The laboratory clerk then enters patient demographic details from a specimen order 
form into a register book and LIS database. Once this is done, the specimen is delivered to 
the bacteriology laboratory for processing.  
 
Step 5: In the bacteriology laboratory, the technician receiving the specimen then enters the 
patient’s details into yet another register book so as to track samples and minimise loss. 
 
Step 6: The blood culture specimen is then placed into the HERA CELL 150 incubator and 
physically monitored each morning to detect bacterial growth. If visible signs of positive 
culture are noted, the specimen is taken out for Gram staining and susceptibility testing.  
 
Step 7: The results of blood cultures (both positive and negative specimens), are documented 
on the blood culture results form, which is then attached to the original laboratory request 
form. 
 
Step 8: Verification of blood culture results is done by the Microbiologist who heads the 
department or his immediate representative. Once results are signed off, the results are ready 
to be released to the wards. 
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Step 9: The blood culture results are handed back to the laboratory clerk, who manually 
enters them into the JEEVA LIS. The electronic record is linked to the ward in such a way 
that the clinicians in the ward can access the results directly online, through the LIS computer 
network installed in the wards. The hard copies of the results are also sent to the requesting 
clinician. (See an example of MNH laboratory request form, Appendix 12.6) 
 
Step 10: The blood culture specimen is discarded after 5 days once no indication of positivity 
is observed. All necessary protocols for blood culture are followed so as to minimise errors.  
 
8.3.2 Sample volumes 
Muhimbili National hospital is a large and busy hospital that serves approximately 1,500 out 
patients per day. However, the number of blood culture specimens received each day by the 
microbiology department, is in the region of 25 – 30 thus providing a clear indication that 
blood culturing is not a routine practice. In the wards, blood culture is only requested in 
specific clinical circumstances such as failed empirical antibiotic treatment. As per 
information from the laboratory register, it was clear that more blood culture requests 
originate from the paediatrics department’s neonatal unit. 
 
8.3.3 Blood culture processing 
Susceptibility testing of isolates is dependent on the availability of disk panels and therefore, 
not all isolates are tested for resistance to all antibiotics. Sometimes, testing is only done on 
second line drugs which are not the standard of care in the hospital. The results of these tests 
are therefore, of little help to clinicians who manage patients with blood borne infections. It 
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was observed that all Staphylococcus aureus isolates were tested for vancomycin resistance, 
as a way of monitoring emerging vancomycin resistant Staphylococcus aureus (VRSA). 
 
8.3.4 Common antibiotics tested 
The most common antibiotics subjected to susceptibility testing of blood culture isolates at 
this hospital were: 
Staphylococcus species: amikacin, penicillin, ampicillin, cloxacillin, tetracycline, 
erythromycin, gentamicin, cephalothin, chloramphenicol, vancomycin. 
Klebsiella species: ampicillin, chloramphenicol, tetracycline, amikacin, amoxyclav, 
cefuroxime and imipenem. 
Pseudomonas species: ampicillin, amikacin, ciprofloxacin, chloramphenicol, gentamicin and 
cotrimoxazole. 
Escherichia coli: chloramphenicol, gentamicin, amikacin, ampicillin and cefuroxime. 
 
8.3.5 Antibiotic susceptibility testing 
The antibiotic susceptibility testing procedures at this site are done in accordance with the 
Clinical Laboratory Standards Institute (CLSI), 2010 guidelines. The minimum inhibitory 
concentration (MIC) for each antibiotic to determine cut off for antibiotic resistance as 
outlined in these guidelines are followed. External quality control is done on a regular basis 
using specimens from the Centres for Disease Control (CDC) to ascertain validity and 
reliability of antibiotic susceptibility results produced by this laboratory. 
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8.3.6 Challenges in blood culturing 
 
8.3.6.1 Automated laboratory equipment 
Lack of a functioning automated microbial detection system was observed to be important 
obstacles to effective blood culturing at this laboratory. The automated blood culturing 
equipment is often not in good working order and servicing takes a long time to be done. The 
laboratory often relies on manual blood culturing technique which has its own limitations, 
such as subjective determination of a positive culture through visual assessment. Accuracy is 
dependent on individual technician’s visual acuity, hence subject to over or under estimations 
of true positives. However, manual blood culturing is still the most common mode of blood 
culturing in most resource constrained countries.  
 
8.3.6.2 Blood cultures results 
As per records entered into the blood culture register book, high rates of negative cultures 
were observed. This might be due to prior antibiotics used before a blood culture specimen 
was taken or it might be a true representation of negative blood cultures. In addition, we also 
noted that there was a high rate of coagulase negative S.aureus which might be due to 
contamination of the blood culture samples at the point of collection.  
 
8.3.7 Common challenges and errors in blood culture data recording 
The outline here gives some of the common challenges and errors in data recording found at 
MHN microbiology laboratory. 
 There was lack of a standardised way of entering data. For example, age can be entered as 
date of birth, age in months, days, years, etc. It was also often just documented as adult or 
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child. This created confusion in terms of knowing the exact ages of the patients who had 
blood cultures done.  
 Missing data was a major issue, as information on gender, age, hospital ward, type of 
organism and clinical data was often not available. 
 Lack of standardised reporting of the blood culture results i.e. results would be reported in 
the following ways: no bacterial growth; +ve. Neg, -ve, NEGATIVE, NBG etc.  
 Mixture of data type entered and only a few had sensitivity results entered. 
 Lack of specific dates that specimens were taken e.g. the record would just show July: but 
no date was specifically mentioned. (i.e. which date in July?) 
 
8.4.8 Standard operating procedures (SOPs) 
The microbiology department operates on principles laid down in the standard operating 
procedures (SOPs) manual. These procedures are overseen by a Quality Control Office, who 
is a member of the team in the microbiology laboratory. The controlling officer is responsible 
for effecting and approving any changes to the SOPs. Implementation of the SOPs is 
overseen by the microbiologist, who is the head of department. The manuals are kept in the 
microbiology laboratory for ease of reference by all team members. 
 
8.4.9 Challenges with data quality 
 
8.4.9.1 LIS data entry format 
Entry of blood culture results into the JEEVA LIS database was done by a single individual. 
There was no verification of data entered by a second individual to check for accuracy of data 
entered and to allow for timely correction of errors. The system does not have check codes to 
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control data that is being entered. For example, a characteristic such as ‘age’ the system could 
take in data in any numerical format such as absolute age, year/date/month, year, months and 
days. This was certainly problematic and a huge source of error.  
8.4.9.2 Clinical data 
There was often no documentation of patient’s prior antibiotic use, before a blood culture 
sample was taken. No provisional diagnosis was captured on the laboratory request form. 
Should the laboratory request form have some clinical history documented, such information 
would not be captured onto the system, as the database structure of the LIS was not 
programmed to capture such information.  
 
8.4.9.3 Determination of nosocomial bactereamia 
There was no documentation on the laboratory request forms on duration of in-hospital stay 
prior to blood culture specimen being taken. Lack of this information makes it difficult to 
separate nosocomial from community acquired bacteraemia. In so doing, the burden of 
antimicrobial resistance due to nosocomial infection becomes difficult to effectively 
ascertain.  
 
8.5 Discussion and Conclusion 
Surveillance of antimicrobial resistance is primarily dependant on good laboratory 
procedures, good quality and reliable routine blood culture data. To improve the quality of 
blood culture data and minimise improper estimates of antimicrobial resistance, it is essential 
that important steps be taken to improve the system of specimen collection at the point of 
care, registration and blood culture procedures in the microbiology laboratory. High rates of 
specimen contamination, as evidenced by more coagulase negative culture results shown in 
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section 8.3.6.2, ‘blood culture results’ calls for the need to, proactively, improve blood 
culture specimen collection procedures as this would ultimately lead to a reduction in blood 
culture contamination, and provide proper estimates of bacteraemia episodes and rates of 
antimicrobial resistance.  
 
We also need to place special emphasis on appropriate completion of blood culture request 
forms by clinicians in the wards, specimen registration by laboratory clerk and accurate entry 
of blood culture results by laboratory technician. Accuracy of blood culture results could also 
be improved if the automated blood culture machines were functioning properly. 
Improvements in quality of data could also be enhanced through improved data entry process 
into LIS either by introducing another software such as WHONET free access software 
developed since 1989 by the WHO Collaborating Centre for Surveillance of Antimicrobial 
Resistance specifically for antimicrobial susceptibility monitoring plus introducing a system 
of validating data entered into the LIS. (80) 
 
The LIS need check codes to be built in, so that the system also helps to track errors on data 
entry. Simple improvements in the current system could update the system to be an effective 
surveillance tool to help monitor development and spread of antimicrobial resistance among 
blood borne pathogens in Tanzania. Such information in the long run will help in policy 
formulation around antimicrobial usage to contain the growing crisis of antimicrobial 
resistance in the country. 
P a g e  |207 
 
  
 
Chapter 9  Discussion 
 
This chapter provides a detailed discussion of the relevant findings of the study. Firstly, a 
comprehensive summary of the study findings is presented followed by a detailed discussion 
of each of the findings and comparing these to what is found in the global literature. This is 
followed by a description of potential measurement errors focusing on bias and confounding 
which might have led to over or underestimation of the resistance pattern observed in this 
study. In this chapter strengths and major limitations of the study methods are discussed as 
well as strength and limitations of the existing LIS as an appropriate tool for monitoring 
antimicrobial resistance. In closing, a summary of key issues discussed and suggestions for 
improvement of the existing system are provided. 
 
9.1 Introduction 
Surveillance of antimicrobial resistance aims to improve the detection, monitoring and 
characterisation of resistant strains in humans with SA, KP and PA bacteraemia among 
others.(179) Thus the study focussed on these pathogens as they were common hospital 
acquired bacterial infections and were prone to antibiotic resistance. (103, 134, 180) 
Identification of resistant isolates through use of routine laboratory data will allow effective 
interpretation and mapping of trends and patterns of AMR, thus leading to formulation of 
strategies to prevent and/ or control development and spread of such resistant isolates.  
 
‘Combat Drug Resistance’ was the theme of the World Health Day on 7 April, 2011 aimed at 
raising awareness and putting across a six-point policy package to combat the spread of 
antimicrobial resistance. The focus was “No action today, No cure tomorrow”, so that 
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globally we should all move and invest our resources towards minimising the development 
and spread of antimicrobial resistance. (181) The WHO six-point policy included: i) commit 
to a comprehensive, financed national plan with accountability and civil Society engagement; 
ii) strengthen surveillance and laboratory capacity; iii) ensure uninterrupted access to 
essential medicines of assured quality; iv) regulate and promote rational use of medicines, 
including in animal husbandry, and ensure proper patient care; then reduce use of 
antimicrobials in food-producing animals; v) enhance infection prevention and control; vi) 
foster innovations and research and development for new tools. (181) 
 
Antimicrobial resistance is an old problem. However, due to increasing spread, it has become 
a daunting public health problem requiring urgent and consolidated efforts in order to avoid 
the world from regressing to the pre-antibiotic era. (181) Antimicrobial resistance occurs 
when microorganisms such as bacteria, change in ways that render the medication used to 
cure the infection they cause ineffective. This poses a major concern since resistant infection 
may cause death, can spread across the community forcing individual and society at large to 
incur heavy costs in caring for relatives suffering from a disease of an infectious origin 
caused by a resistant bug.  
 
Antimicrobial resistance is facilitated by many factors including: inappropriate use of 
medicines, e.g. in circumstances where a prescribed dosage is inadequate or a patient is non-
adhering to the prescribed dosage. In addition, low quality antibiotics, incorrect prescriptions 
and poor hospital infection control, are all factors that promulgate the development and 
spread of antimicrobial resistance. Lack of commitment from ministries of health to address 
the issues highlighted above, poor surveillance systems as well as lack of tools to diagnose, 
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treat and prevent spread of these superbugs, all obstructs effective control of antimicrobial 
resistance. (181) 
 
This thesis was done to contribute towards this fight against the spread of resistant bugs. The 
study focussed on assessing the relevance and utilisation of laboratory based surveillance in 
curbing the development and spread of antimicrobial resistance as per the WHO call alluded 
to earlier. (182) To establish whether the LIS can be effectively used for antimicrobial 
resistance surveillance, we examined in great detail routine blood culture data investigating 
rates of resistance, trends and patterns of antimicrobial resistance including distribution and 
risk factors associated with resistance specifically focusing on SA, KP and PA bacteraemia 
among patients in South Africa. 
 
Our study looked at single episodes of bacteraemia amongst patients attending and admitted 
at public tertiary hospitals associated with academic institutions in the provinces of Gauteng, 
Free State and Western Cape. Of interest were rates of MRSA and ESBL-KP, as well as PA 
resistance to polymyxins. These organisms were of prime interest due to their association 
with hospitalization and high rates of antimicrobial resistance. (183, 184) PA is known to 
commonly be multi-drug resistant, but this was assessed based on retrospective data only. 
 
For us to contain antimicrobial resistance, some of these strategies should be introduced: 
surveillance, infection prevention and control, product development as well as regular 
research. (185) In this thesis, we mostly focused on surveillance as an effective method to 
reduce the development and spread of resistant isolates in the population. Knowledge of 
antimicrobial resistance guides or determines the choice of antimicrobial therapy during an 
episode of bacteraemia. 
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9.2 Evaluating a Public Health Surveillance System 
The CDC defined surveillance as: “the ongoing systematic collection, analysis, and 
interpretation of data essential to the planning, implementation, and evaluation of public 
health practice, closely integrated with the timely dissemination of these data to those 
responsible for prevention and control.” In this thesis we have used antimicrobial resistance 
as example of such surveillance.  
 
This section highlights the pros and cons of the currently used JEEVA operated LIS as a 
possible effective tool for antimicrobial resistance surveillance. As reiterated by Langmuir 
A.D.,"Good surveillance does not necessarily ensure the making of right decisions, but it 
reduces the chance of wrong ones."(186) The parameters for evaluating a public health 
surveillance system are described below focussing on surveillance of antimicrobial resistance 
and making reference to specific laboratories that were part of the study. 
 
Simplicity: Data collection is on-going as part of the service provision. This will only require 
improvement in using available resources. 
Flexibility: The system will need modification of data entry parameters within the existing 
data collection structures. 
Data quality: Manual entry of data is subject to errors and omissions. Also, missing data is a 
major challenge.  
Acceptability: Upon obtaining permission from relevant authorities, data can be made 
available to other people.  
Sensitivity: Susceptibility based on culture procedures follows the international acceptable 
standards of antimicrobial susceptibility testing. 
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Positive Predictive Value: Resistance and or burden of blood borne pathogens can be 
assessed monthly/yearly using available data. 
Representativeness: Blood culture samples were from patients within certain defined 
geographical areas, i.e. Gauteng, Western Cape, Free State provinces in South Africa.  
Timeliness: Turn-around time is difficult to determine as time in and time out is not recorded 
in the LIS. However, time when results are made available is documented hence it can be 
determine how many days it took for the blood culture results to be released.  
Stability: The surveillance system in our case is well established, as it is ongoing, and 
involving routine data collection of service related data.  
 
9.3 Surveillance of Antimicrobial Resistance 
Continuous monitoring of antimicrobial resistance would allow quantifying the magnitude of 
antimicrobial resistance and demonstrate what public health challenge it poses. Such 
monitoring would also help to track down emerging resistant bacterial strains. Surveillance 
would also help to reinforce identification and molecular characterisation of bacterial strains. 
Such an undertaking would ultimately help to contain new resistant strains but also allows for 
systematic comparison of data across sites. (137) Data from a surveillance model also helps 
to assess effectiveness of interventions implemented in hospitals, such as the hospital 
infection control programs, to determine if the intervention was associated with reduction in 
prevalence of resistant bugs such as MRSA.  
 
Our analysis demonstrates that routine antimicrobial susceptibility tests that are performed on 
a daily basis in the clinical microbiology laboratories, despite their subtle shortfalls, are a 
major source of data for antimicrobial resistance surveillance and produce comparable results 
of resistance patterns with data collected in a research environment. However, it should be 
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taken into account that the quality and reliability of the routine data are usually uncertain. To 
achieve and derive satisfactory results of estimates of resistance patterns, efforts need to be 
invested in terms of quality control procedures to improve the overall quality of blood culture 
data. In this study only the first isolate per patient was included in the analysis. In addition, in 
order to facilitate comparison of rates of resistance between different hospitals/ geographical 
areas, the LIS needs to set on a common file format for analysis, (132) such as the DISALab 
platform across NHLS sites.  
 
9.4 Burden of MRSA & ESBL 
Nearly all strains of SA in South Africa are resistant to penicillin, and >30% up to as high as 
80% (range 30.4-98.8%) are resistant to methicillin-related drugs (Chapter 5, Table 5.3 and 
Chapter 6, Table 6.7). MRSA rates in this range are similar to those reported from North 
America and Europe. (187) Significantly lower rates of MRSA were observed at SBPAH, 
which might possibly be due to sampling bias of MRSA isolates obtained from different 
hospitals. Vancomycin for many years has been the main stay and effective treatment for the 
clinical management of methicillin resistant strains. However, there have been reported 
strains of SA isolates resistant to vancomycin (VRSA) (Chapter 5, Table 5.3 and Chapter 6, 
Table 6.2).  
 
In 2006, only 1 isolate was reported (Chapter 5, Table 5.4) while in the period July 2010 and 
June 2011, 9 isolates of vancomycin intermediate S.aureus (VISA) were identified, (Chapter 
6, Table 6.2) an indication of emerging development of glycopeptide resistance among SA 
isolates in South African tertiary public hospitals. The magnitude of methicillin-resistant SA 
is estimated at ~560 invasive isolates per year from the 7 tertiary public hospitals in three 
provinces in South Africa, July 2010-June 2011 data, (Chapter 6, Table 6.3). MRSA rates in 
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this range are high, compared to present resistance rates of <20% for European countries, 
including those from southern Europe. (188, 189) However such a similar trend was also 
observed in the USA as reported by Klevens et al. (187)  
 
The mean rate of ESBL-KP was 74.25% while the rates for UH and SBAH were 81.3% and 
62.4% respectively. Although numerically the rates were statistically significantly different 
(p= 0.022), from a treatment and infection control point of view the figures are all high 
hence cause for alarm. Such geographical differences have been reported from previous 
studies which also documented ESBL-KP rates as low as 13.5% (95% CI 12.8%-14.1%) 
among KP isolates. (190, 191) Separate analyses of factors associated with antimicrobial 
resistance were performed for both retrospective and prospective data to determine which 
demographic characteristics were significantly associated with resistance. 
 
Analysis of retrospective data to carry out risk factor models focused on resistance to one or 
more of the standard antibiotics used in clinical practice and for prospective data, we 
streamlined our analysis to focus at factors associated with MRSA and ESBL-KP isolates. In 
the prospective analysis, adjusting for other factors in the multivariate model, age <5 years, 
male gender, and hospital location showed to be significantly associated with MRSA. ESBL-
KP resistance was associated with factors such as age <5 years and hospital location.  
 
9.5 Representativeness of the study sample 
The populations included in the univariate and multivariate analysis were cases of clinical 
isolates from patients who were admitted in hospitals that fell within our study sites. All cases 
that had a positive culture for SA, KP, and PA with available data on susceptibility testing 
were included. We compared susceptibility test results of such cases between different 
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demographic factors and hospitals. This was done to assess whether distribution of the case 
population differed by these characteristics. All isolates included in this study originated from 
enhanced surveillance areas which form part of GERMS-SA surveillance network.  
 
There were some differences in the proportion of isolates from these sites, with higher 
proportions of SA isolates from Helen Joseph, Tygerberg, and Groote Schuur hospitals than 
KP and PA. The proportion of KP isolates, were greater at CHBH and SBPAH than SA and 
PA, while the proportion of PA isolates were greater at SBPAH and CHBH than SA and KP. 
The proportion of individual isolates was higher than the mean distribution of isolates for the 
7 hospitals included in the study. This could suggest a possible excess of SA, KP, and PA 
cases, but also may be an indication of differences in effectiveness on hospital infection 
prevention programs between hospitals. 
 
The rates of antimicrobial resistance were different between three provinces with a higher 
rate of SA, KP, PA observed in Gauteng followed by the Western Cape and lowest in the 
Free State. This might be due to the fact that these provinces are mostly in the urban settings 
with bigger tertiary hospitals and dense populations. The other reason could be differences in 
clinical practice regarding blood culture procedures or differences in hospital protocols 
regarding blood cultures specimen collection practices with other settings being unrestricted 
in terms of doing blood cultures or having over diagnosis of clinical bacteraemia by some 
clinicians who are more likely to order or do blood cultures.  
 
The proportion of antibiotic resistant isolates was different between age-groups with greater 
proportions of antibiotic resistance noted in the <5 years age group. The reason might be due 
to high utilization of antibiotics in this age group since more bacteraemia episodes occur in 
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the under-five children compared to older children and adults. This is due to high 
colonization of SA, KP and perinatal acquisition of PA during birth, and immature immune 
function making children, particularly neonates, at higher risk of bacteraemia. (192) 
 
The proportion of males with resistant isolates was generally greater than females, which 
could be due to the fact that there were more isolates of SA, KP and PA in males. On the 
other hand, this could be a sign that occurrence of episodes of bacteraemia due to these 
pathogens is higher in the male population. Such differences might also be a sign of 
preponderance for bacteraemia due to these organisms among males, but could presumably 
also be due to selective blood culturing that favours the males population. 
 
In summary, there were relative differences in distribution of resistant isolates due to SA, KP 
and PA by geographical location (province, hospital) and demographic factors (age, gender) 
across the duration of the study. Such differences may limit generalizability of findings and 
of patterns of resistance to other hospitals or provinces. Our main interest was analysis of 
trends and patterns of antimicrobial resistance of pathogens commonly associated with 
hospitalization. The purpose was to assess, if the LIS at NHLS could be a sufficient tool to be 
effectively used to monitor resistance. To achieve that, we focused on data from the 7 
hospitals collected retrospectively and prospectively investigating the quality and availability 
of data on antimicrobial susceptibility test results.  
 
To ascertain reliability of the LIS as an effective tool to determine patterns and trends of 
resistance, completeness of routine susceptibility data were important to the study. Even 
though data were incomplete for most of the antimicrobials that had undergone susceptibility 
testing, data for retrospective analysis did produce results that were compatible with previous 
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findings. (31) Examining the proportion of isolates across the three organisms, there were no 
obvious incorrect findings to suggest major errors in data entry or selective blood culturing.  
However there were discrepancies between the hospitals from Gauteng, Western Cape and 
Free State in terms of MRSA proportions. 
 
The proportions are pretty similar for all the three organisms despite subtle differences seen. 
Even though our study sample was convenient, it appears homogeneous and relatively 
representative of all patients admitted with bacteraemia due to SA, KP, and PA to these 
hospitals. Therefore, we can say with a certain degree of confidence that it is not very likely 
that the validity of our findings of trends, patterns and distribution of antimicrobial resistant 
isolates presented in this report could have been underestimated. 
 
9.6 Systematic overview of study findings 
 
9.6.1 High rates of resistance to antimicrobial agents 
9.6.1.1 Staphylococcus aureus 
Antimicrobial resistance is a public health problem that is well recognised globally. (193) 
Infection caused by S. aureus, particularly MRSA, has been increasing worldwide since its 
first discovery in a British hospital. (194, 195) Our data subscribes to these observations from 
previous studies, and reports a crude MRSA rate of 15% in the 2005-2009 period using 
retrospective routine laboratory data (due to antimicrobial suppression policy). This was 
however inconsistent with a crude rate of 54% observed with prospective data collected 
through an active surveillance mandate in the same hospitals over a 12 months period (July 
2010-July 2011).  
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MRSA propagates therapeutic challenges in the management of patients; is a major cause of 
morbidity and mortality; and leads to high costs of health care services due to long 
hospitalisation and use of vancomycin, which is a more expensive alternative treatment. (196, 
197) There is however a growing worry due to emerging vancomycin resistant SA strains 
similar to observations of Appelbaum. (198) Our data showed emerging vancomycin-
resistant SA in South African hospitals. While only 1 isolate was reported in the 2005-2009 
retrospective data, 9 isolates were identified in the prospective analysis over a 12 months 
period (8 of them reported from the hospitals in Gauteng province). MRSA varied and 
significantly differed between hospitals (p = <0.001).  
 
This confirms observation from previous studies that showed that prevalence of MRSA 
differs widely between countries and among different hospitals in the same country. (147, 
199, 200) Increasing prevalence of MRSA might be due to differences is prescribing practice 
or antibiotic controls between hospitals or differences in infection control practices or may be 
inherent geographical differences in genetic characteristics such as the mecA gene, which 
encodes an altered penicillin-binding protein (PBP 2a), a membrane-bound protein. This is a 
key genetic component responsible for resistance which is not native to the S.aureus genome. 
(201, 202) 
 
In our study, despite challenges in the quality of retrospective data that we extracted from the 
CDW, the analysis showed a significant downward trend of MRSA from 22.2% in 2005 to 
10.5% in 2009 (p=0.042). Because of the systematic error in recording MRSA in Gauteng 
hospitals by “antibiotic suppression” of data, the apparent decline of MRSA over the study 
period (p=0.042) cannot be accepted at face value. In the case of a real decline in MRSA this 
could have been as a result of an improvement in infection control practices in tertiary 
P a g e  |218 
 
  
hospitals over this period. This could potentially be a real decline in MRSA in South Africa, a 
sign that there might have been an improvement in antimicrobial prescription control or in 
hand washing practices in these tertiary hospitals over this period. A similar pattern was 
reported by Adam et al. in a study done in Canadian hospitals where they showed a drop of 
MRSA rates from 26.7% in 2007 to 19.8% in 2009. (115) This shows that there is sufficient 
evidence from developed countries that improved infection control led to a decline in MRSA 
in hospitals. This is an indication that should a similar intervention have taken place in SA, it 
might have led to a similar observed outcome. 
 
9.6.1.2 Klebsiella pneumoniae 
There is an increase in carbapenem-resistant K. pneumoniae isolates worldwide. (134) Our 
study reported imipenem resistance among KP of 0.4% in 2005 to 4.0% in 2011. The pattern 
is consistent with what was reported by Braykov et al. (190) in the USA showing an 
increasing trend of carbapenem-resistant K. pneumoniae from 0.1% to 5.4% between 2002 
and 2010; and from 1-2% in the years 2006-2009 to 15% in 2010 in Italy. (203) The 
frequency of resistance to extended spectrum of cephalosporins in our study was above 70%, 
which is much higher than what was reported by the Braykov et al, (190) study, reporting 
rates of 5.3% - 11.5% between 1999 and 2010.  
 
This is an indication of a more serious challenge of increasing resistance to extended 
spectrum of cephalosporins in South Africa compared to the USA. These pathogens were 
traditionally endemic in hospitals but are posing a challenge as they might slowly be 
spreading to non-health care settings. The spread of these organisms is usually facilitated by 
patient mobility as they get transferred from one facility to the other such as from long term 
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care facilities, which happen to be a breeding ground for antimicrobial resistant bugs. (204, 
205) 
 
In addition to challenges with spread of antimicrobial resistance, carbapenems are reserved as 
treatment of choice for severe infections caused by ESBL-producing organisms making the 
global emergence of carbapenem-resistant Enterobacteriaecea strains a cause of great public 
health concern. (206, 207) Carbapenem-resistant K. pneumoniae pockets of outbreaks have 
also been described worldwide (208, 209) and have been reported as a common type of 
carbapenem-resistant Enterobacteriaecea in North America. (210, 211) 
 
Due to increasing rates of resistance and associated therapeutic challenges of clinically 
managing carbapenem-resistant Enterobacteriaecea, there is therefore an overemphasis to 
intensify monitoring spread of resistant pathogens. This underscores the value of routine 
antimicrobial resistant surveillance both at local and national level. (117, 212) 
 
9.6.1.3 Pseudomonas aeruginosa 
There has been a tremendous increase in infections caused by multidrug resistant Gram 
negative bacteria especially P. aeruginosa, K. pneumoniae among others. For these 
organisms, treatment options become very limited, such that polymyxins are therefore the 
only available active antibiotics for P. aeruginosa. (213-217) In vitro colistin has shown 
excellent activity against Gram-negative bacilli including multidrug-resistant P. aeruginosa.  
 
Our data seem to confirm this observation and showed that colistin resistance rate was 1.9% 
over the 5 years period of which data were available. This is consistent with several studies 
that reported low rates of colistin resistance.(139, 218-222) Despite adverse effects of 
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nephrotoxicity and neurotoxicity experienced by patients taking polymyxins which lead to its 
discontinuation in the 1970s, (214, 215, 223-225) treatment outcomes are good and it is now 
considered as the last alternative treatment of Gram-negative sepsis when other drugs such as 
extended spectrum cephalosporins, aminoglycosides and quinolones are found to be 
ineffective. (215, 225) Our data showed similar high rates of resistance as were previously 
documented by Pfaller et al. (113) to carbapenemes, extended spectrum cephalosporins as 
well as fluoroquinolones (Chapter 5, Table 5.3), which means that treatment options for such 
infections are minimal and quite challenging.  
 
It is disheartening to learn from previous studies done in Canada, United Kingdomand India 
have reported high rates of colistin resistance ranging from 12% to as high as 50%.(226-231) 
This diminishing antimicrobial activity of colistin against Gram-negative pathogenic bacteria 
causing nosocomial infection is a clinical and public health concern due to a tremendous 
increase of multidrug-resistant strains in the absence of new antibacterial agents to treat such 
infections. Therefore, regular and timely monitoring of antimicrobial resistance patterns 
would play a crucial role in slowing down development of resistant strains among Gram-
negative nosocomial pathogens.  
 
9.6.2. Differential patterns of resistance by different age-groups 
The study showed that the frequency of occurrence of nosocomial bacteraemia in the <5 
years old population was high and rates of resistance to antimicrobials i.e. cefepime, oxacillin 
and amoxclav, among others, were proportionately higher among <5 years old and 
significantly different across age-groups (p=0.001). The proportion of MRSA was 
significantly different accross age groups and high among the <5 years olds. A similar pattern 
was observed for KP isolates where the proportion of ESBL-KP was significantly different 
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between age-groups (p=0.003) and 78.2% in the under five years old children. Braykov et al. 
in the USA (190), showed lower KP resistance rates to extend spectrum cephalosporins in the 
paediatric patients in general (i.e. age <18 years) ranging from 5.9%-8.3%, showing that the 
rates of resistance in South African hospitals might be higher than observed in developed 
countries. 
 
Such pattern is not uncommon due to predilection of SA and Gram negative infection in the 
younger age-groups as a result of high colonization of SA bacteria on the skin and nasal area. 
Due to immature immune function, the under five children particularly infants, are prone to 
invasive bacterial infection from normal flora. As a result of frequent bacteraemia episodes, 
exposure to antimicrobials and selective pressure puts them at higher risk of carrying resistant 
isolates. (192) Such evidence should support improved clinical decision making in the 
empirical management of childhood cases of bacteraemia in public sector health services.  
 
9.6.3. Gender differences in the pattern of resistance 
There were more episodes of nosocomial bacteraemia among the male population compared 
to females, for all the three selected pathogens as highlighted in chapter 3, table 3.1 of section 
3.3. Tiemersma et al. (147) reported from the European Antimicrobial Resistance 
Surveillance System, a higher frequency of MRSA isolates from men compared to women 
(21% versus 18%, p = <0.001) respectively. This may be an indication of a global pattern. It 
is however unclear why more males had a bacteraemia episode than females. We can only 
speculate that possible selective blood culturing could have played a role, or more males 
report to the hospital with more severe illnesses than females, hence warranting a blood 
culture investigation. This might speak to differences in health seeking behaviour between 
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males and females, with females being more health conscious thus reporting earlier for 
clinical assessment than males thereby ending up with empirical antimicrobial treatment.  
 
In addition, we observed that females with KP bacteraemia were significantly more likely to 
have antibiotic resistant isolates compared with males. This is contrary to the findings of a 
study done by Braykov et al. (190) in the USA that looked at a large number of isolates that 
were collected over a decade (1999-2010). They found that isolates from male patients had 
significantly higher likelihood of antibiotic resistance amongst 3
rd
 generation cephalosporins 
and carbapenem. Furthermore, we observed that males were significantly less likely to have 
MRSA than females. This might be due to the fact that the frequency of isolates was higher in 
males than females as similar to what was reported by Tiemersma et al. (147) We do not 
know the reason behind these findings, as such, further investigations are warranted. 
 
9.6.4. Geographical differences in antimicrobial resistance (within 
country variation) by hospital and province 
 
Our analysis revealed that there was a wide variation of antimicrobial resistance by hospital 
location and province. Antimicrobial resistance was higher generally in Gauteng Province 
hospitals as opposed to Western Cape Province hospitals. For example, making reference to 
the 2010-2011 study time, data showed that in Gauteng Province, amoxclav resistance (a 
surrogate marker for MRSA) was lowest at SBPAH (38.1%) and highest at CHB (83.6%) 
while in the Western Cape Province, MRSA was lowest at GSH (35.8%) and highest at TH 
(46.2%), while in the Free State Province, at UH resistance was 48.9%. Looking at this 
pattern, we can deduce that MRSA is generally higher in hospitals around Gauteng province 
as opposed to hospitals in Western Cape Province.  
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Stratified analysis by hospitals presented a more robust landscape for comparing distribution 
and patterns of antimicrobial resistance. The results from the retrospective data were similar 
to the July 2010- June 2011 prospective data, confirming a clear variation in resistance 
pattern by geographical location despite systematic error in the reporting of MRSA in 
Gauteng hospitals. We may however suggest that such variation could possibly be due to 
differences in health care services available, including differences in blood culturing practices 
among these hospitals.  
 
Variation in clinical practices regarding blood culture specimen collection might bring 
differences in the spectrum of patients included for blood cultures which may differ between 
hospitals/provinces, e.g. in some hospitals/provinces only very critically ill patients might 
have had blood cultures done. We can assume that selective blood culturing might have 
influenced the pattern of resistance observed as the denominator on which to base the 
proportion or rate of resistance might be different depending on the volume of collected 
blood cultures.  
 
The apparent decline in MRSA in Gauteng province is a unique finding and has not been 
reported before in South Africa. Occurrence of resistant bugs might also be due to climatic 
differences leading to differential occurrence of resistant bugs precipitated by multiple 
factors. Differences in prescribing habits between these hospitals might have led to 
differential antibiotic exposure level among patients to SA bactereamia.  
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9.6.5 Differences in laboratory operations and geographical variations in 
rates of antimicrobial resistance 
 
In the course of conducting our study, we had to understand and bring a plausible explanation 
to answer the question “Would variation in laboratory methods explain the observed 
difference in rates of antimicrobial resistance?” Our data did not allow us to find a definitive 
explanation for the observed variation in rates of resistance between hospitals/provinces.  
 
The 7 NHLS laboratories which were part of this study are all associated with academic 
institutions. We observed that the methodology for performing blood cultures were similar 
across sites (a combination of automation and manual methods), but the automated 
equipment that are used for the identification and evaluation of the susceptibility profiles of 
bacteria (i.e. Vitek 2 and MicroScan) produced comparable susceptibility results as well as 
organism identifications. (232) 
 
All laboratories use similar MIC break-points as per the CLSI guidelines. (151) As alluded to 
in chapter 4, section 4.2, despite slight differences in the type of microbiology systems used, 
such systems were efficiently validated for susceptibility testing and organism identification 
and confirmed to produce comparable results. Therefore, we can conclude that laboratory 
operations might not explain the observed variation in results seen between different hospitals 
in different provinces. 
 
9.6.6 Observed rate of MRSA 
The rate of MRSA of 54.1% observed in the prospective analysis of blood culture data from 
Antimicrobial Resistance Surveillance and Research (ARSR) (Chapter 6, Figure 6.1), was 
found to be higher than what was observed in the systematic review (33.0%) (31) of 
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published data from South Africa over a period of 12 years (2000-2011) but higher than 
15.4% (Chapter 5, Table 5.3) that was observed from the retrospective data over a 5 year 
period (2005-2009).  
 
The rates of MRSA for Gauteng hospitals (0.4-4.5%) were much lower than would be 
expected when compared to baseline data from the systematic review. On the other hand, 
when compared to rates for the Western Cape hospitals and Free State (30.4-43.0%), these 
rates appear closer to the estimated MRSA rates as observed from the systematic review, 
suggesting that MRSA might not be <30% for the Gauteng hospitals (Chapter 5, Table 5.3). 
The reason for this observation remains uncertain however it might be that antibiotic 
susceptibility results documented from Gauteng hospitals were systematically underreported.  
 
This characteristic was observed for SA susceptibility testing done in hospitals around 
Gauteng Province. Why only in Gauteng hospitals and only for MRSA and not other 
antibiotics remains unclear and requires further investigation. Laboratory methodology does 
not seem to explain this anomaly, due to the fact that systematic observation of laboratory 
methods carried out in all hospitals participating in the study, revealed that all laboratories 
used similar methods of blood culturing and susceptibility testing.  
 
Even though NHLS laboratories used different automated microbiology systems for 
susceptibility testing i.e. Tygerberg hospital used Vitek 2 and CMJAH used MicroScan, these 
automated microbiology systems have shown to produce comparable results (123), after 
being appropriately validated by the NHLS. The NHLS break-points used to assess 
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susceptibility level for various antibiotics are according to the CLSI guidelines, (151) which 
means that there is a standardised method of susceptibility testing that is followed across the 
spectrum of the NHLS operations in the country.  
 
In view of this, susceptibility data can be comparable across sites in South Africa. In testing 
MRSA, various laboratories across these sites used either oxacillin or cefoxitin disks (151) to 
assess presence of MRSA among SA isolates from cultured blood. Use of either disk did not 
produce different susceptibility patterns for SA resistance. This made comparability of 
MRSA across the study sites scientifically acceptable. 
 
9.6.7 Comparability of laboratory methods for blood culture and 
susceptibility testing between two different geographical locations 
 
Our study found that laboratory methods for blood culturing and antimicrobial susceptibility 
testing that were followed by the diagnostic microbiology laboratory at Muhimbili National 
Hospital, Dar es Salaam in Tanzania were similar to those followed by NHLS microbiology 
laboratories in South Africa. In Tanzania, blood culturing was not a routine laboratory 
investigation; the test is ordered by clinicians in special circumstances such as persistence of 
clinical symptoms suggestive of bacterial infection after initiating patients on empirical 
antimicrobial treatment. The choice of the antibiotics is guided by local knowledge of the 
epidemiology of common bacterial pathogens in the area.  
 
Observation of continued or worsening of clinical symptoms indicative of invasive bacterial 
infections spurs the clinicians to order a blood culture test, in order to identify the offending 
bacterial pathogen and assess susceptibility of available antibiotics to guide clinical 
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management of treatment failed patients. The challenge of such an approach is that since 
patients would already have been exposed to antimicrobials, the probability of a positive 
blood culture outcome becomes minimized. As such a majority of blood cultures end up 
being negative and are recorded as no growth. 
 
The reason being that pre-exposure to antimicrobials may have led to suppressed bacterial 
activity which reduces the viability of bacterial pathogens. (233) This might have led to an 
underestimation of the actual burden of invasive bacterial infections, enhanced resistance 
development as bacterial pathogens were exposed to antimicrobial agents which they are not 
sensitive to, and creates an unwanted clinical situation due to challenges in effective 
management of patients who have masked clinical symptoms and negative blood culture 
results. (233) This status is a common occurrence in less developed and low income countries 
due to limited resources to perform blood cultures.  
 
The situation was somewhat different from that of South Africa as the volumes of blood 
cultures done generally looked high due to non restriction of blood culture tests. In most 
cases in South Africa, patients would access a blood culture test before being prescribed an 
antibiotic. Once the index of suspicion for bacteraemia is high, requests for blood culture 
tests are done routinely. It was observed that multiple blood cultures are done, causing an 
influx of duplicate blood cultures results (Chapter 2, Table 2.2), which if overlooked during 
analysis of blood culture data, may lead to an overt overestimation of the burden of 
bacteraemia in the population as a direct consequence of multiple blood cultures. 
 
The laboratory at Muhimbili hospital looked greatly under resourced in both personnel and 
equipment. At the time the laboratory audit was being conducted, automated blood culturing 
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machines had not been functioning for over 6 months, meaning that the laboratory relied only 
on manual processing of blood culture specimens including antimicrobial susceptibility 
testing. This might cause a strain on the limited human resources available. However, since 
the blood culturing is selective, the volume was quite low compared to what was observed in 
the microbiology laboratories in South Africa. It must be noted that manual methods have 
been the traditional way of blood culturing over many years and have shown comparable 
results with automated machines (234) hence are not inferior to the automated methods.  
 
In addition to this, all microbiology laboratories i.e. NHLS laboratories and the laboratory at 
Muhimbili hospital use CLSI guidelines for MIC break points in the conduct of susceptibility 
testing, (151) which means that susceptibility test results between these laboratories are 
expected to show similar results. For this reason, we may conclude that the observed 
differences in the processing of blood cultures may not produce variation in the patterns of 
resistance among the tested antimicrobials other than that which is inherent. Since these are 
geographical distinct areas, the local epidemiology of bacterial pathogens and exposure to 
antibiotics might be different.  
 
Differences in racial composition, socio-economic status, antimicrobial prescribing, infection 
control adherence, duration in hospital stay, patterns of hospital admission, laboratory 
methodology with appropriate quality control practices and recording systems may all affect 
bacterial resistance patterns. Therefore, susceptibility data produced by laboratories from 
these two geographically distinct areas with different resources and population structure 
could produce comparable findings provided the methodologies are standardized according to 
international norms and laboratories employing appropriate quality assurance practices. 
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However, sampling between hospitals based on clinicians’ decisions on when to perform 
blood cultures is likely to differ. 
 
9.6.8 Comparability of blood culture data and antimicrobial resistance 
patterns between CDW and GERMS-SA databases 
 
A systematic evaluation of the two databases revealed wide variations in SA and KP isolates, 
which were on the CDW database but were not found on the GERMS-SA database, which we 
defined as cases in the audit procedure. This has major implications when it comes to 
estimating the burden of SA and KP bacteraemia reported in various hospitals across the 
study sites. For example, Chapter 7, Table 7.1, shows the number and proportion of cases 
which were missing in the GERMS-SA database from 1
st
 January - 31
st
 December 2011, by 
hospital location, specifically looking at SA and KP isolates. In total, 409 SA and 365 KP 
isolates were identified as missing in the GERMS-SA database during the audit process. High 
proportions of missing isolates were from hospitals in Gauteng Province, predominantly from 
CMJAH, contributing almost 30% of SA and 36% of KP isolates respectively. The lowest 
proportions of missing isolates were from Groote Schuur hospital in the Western Cape 
Province, contributing only 5.6% of SA and 0.3% of KP isolates.  
 
All cases were identified and tested at the NHLS laboratory and then shipped to GERMS-SA 
and added to its data base so as to improve its completeness of the number of identified 
isolates. It remains unclear why hospitals such as CMJAH had a higher percentage of missing 
isolates on the GERMS-SA database while GSH had only few missing cases. Since GERMS-
SA isolates require shipment, GERMS-SA based surveillance is more labour-intensive and it 
is possible that some hospitals shunned this extra effort. We therefore assume that differences 
in the rigour regarding collection and reporting of isolates under surveillance program might 
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be a contributing factor to missing data. This might have been due to, among other reasons: 
lack of understanding of the value of the surveillance regarding these organisms; lack of 
enthusiasm or diligence among the laboratory staff to report these organisms; negligible level 
of awareness regarding the need to collect and report such isolates, lack of human resource 
leading to high work load among laboratory technologists dealing with blood culture 
procedures leaving no room for them to focus on reporting isolates of SA and KP to the 
ARSR.  
 
These might be among the most plausible reasons why there is a difference in the number of 
isolates in the GERMS-SA database, which draws its samples from the same source as that of 
the CDW database. In this case GERMS-SA data might not have been a proper gold standard 
for determining incidence but could assess reliability of blood culture data drawn from the 
CDW database. In addition, since both databases generate their data from the same source, 
which is the laboratory request form which was completed at the hospital where the blood 
cultures were done, missing data in terms of age, gender, and other demographic parameters 
remained the same in both situations.  
 
This means, missing data on demographic parameters on the CDW database will be the same 
as on the GERMS –SA database as the surveillance does not particularly collect data from the 
point of blood culture collection but from the laboratory after blood culture procedures have 
been completed. Therefore, as data were being analysed and compared, we expected that 
there will be no differences in completeness of data for demographic parameters between 
CDW and GERMS-SA with the exception of Gauteng MRSA data that showed there was a 
systematic error in reporting. The reason being ARSR receives clinical isolates from the same 
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microbiology laboratories. As a result incomplete data on laboratory request forms reflect the 
same missing data in the ARSR program at the NICD. Hence using ARSR as gold standard 
comparator for demographic data such as age and gender was not suitable and was therefore 
not taken further. 
 
9.6.9 Quality of antimicrobial resistance data of SA and KP: CDW versus 
GERMS-SA 
 
When assessing the quality of resistance data denoted in the database as antimicrobial 
susceptibility, it is evident that the quality of susceptibility data drawn from the prospective 
study, i.e. for the period July 2010 to June 2011, was good. No missing data on susceptibility 
test results were seen during cleaning and coding of the data. All antibiotics tested 
intrinsically or as part of the requirement for the surveillance or quality assurance were 
available.  
 
Most of the antibiotics were tested against the same number of isolates, which means that the 
denominator remained constant when assessing resistance rates of different antibiotics. This 
meant that more precise estimates of resistance were generated from this data as opposed to 
the retrospective data of 2005-2009, which had a lot of missing data on antimicrobial 
susceptibility test results. Therefore, many other antibiotics were not assessed for resistance 
as there was a sign of incompleteness. 
 
In view of this, we can deduce that data collected prospectively might have provided a clearer 
picture of the resistance pattern. However, despite challenges in completeness of resistance 
data, rates of resistance to antibiotics of clinical relevance generated from GERMS-SA, 
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ARSR database and CDW database with exception of Gauteng MRSA, data were quite 
comparable (Chapter 7, Tables 7.2 and 7.3). This is an important observation as it signifies 
that routine blood culture data source could sufficiently be used for antimicrobial resistance 
surveillance after considering areas requiring improvement, i.e. point of data correction in 
clinical departments i.e. wards, casualty, intensive care unit etc., as completion of laboratory 
request forms are done there. Once information is omitted from the laboratory request form, 
such omission does not get resolved at the laboratory level.  
 
9.6.10 Active laboratory based invasive pneumococcal disease 
surveillance: A model surveillance system 
 
The invasive pneumococcal disease (IPD) surveillance carried out nationally by GERMS-SA 
can be highlighted as a model of an effective surveillance system (Appendix 12.2). Using 
data through this surveillance, we were able to show through a systematic analysis using 
multivariate logistic regression modelling that age, younger than 1 year, Pitt Bacteraemia 
Score ≥4 and HIV infection were independent risk factors for death in children with 
meningitis, and notably that malnutrition increased the risk of death among children with 
other IPD.  
 
This data added to the body of knowledge regarding identification of population at risk for 
death that needs enhancement of targeted preventive health services, including among others 
a catch up program for pneumococcal conjugate vaccine for immunization of children 
particularly in HIV high burden areas, so as to reduce incidence and excess mortality in the 
risk children. This fulfils the aim of a surveillance system, which is to collect, collate, 
analyse, interpret, make data available and apply such information to the control of 
communicable diseases. (63, 235) 
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In spite of the fact that this was a laboratory based surveillance such as that presented in 
preceding chapters for antimicrobial resistance, the distinct difference is that IPD surveillance 
data includes clinical parameters as well as data on outcome and therefore, we were able to 
predict treatment outcomes using such surveillance data as highlighted earlier. This 
information is gathered by surveillance officers as part of an active surveillance program. 
Presence of clinical information adds value to the surveillance data as information obtained 
can be used to formulate strategies on how disease can effectively be controlled.  
 
That is the main challenge of antimicrobial susceptibility data, as the only information we can 
come up with is patterns of resistance, but we have no idea if such resistance has a direct 
impact on patient survival. We are also not able to find out if certain clinical conditions such 
as HIV are potential drivers of resistance, since we do not have such data available. (148) 
 
9.7 Potential Study Biases 
9.7.1 Completeness of antimicrobial resistance data 
The study used data extracted from the CDW which showed a reasonable degree of missing 
parameters on demographic factors and susceptibility test results. This created a window of 
opportunity for information bias to introduce potential underestimation of the actual 
magnitude of antimicrobial resistance over the given study period would occur. It can be 
assumed that particular antibiotics which might have been tested and had missing data, might 
not display actual patterns and rates of resistance due to insufficient data. We therefore did 
not further analyse such data for rates of resistance amongst antibiotics if less than 20 isolates 
were tested for antimicrobial susceptibility.  
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It should also be noted that, blood culture data transmitted via the file transfer protocol (FTP) 
from all NHLS laboratories to the central data repository, had an inherent weakness of data 
loss due to among other reasons, the slowing down or breakdown of internet service or as a 
result of manual entry of laboratory results without a back up of double entry or validation 
system of data entry. Comparing retrospective (routine activity) and prospective data (in a 
research environment), we observed a systematic difference in the quality of data which 
might have arisen due to differences in rigorousness in maintaining data quality, or strictness 
in conducting susceptibility tests, or procedures for data entry of blood culture test results as 
well as an active verification blood culture of data. Prospective blood culture data were more 
complete hence of better quality with regard to antimicrobial susceptibility test results 
compared to retrospective data.  
 
9.7.2 Underestimation of antimicrobial resistance rates 
Invasive bacteraemia cases captured and reported by the routine system (CDW) and GERMS-
SA surveillance system might not be representative of all the cases of invasive SA, KP and 
PA bacteraemia occurring in South Africa over the study period. This might be because of 
differences in blood culture taking practices between the different hospitals or due to 
selective blood culturing.  
 
It is not a common practice to do blood cultures in all febrile illnesses that present to a clinic 
or hospital; hence some patients who genuinely had bacteraemia caused by any of the 
selected organisms might have been missed. Patients who were sick and self medicated 
themselves or died at home due to a febrile illness or in transit to a clinic or hospital, might 
also not have been captured by the surveillance system. Therefore, the incidence of 
bacteraemia and antimicrobial resistance rates reported earlier is certainly an underestimation 
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of the true magnitude of bacteraemia and associated antimicrobial resistance due to these 
selected organisms. Thus surveillance bias might likely have existed in this study. (63) 
 
9.7.3 Bias in analysis of associated risk factors 
Underestimation of disease burden might have introduced an erroneous estimation of rate of 
resistance and associated factors in our study. Even though, missing data are a common 
problem with routine or passive surveillance system, the coverage of our sample population 
was quite broad. We analysed all reported isolates over the study period from the seven major 
hospitals in South Africa.  
 
Since there are no major differences observed in laboratory methods between various NHLS 
clinical microbiology laboratories, we can deduce that susceptibility data from these areas is 
quite comparable, except for Gauteng MRSA data that showed there was a systematic error in 
reporting. Use of strict case definitions for antibiotics to be included in the risk factor analysis 
(resistance to at least 1 antibiotic for retrospective data) might have helped to minimize such 
form of bias. To minimize bias in risk factor analysis for prospective data, we restricted our 
analysis to isolates that showed MRSA and ESBL on susceptibility testing. 
  
9.8 Potential residual confounding factors 
In assessing factors associated with antimicrobial resistance, we, initially, examined all 
factors in a univariate model to find out if they were associated with increased likelihood of 
resistance. Significant factors at P≤0.1 were included in the multivariate logistic regression 
model where each factor controlled for the confounding effect of the other. This method 
helped to control for the confounding effect of several factors at the same time. Factors 
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significant at P≤0.05 were then considered independent significant factors associated with 
antimicrobial resistance. However, residual confounding factors affecting the association 
between the exposure factors identified and resistance remains a possibility.  
 
In this study, due to lack of data, we did not examine all factors that could potentially be 
associated with resistance such as pre antibiotic exposure before accessing a blood culture 
test. However, our findings seem to suggest that the association observed between factors 
associated with resistance might not have been due to chance, random error or residual 
confounding. (63) 
 
9.9 Generalizability 
Blood culture data used in this study originated from tertiary public hospitals all of which 
were associated with academic institutions. There might be relative differences in terms of 
operations and access to laboratory services between academic and non-academic hospitals 
such as those from rural areas. This might limit generalizability of our study findings beyond 
the populations from which data originated.  
 
In addition the difference in the distribution of isolates by province and hospital location as 
observed, might also limit generalizability of our study results to other provinces and 
hospitals situated in more rural areas. In the light of the foregoing facts, our findings might 
only be extrapolated to the defined area where the study was done.  
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9.10 Study Strengths 
 Our study used data over a 6 year period from tertiary academic hospitals in three of 
the densely populated provinces in South Africa to evaluate trends and patterns of 
resistance and determine factors associated with antimicrobial resistance amongst SA, 
KP and PA bacteraemia. The coverage was wide and over a longer period of time, 
unlike most studies done are usually local and over a short time interval. (26, 99) 
 The large numbers of isolates that were included in our study enabled us to detect 
significant differences in risk factors for antimicrobial resistance amongst the three 
pathogens that were investigated. 
 Systematic comparison of resistance patterns between retrospective data aggregated 
routinely and prospective susceptibility data (with well designed quality assurance 
procedures) adds a great value to this study. Such an undertaking has not been carried 
out before and exposes the value of routine data and its ability to be used to monitor 
patterns and trends of resistance in South Africa, of course with some improvement to 
be done. 
 
9.11 Study Limitations 
 The study used laboratory data which, unfortunately, did not have details on clinical 
parameters including treatment outcomes (i.e. death, severity of illness etc.). We were 
therefore, not able to make an in-depth analysis to assess the association between 
resistance and clinical outcomes. 
 Our study involved retrospective data analysis using CDW and GERMS-SA 
surveillance database. The data we analysed was not collected with our research 
questions in mind as such, some parameters which would have been of interest to us, 
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such as date of admission which would have helped to determine nosocomial 
infection, were not collected. 
 We did not have complete data on all antibiotics tested particularly from the CDW 
repository, which was critical to this study; as such we may have potentially 
underestimated the magnitude of nosocomial bacteraemia and that of antimicrobial 
resistance. To minimize this we restricted our analysis to include only antibiotics that 
had complete data on susceptibility test results.  
 This was an analysis using an existing dataset hence other than knowing the antibiotic 
that were tested, we did not have information on the antibiotics that were prescribed 
for patients from whom the isolates were identified, neither dosage nor duration of 
treatment that was given, and not even the outcome of the patients. We were thus 
unable to assess association between resistance and antibiotic treatment prescribed 
during the episode of bacteraemia. 
 Data for antibiotic susceptibility for year 2005 was available only from the second 
half of the year. This might have made comparison of resistance by year a bit obscure 
for the year 2005, despite the fact that similar proportion of isolates were observed for 
the three pathogens in that year. 
 Blood culture data from CDW and GERMS-SA databases shared a common 
weakness which was that, demographic data are completed on the laboratory request 
form by the clinical departments such as admission wards, casualty etc. which are the 
point of blood culture collection. Once an isolate is identified, the laboratory sends 
isolates to the ARSR, completes a GERMS-SA surveillance form using data from the 
original laboratory request form. This means that all missing data on the laboratory 
request forms in the wards are then passed on to the GERMS-SA database at the 
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ARSR making GERMS-SA data an effective gold comparator against the CDW data 
except for susceptibility data.  
 We might have underestimated the overall antimicrobial resistance rates for SA, KP, 
PA due to use of blood samples only excluding other samples i.e puss swabs, urine, 
stool, sputum etc.  
 
9.12 Suggestions for Improvement 
In view of the findings discussed in this chapter, there is need to enhance the laboratory 
information system as well as laboratory operations in order to improve the quality of 
antimicrobial susceptibility data. In doing so, precise estimates of patterns and trends of 
antimicrobial resistance will be determined. To enable this to be achieved, the following 
needs to be considered: 
 Completeness of demographic data such as age and gender at the point of clinical 
request of and collection of a blood culture in the clinical departments. This requires 
proper completion of a laboratory request form and labelling of the blood culture 
bottles.  
 Complete and appropriate entry into the DISALab LIS of data of antimicrobial 
susceptibility results in the microbiology laboratory. 
 Relegation of the policy to suppress antimicrobial susceptibility results by 
pathologists in the microbiology laboratory. Such a practice, evident in the Gauteng 
hospitals, gives erroneous picture of the state of antimicrobial resistance particularly 
amongst antibiotics that were suppressed hence their data were not seen on DISALab 
LIS, for example the pattern of MRSA in Gauteng Province detailed in Chapter 5, 
Table 5.3). 
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 Maintain regular quality control of blood culture data to assess reliability of 
susceptibility results and identify if the microbiology laboratories produce comparable 
results to other well established laboratories such as the CDC.  
 The NHLS should fast track the implementation of Trackcare LIS, a system that 
operates in real time, as this will provide timely data. Such a system would improve 
timeliness on delivery and dissemination of patterns of antimicrobial resistance to 
clinicians and public health practitioners. 
 The active surveillance of antimicrobial resistance (ARSR) which is part of the 
GERMS-SA should enhance its operations by including clinical data on their data 
collection form. This among others should incorporate data on duration the patient 
stayed in hospital before blood culture was taken; name of antibiotics taken before a 
blood culture was done; clinical syndrome as well as outcome of the illness on 
discharge (i.e. discharged alive, dead); acute physiology, age, chronic health 
evaluation (APACHE III) score etc. for patients admitted in intensive care unit. (236) 
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CHAPTER 10  Conclusions and Recommendations 
 
This chapter provides some conclusive detail on the status of antimicrobial resistance in 
South Africa with a focus on the seven sites that were part of the study. Here, we highlight 
the main findings and bring in the public health implications, suggestions for improvement as 
well as perspectives for future research. 
 
10.1 Conclusions 
The patterns of antimicrobial resistance are varied, high rates of resistance against a wide 
spectrum of antibiotics were observed among the selected pathogens. Multi drug-resistant 
strains of MRSA seem to be rapidly increasing, including the more serious vancomycin 
resistant strains of SA seen in some hospitals in Gauteng Province. An increase in 
bactereamic episodes due to glycopeptides non-susceptible SA strains will be predictably 
detrimental in managing MRSA. This is because clinicians managing such patients will be 
left with very few therapeutic options to choose from or no options for effective treatment of 
the patient. This calls for action to enhance laboratory procedures and optimum practices in 
order to detect MRSA on time including accurate and ongoing identification of glycopeptides 
resistant strains.  
 
In addition, regular, active, and standardized surveillance of MRSA across sites to provide 
timely data on the antibiotic susceptibility pattern for implementation of effective hospital 
infection control programs need to be emphasized. Furthermore, such data will also aid the 
formulation of antibiotic prescription policy to guide empiric treatment and avoid misuse of 
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the valuable antibiotics. Studies to monitor the epidemiology of MRSA using molecular 
techniques in these hospitals are highly recommended.  
The frequency of ESBL as well as carbapenems-resistant K. pneumoniae is on the rise as 
evidenced by our data which supports global trends.(190) Similarly our data supports 
previous reports of emerging resistance amongst polymyxins (Chapter 5, section 5.3.10), 
which are the last line antibiotics in treating multi-drug resistant P. aeruginosa. (214, 215, 
225) Carbapenems are reserved drugs in the clinical management of K. pneumoniae 
bactereamia and therefore effective intervention to curb the growing crisis of carbapenems-
resistance should be reinforced. (134, 206, 207) 
 
It is therefore imperative to reinforce ongoing surveillance of invasive bacterial infections, 
paying special attention to the resistance profile of individual pathogens both at a local, 
national and regional level. Taking cognizance that resistance varies by geographical area 
including by different hospitals (237) it is important that regular assessment of local 
resistance data be enhanced as that would guide choice of antibiotic treatment by physicians 
in managing patients with multi-drug resistant nosocomial bacteraemia. 
 
10.2 Public Health Implications 
The study found emerging vancomycin resistant S. Aureus (VRSA), carbapenem-resistant K. 
pneumoniae (CRKP) and colistin resistant P. aeruginosa in South African tertiary public 
hospitals. In addition, geographic variation, gender and age differences in resistance were 
clearly demonstrated. These findings, as outlined above, are valid and unlikely to be due to 
chance, sampling bias or residual confounding. Age, gender and geographic variations in 
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antimicrobial resistance in patients with invasive nosocomial infection in South Africa have 
not been examined before at such a large scale since good quality data on laboratory-
confirmed invasive nosocomial infections were lacking. To our knowledge, the utilisation of 
LIS as a tool for monitoring antimicrobial resistance surveillance among nosocomial 
bactereamia has not been previously assessed in South Africa. In addition, assessment of 
factors associated with resistance using multivariate logistic regression models has also not 
been done before.  
 
Furthermore, this was the first time to conduct a comparative assessment of resistance data 
comparing resistance patterns found through a systematic review, retrospective and 
prospective analysis for the purpose of validating the reliability of routine blood culture data 
from the NHLS microbiology laboratories that aggregates at a central repository. Most 
studies done in South Africa have focused on analysis of small scale data either from a single 
hospital or simply presenting frequency of resistance for selected antibiotics. (26, 99, 123) 
We believe our study is robust and provided solid evidence on the reliability and utility of 
LIS as an effective tool for surveillance of antimicrobial resistance. 
 
We believe that our study is unique and provides information to individuals in clinical and 
public health practice to understand the challenges regarding patient management if faced 
with few treatment options due to increasing resistance and to understand the population with 
a high burden as well as at risk of carrying resistant bugs. Clinicians should be aware that 
young children particularly under the age of 5 years have a higher burden of nosocomial 
bacteraemia and they also have higher rates of antimicrobial resistance.  
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Therefore, this group of patients carrying the greatest risk of resistance needs to be managed 
effectively to minimize adverse outcomes such as prolonged hospitalisation and death. 
Hospital infection control epidemiologists and public health practitioners should therefore 
reinforce targeted preventive health services to control nosocomial bacteraemia in this age 
group.  
 
The findings from this study have broader implications on public health policy, to slow down 
the development of resistance to antibiotics that are key to effective management of 
bacteraemia. In addition, the study advocates for effective commitment to hospital infection 
prevention to reduce the burden of nosocomial infections as there are no new drugs to treat 
multi-drug resistant bugs.  
 
10.3 Recommendations 
In view of the foregoing, the following recommendations are made: 
 Active surveillance of antimicrobial resistance that is carried out by GERMS-SA should 
incorporate clinical data so as to use such data to find the association between resistance 
and clinical outcomes such as mortality. 
 More focused testing of antibiotic susceptibility, aiming at assessing resistance among 
antibiotics in regular use. Laboratories should minimize intrinsic testing, such action will 
improve the quality of data as the DISALab will only handle data for few antibiotics 
tested other than a large battery of antibiotics. Focussed testing should target the 
following antibiotics: S.aureus: ampicillin, cloxacillin, vancomycin, gentamicin, 
erythromycin, linezolid, clindamycin, rifampicin, fusidic acid, cotrimoxazole;  
K.pneumoniae: ampicillin, amoxycillin-clavulanate, imipinem, ertapenem, cefazolin, 
ceftazidime, cefuroxime, cefoxitin, cefotaxime, ceftriaxone, cefepime, piperacillin-
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tazobactam, gentamicin, amikacin, ciplofloxacin, nalidixic-acid, colistin, cotrimoxazole; 
P.aeruginosa: imipinem, meropenem, ceftazidime, cefepime, piperacillin-tazobactam, 
tobramycin, amikacin, ciprofloxacin, colistin. 
 Enhanced regular monitoring of patterns of antibiotic resistance in hospitals as data from 
such system would guide formulation of standard treatment guidelines to be based on 
local and objective data. In addition data required for efficient linkage of the frequency of 
resistance to prescribing must be collected within the antimicrobial resistance surveillance 
system. 
 Antimicrobial prescription policy should be developed based on local patterns of 
resistance to guide antimicrobial prescriptions in hospitals; hence the national treatment 
guidelines should be used for purposes of reference only. 
 Regular in-house training of both ward and laboratory staff regarding the value of 
antimicrobial resistance surveillance and how such is affected by the quality of data 
captured.  
10.4 Suggestions for further studies 
In view of the findings discussed in this chapter, further research is needed to gain a 
clearer understanding regarding the geographical differences in the patterns of 
antimicrobial resistance among SA, KP, and PA. In addition future studies should 
investigate: 
 The association between antibiotic resistance and mortality in a South African 
context. This should focus on assessing clinical outcomes of patients who received an 
antibiotic that is resistant to the isolated bug. 
  The influence of gender on antimicrobial resistance since the study showed that a 
higher proportion of resistant isolates were found in men, but also that male gender 
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was associated with increased risk of antimicrobial resistance as shown in both 
retrospective and prospective data analysis.  
 The association between antibiotic resistance and antibiotic use, which will involve 
linking data on antibiotic resistance and antibiotic use. 
 The effect of discordant therapy on treatment outcome, which will involve relating 
antibiotics prescribed in hospitals versus antibiotics tested for resistance and clinical 
outcome. 
 The prevalence of both community and hospital acquired MRSA in South Africa (i.e. 
MRSA identified on admission versus MRSA identified ≥2 days after admission). 
 
10.5 Contribution of this work to the field of research in 
antimicrobial resistance 
 
This research has clearly demonstrated that antimicrobial resistance is high in South Africa. 
Of interest is the significant variation of antimicrobial resistance by geographical location, 
gender and age, with children <5 years being more at risk of carrying a resistant strain. 
Lastly, we have also shown the value of the LIS as an essential tool for public health 
surveillance of antimicrobial resistance in spite of its inherent weakness of incompleteness of 
susceptibility data. 
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12.0 Appendices 
Appendix 12.1: A narrative Review of the Laboratory Information 
System and Its role in Antimicrobial Resistance Surveillance in 
South Africa 
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Appendix 12.2: Understanding laboratory methods and their 
impact on antimicrobial resistance surveillance, at Muhimbili 
national hospital, Dar es Salaam, Tanzania. 
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Appendix 12.3: Antimicrobial Resistance Surveillance among 
Nosocomial Pathogens in South Africa: Systematic Review of 
Published Literature. 
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Appendix 12.4: Increased Risk of Death in Human 
Immunodeficiency Virus-infected Children with Pneumococcal 
Meningitis in South Africa, 2003-2005. 
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Appendix 12.5.1 Presentation at 14th Congress of the International 
Federation of Infection Control, Portomaso, Malta 
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  Appendix 12.5.2 Presentation at 4th ICAN, Cape Town, South Africa 
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Appendix 12.5.3: 7th PHASA, Sandton, Johannesburg 
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Appendix 12.5.4: 15th International Congress of Infectious Diseases, 
Bangkok, Thailand. 
 
Trends and pattern of antimicrobial resistance among blood culture isolates of selected 
bacterial pathogens in South Africa, 2005-2009 
 
P. Nyasulu
1
*, O. Perovic
2
, J.Murray
3
, S. Luchters
1
, C. Chasela
1
, H.Koornhof 
2
 
 
1 University of the Witwatersrand, Johannesburg, South Africa 
2 National Institute for Communicable Diseases, Johannesburg, South 
Africa 
3 National Institutes of Occupational Health, Johannesburg, South 
Africa 
 
Background: To investigate prevalence, patterns and time trends of resistance to commonly used 
antibiotics and factors associated with antimicrobial resistance of selected isolates from blood-
specimens collected from patients with bacteraemia and submitted to diagnostic microbiology 
laboratories at 7 tertiary public hospitals in South Africa. 
 
Methods: We conducted a retrospective cohort analysis of routine data of blood culture-positive 
Staphylococcus aureus (SA), Klebsiella pneuomoniae (KP), and Psuedomonas aeruginosa (PA) 
submitted to the National Health Laboratory Services (NHLS) between January 1, 2005 and 
December 31, 2009. Antimicrobial resistance to commonly used antimicrobials was systematically 
investigated. Multivariable logistic regressions models were used to assess factors associated with 
antimicrobial resistance. 
 
Results: A total of 9,969 isolates were reported 3942 (39.5%) SA, 4466 (44.8%) KP and 1561 
(15.7%) PA. There were more resistant isolates in 30-39 years age-group for SA 28.4% and PA 
51.5%. For KP, 73.3% were in the 5-9 years age-group. SA and PA resistance was similar between 
males and females, for KP 66.8% were among females; 47.9% SA, 72% KP and 67.1% PA 
respectively were found to be resistant in three different hospitals from three provinces. SA 
resistance to ampicillin was >98% and to vancomycin <0.1%. KP resistance to carbapenems was 
very low: ertapenem 2% (range 0.5%-4.6%), imipenem 0.1% (range 0%-0.5%) and meropnem 0.1% 
(range 0%-0.3%); and to colistin 1.7% (range 0-2.6%). PA resistance to colistin was 1.9% (range 0 - 
13.3%). There was a significant increase in trend of KP resistance to ciprofloxacin (32.6% to 64.9%, 
p<0.001), cotrimoxazole (67.5% to 81.6%, p<0.001) and cefazolin (80.9% to 95.7%, p<0.00)1. PA 
resistance to meropenem showed a significant increasing trend from 2006 (27.5%) to 2009 (53.9%) 
p<0.001. Age group <5 years; female sex; hospital location and year of infection were significantly 
associated with antimicrobial resistance. 
 
Conclusion: The prevalence of antimicrobial resistance was high among children <5 years old and 
females with bacteraemia. Enhancement of continued surveillance of hospital acquired infections 
is therefore recommended as trend of antimicrobial resistance is increasing. Such data would 
provide understanding of the extent of the problem and present evidence for future policies and 
practices aimed at containing antimicrobial resistance. 
 
http://dx.doi.org/10.1016/j.ijid.2012.05.598 
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Appendix 12.5.5: 1st Global Forum for Bacterial Infections, India. 
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Appendix 12.5.6: Wits SoPH Biennal Research Day, Johannesburg. 
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Appendix 12.5.7: Post Graduate Approval Certificate 
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Appendix 12.5.8: Approval Letter to Access and Use the CDW Data   
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 Appendix 12.5.9: Ethics Approval Certificate 
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Appendix 12.5.10: Approval Letter for Laboratory Visit at Muhimbili 
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Appendix 12.6: Laboratory Visits Observation Checklist 
 
 
                                          Observed parameters Yes/No 
1 Availability of a standard operating procedure 
 
 
2 Flow of blood culture specimen in the laboratory 
 
 
3 Blood culture procedures: Manual/automated 
 
 
4 Susceptibility testing procedures: Manual/automated 
 
 
5 MIC break points: CLSI Guidelines in use 
 
 
6 Quality Assurance & Control Methods (QA/QC) 
 
 
7 Staffing for blood cultures (always same individual/rotational) 
 
 
8 Data entry methods: manual/automated 
 
 
9 Database: localised or network  
 
 
10 Blood culture database: localised or on network linked to CDW 
 
 
11 Data transfer : localised entry/automated 
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Appendix 12.7: NHLS Laboratory Request Form 
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Appendix 12.8: MNH Laboratory Request Form 
 
 
 
 
